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Abstract 
 
Devil facial tumour disease (DFTD) is a transmissible cancer that threatens the survival 
of the Tasmanian devil (Sarcophilus harrisii), the world’s largest living carnivorous 
marsupial. Despite devils having a competent immune system, there is no evidence of 
natural immunity to the tumours. Affected animals die within months of tumour 
appearance. The species could face extinction within 25 to 35 years. Cytogenetic and 
molecular studies have confirmed that the infectious agent is the cancer cell itself. 
However, our knowledge about the nature and biology of this tumour is limited.  
Tumour transcriptome analyses of DFTD tumours and devil tissues revealed that DFTD 
expresses a set of genes related to the myelination pathway in the peripheral nervous 
system. This thesis examined the protein expression of peripheral nerve and other 
neuronal markers in DFTD to further elucidate the nature of the tumour. It also 
evaluated the utility of neuronal and peripheral nerve proteins as diagnostic markers for 
the disease. Immunohistochemistry and flow cytometry confirmed that DFTD tumour 
cells express a number of proteins found throughout the neuronal system. Notably, 
DFTD tumour cells expressed structural proteins found in myelinating Schwann cells in 
the peripheral nervous system. These included peripheral myelin protein 22 (PMP22), 
myelin protein zero (MPZ), myelin basic protein (MBP), and the recently described 
periaxin (PRX). Nerve growth factor receptor (NGFR), which is involved in the 
differentiation of Schwann cells, was also detected in DFTD tumour cells. These results 
coupled with the available genetic data confirm that DFTD cells are of Schwann cell 
origin.  
Furthermore, this study showed that periaxin, a specific marker of Schwann cells, is 
consistently expressed in DFTD primary tumours, DFTD metastases, DFTD cell lines 
and murine xenografted DFTD tumours. Therefore, this thesis identified periaxin as a 
sensitive and specific marker for DFTD. This will greatly facilitate the diagnosis of the 
disease.  
How DFTD can be transplanted across major histocompatibility (MHC) barriers is an 
aspect of DFTD that is not understood. Initially this was attributed to the reduced 
x 
diversity at the major histocompatibility complex (MHC) loci. However, recent studies 
showed that the limited MHC diversity in devils is sufficient to produce measurable 
mixed lymphocyte reactions and the rejection of skin allografts. Thus, this thesis 
investigated the expression of MHC to determine if this may explain the lack of 
immune response to DFTD cells.  
Analysis of the expression of MHC proteins in devils has been hindered by the lack of 
cross-reacting reagents. During the course of this study collaborators from the 
University of Cambridge (UK) developed the first anti-devil MHC class I (MHC-I) 
antibody. This antibody was used to examine the expression of MHC-I in devil tissues 
and DFTD. MHC-I protein expression in primary tumours and metastases was lower 
than normal tissues. Its expression was also variable within a tumour and among 
different tumours. These results suggest that alteration of MHC-I expression could 
contribute to the immune escape of DFTD. 
Immunisation trials with non-viable DFTD cell lines revealed that some Tasmanian 
devils can produce antibodies against DFTD cells. This thesis utilised an 
immunoproteomic approach to identify immunogenic proteins in DFTD. Several 
candidates were identified as DFTD tumour associated antigens. These include heat 
shock proteins, tubulin, histone H2B, stathmin protein, and proliferating cell nuclear 
antigen (PCNA). These proteins are excellent targets for the development of early 
diagnostic tools as well as therapeutic approaches. 
In summary, this thesis provided strong supporting evidence for a Schwann cell origin 
of DFTD and generated a specific diagnostic marker for the disease. Additionally, this 
thesis opened new opportunities for the understanding of the mechanisms that allow 
immune evasion and the interaction between the tumour cells and the devil’s immune 
system. These results will have direct implications for the future development of a 
vaccine approach.  
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Abstract 
 
Devil facial tumour disease (DFTD) is a transmissible cancer that threatens the survival 
of the Tasmanian devil (Sarcophilus harrisii), the world’s largest living carnivorous 
marsupial. Despite devils having a competent immune system, there is no evidence of 
natural immunity to the tumours. Affected animals die within months of tumour 
appearance. The species could face extinction within 25 to 35 years. Cytogenetic and 
molecular studies have confirmed that the infectious agent is the cancer cell itself. 
However, our knowledge about the nature and biology of this tumour is limited.  
Tumour transcriptome analyses of DFTD tumours and devil tissues revealed that DFTD 
expresses a set of genes related to the myelination pathway in the peripheral nervous 
system. This thesis examined the protein expression of peripheral nerve and other 
neuronal markers in DFTD to further elucidate the nature of the tumour. It also 
evaluated the utility of neuronal and peripheral nerve proteins as diagnostic markers for 
the disease. Immunohistochemistry and flow cytometry confirmed that DFTD tumour 
cells express a number of proteins found throughout the neuronal system. Notably, 
DFTD tumour cells expressed structural proteins found in myelinating Schwann cells in 
the peripheral nervous system. These included peripheral myelin protein 22 (PMP22), 
myelin protein zero (MPZ), myelin basic protein (MBP), and the recently described 
periaxin (PRX). Nerve growth factor receptor (NGFR), which is involved in the 
differentiation of Schwann cells, was also detected in DFTD tumour cells. These results 
coupled with the available genetic data confirm that DFTD cells are of Schwann cell 
origin.  
Furthermore, this study showed that periaxin, a specific marker of Schwann cells, is 
consistently expressed in DFTD primary tumours, DFTD metastases, DFTD cell lines 
and murine xenografted DFTD tumours. Therefore, this thesis identified periaxin as a 
sensitive and specific marker for DFTD. This will greatly facilitate the diagnosis of the 
disease.  
How DFTD can be transplanted across major histocompatibility (MHC) barriers is an 
aspect of DFTD that is not understood. Initially this was attributed to the reduced 
x 
diversity at the major histocompatibility complex (MHC) loci. However, recent studies 
showed that the limited MHC diversity in devils is sufficient to produce measurable 
mixed lymphocyte reactions and the rejection of skin allografts. Thus, this thesis 
investigated the expression of MHC to determine if this may explain the lack of 
immune response to DFTD cells.  
Analysis of the expression of MHC proteins in devils has been hindered by the lack of 
cross-reacting reagents. During the course of this study collaborators from the 
University of Cambridge (UK) developed the first anti-devil MHC class I (MHC-I) 
antibody. This antibody was used to examine the expression of MHC-I in devil tissues 
and DFTD. MHC-I protein expression in primary tumours and metastases was lower 
than normal tissues. Its expression was also variable within a tumour and among 
different tumours. These results suggest that alteration of MHC-I expression could 
contribute to the immune escape of DFTD. 
Immunisation trials with non-viable DFTD cell lines revealed that some Tasmanian 
devils can produce antibodies against DFTD cells. This thesis utilised an 
immunoproteomic approach to identify immunogenic proteins in DFTD. Several 
candidates were identified as DFTD tumour associated antigens. These include heat 
shock proteins, tubulin, histone H2B, stathmin protein, and proliferating cell nuclear 
antigen (PCNA). These proteins are excellent targets for the development of early 
diagnostic tools as well as therapeutic approaches. 
In summary, this thesis provided strong supporting evidence for a Schwann cell origin 
of DFTD and generated a specific diagnostic marker for the disease. Additionally, this 
thesis opened new opportunities for the understanding of the mechanisms that allow 
immune evasion and the interaction between the tumour cells and the devil’s immune 
system. These results will have direct implications for the future development of a 
vaccine approach.  
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1.1 Introduction 
Devil facial tumour disease (DFTD) is a recently emerged transmissible cancer that is 
threatening the survival of the Tasmanian devil (Sarcophilus harrisii), the largest extant 
carnivorous marsupial (Hawkins et al., 2006, McCallum and Jones, 2006). Primary 
tumours located around the mouth and face that grow to in excess of 10 cm in diameter 
and often ulcerate characterize this cancer. Karyotypic analysis of DFTD tumours has 
revealed a substantial and consistent pattern of chromosomal abnormalities from 
different animals. This similarity led to the proposal that DFTD is transmitted as an 
allograft (Pearse and Swift, 2006). Genetic analysis of DFTD tumours at the DNA, 
microsatellite, and major histocompatibility complex loci, provided further support for 
the clonal transmission and therefore the contagious nature of this tumour (Murchison et 
al., 2010, Siddle et al., 2007b). DFTD transmission occurs by facial biting with the 
transfer of viable cancer cells dislodged from ulcerated tumours in close proximity to 
the canine teeth (Obendorf and McGlashan, 2008).  
There is no evidence of natural immunity to the establishment and growth of the 
tumours, and affected animals die within months of tumour appearance (Hawkins et al., 
2006, Woods et al., 2007). At the current rate of spread of disease, the species could 
face extinction within 25 to 35 years (McCallum et al., 2007). Conservation 
management trials have already begun (http://www.tassiedevil.com.au/tasdevil.nsf/). 
These include the removal of DFTD-affected devils from relatively isolated local 
populations in Tasmania and the establishment of insurance populations of healthy 
devils in mainland Australia, in free-range enclosures and in islands off the Tasmanian 
mainland  
DFTD was initially described as a malignant neuroendocrine neoplasm (Loh et al., 
2006b). Recent studies on the Tasmanian devil transcriptome supported the 
neuroectodermal origin and revealed that DFTD expresses a set of genes related to the 
myelination pathway in the peripheral nervous system (PNS) (Murchison et al., 2010). 
Analyses of protein expression are required to confirm the nature of the tumour and to 
identify potential diagnostic biomarkers for the disease. 
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DFTD is a unique cancer as it is transmitted between unrelated individuals without 
evoking an immune response (Woods et al., 2007). The lack of immune allorecognition 
was initially attributed to the reduced genetic diversity that characterises the devil 
populations and the lack of genetic diversity at the major histocompatibility complex 
(MHC) loci (Siddle et al., 2007a). However, recent studies showed that the limited 
MHC diversity is sufficient to produce measurable mixed lymphocyte reactions and the 
rejection of skin allografts (Kreiss et al., 2011a). Therefore, the mechanisms that 
explain the lack of immune response to the transfer of DFTD cells require further 
investigation.  
Canine transmissible venereal tumour (CTVT) is another naturally occurring contagious 
cancer that may provide clues about the mechanisms that allow transplantation of cells 
across MHC barriers. CTVT is sexually transmitted and affects dogs worldwide 
(Rebbeck et al., 2009). However, CTVT is not a fatal cancer. Initial transplantation of 
CTVT tumour cells occurs through the downregulation of MHC molecules and immune 
suppression induced by the tumour. This is followed by a complex interaction between 
the cancer cells and the dog’s immune system that ends with the regression of the 
tumours (reviewed in Murchison, 2008). Hence, CTVT provides a useful model for the 
study of the mechanisms of immune evasion in DFTD. 
Understanding the circumstances that allow transmission of DFTD is also essential for 
the development of therapeutic strategies. Immunisation trials with non-viable DFTD 
cell lines revealed that Tasmanian devils are able to produce a humoral (antibody) 
response against the cancer cells. The identification of the specific antigenic and 
immunogenic proteins in DFTD is of paramount importance. It will open new 
opportunities for the understanding of the interaction between the tumour cells and the 
devil’s immune system and have direct implications for the future development of a 
vaccine approach.  
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1.2 Transmissible cancers 
Specific infectious agents including viruses, bacteria and parasites can cause cancer, 
however, the disease per se is not generally considered transmissible (Zur Hausen, 
2009). In humans, there is no evidence for direct person-to-person transmission of 
tumour cells during normal social interaction (Dingli and Nowak, 2006). The 
transmission of cancer between individuals occurs only under very particular biological 
settings. Pregnancy and foetal to foetal transmission are the only known physiological 
routes of tumour cell transmission in humans (Dessolle et al., 2007). Organ or 
hematopoietic cell transplantation are other possible route of cancer transmission 
between people (Birkeland and Storm, 2002, Brunstein et al., 2002, Buell et al., 2004, 
Gandhi and Strong, 2007, Strauss and Thomas, 2010, Wang et al., 2011). However, 
these cases are extremely rare and less than 0.06% of recipients of transplants develop 
cancer from the transferred organ or cells (Feng et al., 2003, Kauffman et al., 2002). 
Finally, there is a case report of a surgeon developing a malignant histiocytoma after an 
accidental injury during the surgical removal of a tumour from his unrelated patient 
(Gartner et al., 1996).  
The fact that transmission of cancer between people is very rare supports the notion that 
the immune system prevents such cancers to take. In humans and other jawed 
vertebrates, specialised proteins encoded by genes called the major histocompatibility 
complex (MHC) are responsible for graft rejection. The immune system uses MHC 
antigens to differentiate “self” from “non-self” because these proteins vary between 
individuals. The immune system reacts against those cells displaying non-self MHC 
antigens (Bradley, 1991). Therefore, MHC genes play a critical role in protecting 
vertebrate species from infectious diseases and contagious cancers (Belov, 2011).  
There are only two cases of naturally occurring contagious cancers: the canine 
transmissible venereal tumour (CTVT) and devil facial tumour disease (DFTD). CTVT 
is a sexually transmissible tumour in dogs that originated thousands of years ago 
(Murgia et al., 2006, Rebbeck et al., 2009). DFTD is an aggressive facial tumour that 
emerged no more than 20 years ago and is threatening the survival of the Tasmanian 
devil in the wild (Hawkins et al., 2006). CTVT and DFTD tumour cells behave like 
infectious parasites passing from one host to another across MHC barriers. Although 
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these two cancers have similar origin, the host immune response and adaptation are 
unique. CTVT and DFTD are therefore excellent models to study tumour immunology 
and the evolution of infectious cancers.  
1.2.1 Canine venereal transmissible tumour 
Canine transmissible venereal tumour (CTVT) is a sexually transmitted neoplasm of 
domestic dogs (Canis familiaris). CTVT causes lesions around the external genitalia 
and affects both sexes of any breed of dog (Figure 1.1) (Brown et al., 1980, Karlson and 
Mann, 1952). Tumours are transferred and maintained in the dog population by coitus 
and other social behaviours such as smelling and licking of the external genitalia (Das 
and Das, 2000, Higgins, 1966, Ndiritu et al., 1977). The disease is globally widespread, 
particularly in subtropical countries, with cases reported in North, Central and South 
America, Europe, Middle and Far East, Asia and parts of Africa (Kabuusu et al., 2010). 
Cytologically, CTVT tumours appear as 
compact masses of neoplastic cells 
arranged in a diffuse pattern and 
supported by a thin fibro vascular 
tissue. The tumour cells are round or 
polyhedral with a prominent nucleus 
and a slightly granular and vacuolated 
cytoplasm (Karlson and Mann, 1952, 
Mukaratirwa and Gruys, 2003). The 
nature and cell of origin of is not yet 
clear but histological studies suggested 
that CTVT evolved from a cell of the 
macrophage lineage (Marchal et al., 
1997, Mozos et al., 1996). 
 
 
 
Figure 1.1 Ulcerated CTVT tumour in a female dog. 
Image from: http://www.carefordogs.org 
 
 
Infectious nature of the CTVT 
For the first time in 1876, Nowinsky demonstrated the transmissible nature of CTVT by 
transplanting the tumour from one dog to another (Nowinsky, 1876). Similarly, Karlson 
and Mann (1952) passaged the tumour through 40 generations of dogs over a period of 
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7 years. Further studies confirmed that transmission of CTVT occurs only by 
transplantation of living tumour cells and not by killed cells or cellular filtrates (Koike 
et al., 1979, Rust, 1949, Stubbs and Furth, 1934). CTVT was also experimentally 
transmitted to other related canids, such as the coyote (Canis latrans) (Cockrill and 
Beasley, 1979) and the grey wolf (Canis lupus) (Karlson and Mann, 1952, Wade, 1908).  
The success of transplantation of CTVT tumours between unrelated dogs led to the 
proposal that the disease is a contagious cancer transmitted as an allograft. Cytogenetic 
studies on spontaneous and experimentally transplanted CTVT supported this theory. 
Studies of tumours from different geographical locations showed that the tumour cells 
were always aneuploidy and had a comparable number of chromosomes. They also had 
similar frequency of metacentric chromosomes and similar incidence of marker 
chromosomes (reviewed in Mukaratirwa and Gruys, 2003). The remarkable similarity 
between CTVT karyotypes, which clearly differ from that of the normal canine cell, 
suggests not only a common origin for CTVT but also highlights the stable nature of the 
clone (Murchison, 2008).  
Recent genetic studies provided further evidence for the clonal transmission of CTVT. 
CTVT tumours have a long interspersed nuclear element (LINE-1) inserted near the 
MYC gene that is not found in any other canine tissue. This element is now a diagnostic 
marker for CTVT (Katzir et al., 1987, Liao et al., 2003b).  
Murgia et al. (2006) and Rebbeck et al. (2009, 2011) used microsatellite diversity to 
analyse the origin and evolution of CTVT. These studies provided the conclusive 
evidence for a monophyletic origin of CTVT. They confirmed that tumours are closely 
related genetically but genetically different from their host. Moreover, they predicted 
that CTVT emerged in inbred wolves more than 6000 years ago, probably when dogs 
were first domesticated. In contrast, the common ancestor of existing tumours probably 
appeared only around 47 and 470 years ago (Rebbeck et al., 2009) or between 250 and 
2500 years ago (Murgia et al., 2006).  
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Tumour immunology 
Typically, CTVT is a benign disease and the progression of CTVT tumours follows a 
predictable growth pattern. In natural and experimental cases, the tumour grows rapidly 
after transplantation, followed by a stable phase, and finally a spontaneous regression 
phase, generally within six months after the first appearance (Higgins, 1966, Karlson 
and Mann, 1952). Metastases are rare and generally occur in puppies and 
immunosuppressed dogs (Cohen, 1985). Dogs in which tumours regressed 
spontaneously are resistant to further transmission of CTVT (Karlson and Mann, 1952).  
The foreseeable growth of tumours and the frequent spontaneous regression of CTVT 
reveal two important aspects of the disease. First, CTVT has evolved to be an effective 
transmissible parasite. Second, it indicates that the dog’s immune response plays a 
major role in defining the course of the disease (Mukaratirwa and Gruys, 2003, Murgia 
et al., 2006). However, the mechanisms of this process are not completely clear.  
CTVT triggers both humoral and cell-mediated immune responses in the host (reviewed 
in Murchison, 2008). However, during the progression phase the tumour cells evade 
immune recognition by different mechanisms. CTVT produces high concentrations of 
TGF-β which decreases MHC expression and suppresses natural killer cell activity 
(Cohen et al., 1984, Hsiao et al., 2002, Hsiao et al., 2004, Murgia et al., 2006); CTVT 
also secretes substances that destroy B-cells (Liao et al., 2003a), and prevents the 
differentiation and activity of dendritic cells (Liu et al., 2008).  
During the progression phase, specific circulating antibodies to CTVT tumour antigens 
can be detected in affected animals (Cohen, 1972, McKenna and Prier, 1966). However, 
the levels of antibodies detected in the serum do not correlate well with tumour growth. 
This indicates that the antibodies are not protective against established CTVT. Instead, 
the humoral response appears to have a more important role in slowing the tumour 
growth, protecting against metastasis, and reducing the susceptibility to future CTVT 
infections (Cohen, 1980, Fenton and Yang, 1988).  
After the progression phase, the tumour growth slows and becomes vulnerable to the 
host immune response. A proposed model suggests that during the regression phase, the 
number of tumour-infiltrating lymphocytes increases. These cells secrete IFN-γ and 
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interleukin-6 (IL-6) which block the inhibitory effects of tumour-derived TGF-β and 
induce the expression of MHC in tumour cells. The expression of MHC by CTVT 
triggers the immune system and the regression of the tumour (Hsiao et al., 2004).  
The fine-tuned interactions between CTVT and the host reveal a process of coevolution 
where the parasite and the host’s immune system have adapted to each other strategies. 
The notion of a cancer somatic cell evolving to become infectious and survive 
thousands of years is intriguing. Certainly, CTVT will continue to provide us with a 
better understanding of the role of the immune system in the evolution of such cancers. 
1.2.2 Devil facial tumour disease  
Tasmanian devils (Sarcophilus harrisii) are the world’s largest extant marsupial 
carnivores and are endemic to Tasmania, Australia’s island state. Tasmanian devil 
populations were isolated from those on mainland approximately 12000 years ago at the 
end of the last glaciation (Turney et al., 2008). The continental populations then became 
extinct approximately 400 years ago, probably due to competition with the dingo (Canis 
lupus) and humans (Johnson, 2003). Tasmanian devils have moderately low genetic 
diversity, possibly due to the island effect and repeated periods of low population 
density over the past 150 years (Jones et al., 2004, Miller et al., 2011, Siddle et al., 
2007a). Although devils are specialist carrion feeders, they have played the role of 
principle native carnivore since the extinction of the thylacine (Thylacinus 
cynocephalus). 
Until the emergence of Devil Facial Tumour Disease (DFTD) in 1996, Tasmanian 
devils were common and found throughout the island (McCallum et al., 2007). This 
unusual transmissible cancer has spread through the island producing substantial 
declines in devil populations. In Tasmania’s north-east, where the disease first appeared, 
spotlighting sightings declined by 80% (Hawkins et al., 2006). Other local populations 
have declined by at least 60% (Lachish et al., 2007). At the current rate of spread of the 
disease it is estimated that species could face extinction within 25-35 years (McCallum 
et al., 2007). The Australian and State Government listed the Tasmanian devil as 
Endangered under environmental law. The species was also listed as Endangered on the 
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Red List of the International Union for the Conservation of Nature and Natural 
Resources (IUCN).  
Clonal transmission of DFTD 
Similar to CTVT, karyotypic analysis of DFTD tumours from different locations 
revealed a substantial and consistent pattern of chromosomal abnormalities among the 
DFTD tumours (Figure 1.2). Moreover, a pericentric inversion of chromosome 5 was 
found in the constitutional karyotype of a devil, but such inversion was not observed in 
either chromosome 5 of the tumour from this animal. These findings led to the proposal 
that DFTD is transmitted as an allograft (Pearse and Swift, 2006). Genetic analysis of 
DFTD tumours at the DNA, microsatellite and major histocompatibility complex loci 
provided further support for clonal transmission and therefore the contagious nature of 
this tumour (Miller et al., 2011, Murchison et al., 2010, Siddle et al., 2007b). Facial 
biting with the transfer of viable tumour cells dislodged from ulcerated tumours in close 
proximity to the canine teeth is considered the most likely means of DFTD transmission 
(Obendorf and McGlashan, 2008).  
 
 
Figure 1.2 Karyotype of the Tasmanian devil and DFTD cells. a, Normal karyotype of a male Tasmanian devil (14 
chromosomes, including XY). b, Karyotype of cancer cells (13 chromosomes; sex chromosomes, chromosome 2 pair 
and one chromosome 6 are lost; four additional marker chromosomes are present (M1–M4). (Image taken from 
Pearse and Swift, 2006) 
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Immunology of DFTD 
Contrasting to CTVT, there is no evidence of host resistance to the establishment and 
growth of DFTD tumours and affected animals die within months of tumour appearance 
(Hawkins et al., 2006, Kreiss et al., 2008, Woods et al., 2007).  
Knowledge of the devil’s immune system was limited before the emergence of DFTD 
and the lack of response against DFTD was initially attributed to a severely 
compromised immune system. However, in vivo and in vitro studies in our laboratory 
demonstrated that devils have a competent immune system: 
 Devils have the full complement of secondary lymphoid organs with a distribution 
of immune cells similar to eutherian animals. These include neutrophils, 
lymphocytes, monocytes, basophils and eosinophils (Kreiss, 2009).  
 Both T and B lymphocytes proliferate in response to mitogen stimulation. The level 
of response from lymphocytes extracted from healthy devils is similar to those from 
lymphocytes extracted from DFTD affected animals. Additionally, neutrophils from 
the peripheral blood show all the major features of the phagocytic process such as 
bacterial attachment and uptake of bacteria and oxidative burst (Kreiss et al., 2008, 
Stewart et al., 2008).  
 Devils are also capable of mounting strong humoral responses against cellular 
antigens injected subcutaneously (Kreiss et al., 2008, Kreiss et al., 2009, Stewart et 
al., 2008, Woods et al., 2007).  
DFTD is an allograft and foreign to the host. With a competent immune system, devils 
should be able to recognise and reject the tumour cells. However, sequence analyses 
showed that devils have extremely low levels of genetic diversity at the MHC genes 
(Siddle et al., 2007b). Additionally, devils from eastern Tasmania showed weak 
responses to allogeneic mixed lymphocytes in culture (Woods et al., 2007). This 
combined data suggested that DFTD and the host might be identical at the MHC loci 
allowing the tumour to spread without encountering any histocompatibility barriers 
(Siddle et al., 2007a, Siddle et al., 2007b).  
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Further studies of microsatellite markers and sequencing of MHC genes showed that 
devils from north-west Tasmania are genetically different from the eastern populations 
(Jones et al., 2004, Siddle et al., 2010). The studies revealed that devil MHC sequences 
fit into two distinct groups based on sequence similarity. DFTD cells and most devils 
have sequences from both groups. A small percentage of animals located in the north-
west have a restricted MHC repertoire with only one group. The level of sequence 
variation between groups is significant. Consequently, animals with a restricted MHC 
repertoire were predicted to recognise DFTD and produce an immune response.  
Unfortunately, monitoring and ecological studies of the disease in the north-west 
showed a different result. DFTD emerged in north-east Tasmania and rapidly spread 
throughout the eastern half of the island. The disease front has now reached the 
populations in the north-west and animals with restricted MHC repertoires have also 
been infected (Coupland and Anthony, 2007, Hamede et al., 2012). Now it is evident 
that the lack of MHC diversity alone does not explain the transmission of DFTD. 
Recent experimental transplantation of skin grafts between unrelated devils and mixed 
lymphocyte reactions (MLR) provided more evidence that the devils are capable of 
allogeneic rejection (Kreiss et al., 2011a). Devils rejected the skin grafts regardless of 
MHC type and the strongest MLR responses occurred when mixing lymphocytes from 
eastern devils with lymphocytes from western animals.  
Therefore, it is likely that DFTD evolved special adaptive mechanisms that allow 
allotransplantation of tumour cells without immune recognition. Downregulation of 
MHC expression and secretion of immune suppression molecules, as those discussed 
previously in CTVT, are very common in cancer (described in Section 1.5). MHC 
expression in DFTD has only been investigated at the genetic level. Further studies are 
required to determine whether MHC genes in DFTD are translated into proteins and 
functionally displayed in the surface of the cells. Immune suppression induced by the 
tumour needs to be explored as well.  
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Histopathology of DFTD  
DFTD is characterized by primary tumours located around the mouth and face, which 
grow to in excess of 10 cm in diameter and often ulcerate (Figure 1.3). Tumours 
generally appear within the dermis or the sub mucosal connective tissue in the oral 
cavity. The neoplasms grow as a multi-nodular compact proliferation of pleomorphic 
round cells with a high nuclear to cytoplasm ratio. The nodular aggregates are well 
vascularized often within a thin fibrous pseudo-capsule and with high mitotic indices. In 
some cases, the cells aggregate as bundles, cords, or streams. Most of the tumours 
present central necrosis(Loh et al., 2006a). An important aspect of DFTD tumours is the 
low evidence of lymphocyte infiltration (Loh et al., 2006a). DFTD metastases are 
frequent in regional lymph nodes and other distant organs (Loh et al., 2006a). Death 
occurs due to an inability to feed, secondary infections and organ failure due to the 
metastases (Pyecroft et al., 2007).  
 
Figure 1.3 Gross appearance of DFTD tumours in a wild Tasmanian devil. Tumours are generally located around 
the face and neck of the individual. Right panel, inferior view showing the ulcerated tumour.  
 
1.3 Nature of devil facial tumour disease 
1.3.1 Neuroectodermal origin  
Studies of captive Tasmanian devils suggested that the species is prone to developing 
tumours (Canfield and Cunningham, 1993). However DFTD lesions do not resemble 
cancers previously described and determining its nature is critical for developing 
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management strategies for the disease (Loh et al., 2006a). Initial immunohistological 
studies using routine diagnostic markers indicated that the tumour cells are of 
neuroectodermal origin and probably of neuroendocrine lineage (Loh et al., 2006b). 
Further molecular analyses confirmed the neuroectodermal nature of DFTD but 
suggested that it is more likely to be related to the peripheral nerve lineage (Murchison 
et al., 2010).  
During vertebrate embryogenesis, the neuroectoderm extends caudally from the head 
region and forms the entire neural plate. Two key structures develop from the neural 
plate: i: the neural tube formed by the folding and fusion of the neural plate. This neural 
tube gives rise to the main cells types of the central nervous system (CNS), including 
neurons, astrocytes and oligodendrocytes (Kulesa et al., 2004, Liu and Zhang, 2011). ii: 
the neural crest which derives from the dorsal lip of the neural tube. The neural crest 
cells formed in the neural crest are embryonic and transient progenitor cells that migrate 
extensively into the periphery. During and after migration these multipotent cells 
differentiate into a wide range of derivatives. Cells include neurons and glial cells from 
the peripheral nervous system (PNS), pigment cells in the skin (melanocytes); endocrine 
cells, and a variety of mesenchymal cell types (Figure 1.4) (Donoghue et al., 2008, 
Dupin et al., 2007, Joseph et al., 2004, Le Douarin et al., 2008). 
Neuroectodermal tumours, also called neurological tumours, include all the neoplasms 
that derive from either the CNS or the PNS. The complexity and diversity of these 
tumours is enormous making classification difficult. In humans, most of the 
neurological tumours are of glial origin. This is related to the fact that glial cells retain 
the capacity to proliferate through life whereas neurons become post-mitotic after 
development (Zhu and Parada, 2002).  
Characterization of neuroectodermal tumours (diagnosis and classification) is based on 
histopathology, clinical features, and molecular signatures of the predominant cell type 
in the tumour. Immunohistochemistry (IHC) is perhaps the most commonly method 
used for the diagnosis of human and animal neoplasms (Bodey, 2002, Heim-Hall and 
Yohe, 2008, Ramos-Vara et al., 2008). The underlying principle of diagnostic IHC is 
that the immunophenotype of a tumour reflects the cell lineage in which the cancer 
originated (the concept of cell of origin in cancer was recently reviewed by Visvader, 
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2011). Thus, IHC benefits from the availability of a wide range of antibodies against 
specific markers of cell lineage and tissue type.  
Loh et al. (2006b) used immunohistochemistry to analyse the expression of a wide 
range of diagnostic markers in DFTD. The pattern of protein expression suggested that 
DFTD was a neural crest-derived neoplasm. Positive markers included S100, neuron-
specific enolase, synaptophysin, and chromogranin A, which are also consistent with 
cells of neuroendocrine origin. Further sequencing of the DFTD transcriptome 
confirmed the expression of neural crest cell markers in the tumour (Murchison et al., 
2010). Moreover, the study revealed a set of genes differentially expressed in DFTD 
tumours compared to normal tissue. Genes included transcription factors, structural 
genes, and receptors, which are involved in the differentiation of myelinating Schwann 
cells within the PNS. Therefore, the DFTD transcriptome suggested that DFTD is more 
likely to be a peripheral nerve tumour of Schwann cell origin.  
As mentioned before neuroendocrine cells and glial cells of the PNS belong to two 
independent lineages that share a common origin in the neural crest. Therefore, it is 
feasible that DFTD express markers of both lineages. Confirmatory studies of the 
expression at the protein level of PNS markers will contribute to the understanding of 
the nature of DFTD. 
1.3.2 Schwann cell development  
The last decade produced important advances in the knowledge of the molecular 
mechanisms and pathways that control Schwann cell development, myelination and 
myelination maintenance within the PNS. Alteration of these processes has been linked 
to a variety of neuropathies and the formation of tumours of Schwann cell origin. These 
mechanisms provide new opportunities for our understanding of DFTD biology and 
behaviour.  
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Figure 1.4 Development of the neural crest. The neural plate derived from the neuroectoderm folds 
and fuse to form the neural tube. Neural crest cells segregate from the tips of the fold and migrate in a 
lateral and ventral direction to generate a diverse type of cells. Adapted from Jessen and Mirsky 
(2005) and Dupin et al. (2007). 
 
Key important findings on the research of the Schwann cell development include: 
 Schwann cell development occurs through a series of transitional embryonic and 
postnatal phases.  
During early embryonic development, neural crest cells (NCC) give rise to Schwann 
cell precursors (SCP) and then these generate the immature Schwann cells (ISC). At 
birth, either the immature Schwann cells differentiate into the myelinating or the 
non-myelinating mature Schwann cells (MSC) in the peripheral nerves. A complex 
network of extra and intra cellular signalling pathways regulates this process. Studies in 
Main cells type derived from neural crest cells
Neurons 
Peripheral nervous system (PNS); sensory, 
sympathetic, and enteric ganglia.
Glial cells
PNS satellite glial cells and Schwann cells of 
peripheral nerves.
Pigment cells (skin melanocytes)
Endocrine cells
Mesenchymal cells in head and neck
Neuroectoderm
Neural fold
Neural plate
Neural crest cells
Neural tube
Notochord
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vitro and in vivo with rat and mouse models showed that at least two signals, 
neuroregulin-1 and endothelin, regulate the survival and differentiation of Schwann 
cells. Similarly, three transcription factors Sox-10, Oct-6 and Krox-20 appear to play 
key roles in the formation of the Schwann cell lineage. Krox-20 is also the major target 
of the signals that induce myelin differentiation (Jessen and Mirsky, 2002).  
 Each individual stage of Schwann cell development (NCC, SCP, ISC and MSC) is 
clearly recognized by a range of phenotypic features including molecular markers, 
signalling responses and relationships to other cells and tissues.  
For instance, Schwann cell precursors can be distinguished from neural crest cells by 
expression of brain fatty acid-binding protein (BFABP), protein zero (P0) and Cadherin 
-19. Differentiation of Schwann cell precursors to immature Schwann cells results in 
upregulation of markers such as GFAP and S100β as well as downregulation of other 
markers such as Cadherin-19 (Jessen and Mirsky, 2005). Additionally, it is likely that 
axonal signals control the differentiation of Schwann cell precursors into immature 
Schwann cells (Woodhoo and Sommer, 2008). The molecular phenotype of both 
immature and non-myelinating Schwann cells are relatively similar (Jessen and Mirsky, 
2005). In contrast, the generation of myelinating Schwann cells involves more profound 
changes. Most of the antigens associated with immature Schwann cells are 
downregulated and there is an upregulation of a number of genes associated with 
control of myelination and formation of the myelination sheath (Jessen and Mirsky, 
2005).  
 The extracellular matrix (ECM) plays a critical role in controlling Schwann cell 
development (Bunge et al., 1986, Chernousov et al., 2008).  
Various studies showed that the basal lamina that surrounds the Schwann cell-axon unit 
is crucial for Schwann cell differentiation and myelination. The interaction occurs 
through specific receptors on the surface of the Schwann cell. The best characterized 
receptors are the integrin receptors (Fernandez-Valle et al., 1994). Distroglycan and 
proteoglycans can also mediate Schwann cell-ECM interactions (Nodari et al., 2008). 
Proteins in the basal lamina that interact with these receptors include laminin and 
various types of collagen (Chernousov et al., 2006, Sherman and Brophy, 2005). Other 
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studies suggested that it is the specific interactions between the receptors and the ECM- 
proteins that is critical for myelination and not the assembly of the basal lamina 
(Podratz et al., 2001).  
 Schwann cells are remarkably plastic and play an active role during nerve repair 
after injury.  
Mature Schwann cells can both form and maintain the myelin sheath around axons and 
rapidly dedifferentiate following injury. During myelination, Schwann cells escape from 
the cell cycle and developmental death signalling and upregulate myelin proteins 
(Parkinson et al., 2004). After injury, myelin proteins are downregulated and Schwann 
cells regain the potential to proliferate. These cells then re-differentiate and re-myelinate 
regenerated axons as a part of the repair process. A process of cross-inhibition between 
positive and active negative regulators controls the myelination and dedifferentiation 
stages. Recent studies by Mirsky et al. (2008) and Parkinson et al. (2008) have 
contributed to the understanding of these sophisticated mechanisms. During 
differentiation, immature Schwann cells receive axonal signals including neuregulin 1 
(NRG) which upregulates the expression of transcription factors including NFκB, Oct-
6, and Brn2. These transcription factors promote the promyelinating stage. Further 
upregulation of the transcription factor Krox-20 induces Schwann cells to express 
myelin-specific proteins and form the myelin sheath. Upon nerve injury, unknown 
signals induce a rapid upregulation of the transcription factors c-Jun and Sox-2. The 
former contributes to the downregulation of Krox-20 and the dedifferentiation of 
Schwann cells.  
An important aspect of this process is that Schwann cells (but not precursors) can 
ensure their own survival in an autocrine way by secreting survival factors. Components 
of this circuit include insulin-like growth factor, neurotrophin-3, and platelet-derived 
growth factor-BB. This mechanism is important in maintaining the survival of Schwann 
cells in injured nerves even after axons have degenerated. Thus, Schwann cells can 
provide the essential support for axon regrowth (Meier et al., 1999).  
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 Schwann cells may modulate local immune responses within the PNS.  
Schwann cells can interact with the immune system by recognizing and presenting 
antigens, and may influence and terminate nerve inflammation by secreting cytokines 
(reviewed in Meyer zu Horste et al., 2008).  
1.3.3 The myelin sheath 
The myelin sheath also called myelin is required for rapid transduction of nerve 
impulses and the normal functioning of the nervous system. The membrane of the 
Schwann cells (and oligodendrocytes in the CNS) wraps around the axon and forms this 
highly specialised cellular structure. The myelin is a lipid-rich multilayered membrane 
and includes a number of structural proteins many of which are only expressed by 
myelination cells. 20% to 25% of the PNS myelin consists of proteins, mainly myelin 
protein zero (MPZ). Other proteins include the myelin-associate glycoprotein (MAG), 
peripheral myelin protein 22 (PMP22), myelin basic protein (MBP), 2’,3’-cyclic 
nucleotide 3’-phosphohydrolase (CNP), connexins (gap junction proteins), periaxin 
(PRX) and protein S100. Myelin also contains 70-80% lipid, including GalC, 
gangliosides and cholesterol (Kursula, 2008, Svaren and Meijer, 2008). Damages to the 
myelin sheath produced by disease and lesions can induce serious neurological 
conditions such as multiple sclerosis (Tzakos et al., 2005). Genetic defects in the myelin 
proteins can also produce inherited peripheral myelinopathies. For instance, mutations 
in the PMP22, MPZ and periaxin genes cause one of the most common neuropathies, 
Charcot-Marie-Tooth disease (Hoyer et al., 2011, Taioli et al., 2011, Williams and 
Brophy, 2002).  
1.3.4 Tumours of Schwann cell origin 
Tumours of the PNS have been described in humans, dogs, cattle and other animals 
(Bundza et al., 1986, Chijiwa et al., 2004, Nielsen et al., 2007, Schoniger and Summers, 
2009, Schulman et al., 2009). In humans, the benign neurofibroma and schwannoma are 
the two most common peripheral nerve sheath tumours (PNST). Malignant tumours 
include the malignant peripheral nerve sheath tumours (MPNST) which mostly derive 
from pre-existing benign neurofibromas. Less frequently, MPNST can arise in 
peripheral nerves without histological evidence of benign lesions. PNST may arise from 
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different type of cells including Schwann cells, perineurial cells, fibroblasts, and other 
cells comprising the nerve sheaths, however, evidence indicates that most neoplasms, 
benign and malignant, are in fact derived from Schwann cells (Carroll and Ratner, 2008, 
Dundr et al., 2009, Gupta et al., 2008, Zhu and Parada, 2002).  
PNST can occur sporadically but the majority arise in individuals affected with 
neurofibromatosis type 1 (NF1) and type 2 (NF2). NF1 and NF2 are autosomal 
dominant tumour-suppressor gene syndromes in which affected individuals are 
predisposed to develop multiple tumours. Neurofibromas are the characteristic tumours 
developed in individuals affected with NF1. Some neurofibromas may undergo 
malignant transformation to MPNST, which are high-grade malignant tumours with 
patients having an average rate of survival of 5 years. NF2 affects approximately 1 in 
35,000 individuals and patients often develop multiple schwannomas as well as a 
variety of clinical lesions (Ferner, 2010, Stemmer-Rachamimov et al., 2004).  
Most of the information into the initiation and progression of PNST tumours comes 
from studies in transgenic and knockout mouse models. Evidence provided by these 
models indicates that loss of NF1 or NF2 functionality in the Schwann cell lineage is 
sufficient to generate tumours. The loss of NF function also initiates a cascade of 
interactions with other cell types in the microenvironment and additional autonomous 
modifications which are also needed for tumour development and progression (Carroll 
and Ratner, 2008, Le et al., 2011, Zheng et al., 2008, Zhu et al., 2002).  
PNST nerves are histologically diverse and diagnosis still remains a challenge mainly 
due to the lack of specific immunohistochemical markers of neural differentiation 
(Sandberg, 2008). Although labelling for S100 protein shows some non-specific 
activity, it is the most commonly used marker to identify PNST of various types 
(Coindre, 2003, Wu and Montgomery, 2008). Other markers normally tested in PNST 
with different levels of reliability include MBP, NGFR, nestin and the neural crest 
transcription factor Sox 10 (Chijiwa et al., 2004, Hoshi et al., 1994, Nonaka et al., 
2008, Shimada et al., 2007, Stasik and Tawfik, 2006). Therefore, diagnosis and 
classification of PNST requires correlation of IHC features with clinical and surgical 
data and in some cases electron microscopy.  
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1.4 The immune response to cancer 
The immune response to cancer has been recognised for more than one hundred years 
and there is enormous research elucidating the molecular and cellular interactions 
between the tumour and the host immune system. The complexity of these interactions 
is so vast that there is still not consensus on the principles that explain why tumours 
develop and escape under the scrutiny of the immune system. A detailed review of our 
current knowledge of the immune response to cancer would be too long. Instead, I will 
focus on presenting the basic concepts that will contribute to the understanding of the 
more general cancer cell-immune system interactions. Another reason for this general 
review relates to the fact that our knowledge of the composition and function of the 
immune system of the Tasmanian devil is still limited. While the research in humans 
and other animal models is focusing on revealing the role of specific molecules, cell 
compartments and biochemical pathways, in the devil we are still trying to identify the 
main elements. Advances in devil research have been hindered by the lack of cross-
reacting reagents. For instance, it is possible to identify T cells and B cells (Kreiss, 
2009), but we still do not know the composition of the cell subpopulations. It is not yet 
possible to identify and characterise the cell types that play an important role such as 
natural killer cell, dendritic cells, regulatory T cells and macrophages. In practice, we 
are revisiting the elementary principles in an effort to understand the tumour-immune 
system interaction in the DFTD model.  
1.4.1 Carcinogenesis and the cancer cell  
Bubanovic and Najman (2005), specialists in comparative oncology and tumour 
immunology, defined tumour growth as a fundamental disorder in the regulation of cell 
division, growth, differentiation and cell socialization. In all vertebrates, neoplasia is a 
disease in which genetically altered cells escape from the normal cell cycle regulation 
and monitoring of the immune system. This results in a persistent, expanding or 
infiltrating growth without control of the architecture of the normal tissue. 
It is generally accepted that one of the primary steps leading towards carcinogenesis in 
all vertebrates is the destabilization of the genome and loss of cell’s ability to repair 
DNA damage. This is the consequence of series of mutations or translocations, and 
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comes largely as a result of the influence of chemical agents, viral infections, radiation 
and chronic inflammation (Bubanovic and Najman, 2005).  
Tumours are transformations of normal cells in which growth control has become 
deregulated. As mentioned above, the molecular hallmark of carcinogenesis is genetic 
instability. This instability allows normal cells to evolve progressively to a neoplastic 
state and acquire the traits that enable them to become tumourigenic and malignant. 
Hanahan and Weinberg (2000) defined six principal biological capabilities (hallmarks) 
that cancer cells acquire during the development of tumours. These include sustaining 
proliferative signalling, evading growth suppressors, resisting cell death, enabling 
replicative immortality, inducing angiogenesis, and activating invasion and metastasis 
Recently, due to the advances in the understanding of the tumourigenesis process, two 
more hallmarks were added: reprogramming of energy metabolism and evading immune 
destruction (Hanahan and Weinberg, 2011). The authors also highlight the importance 
of the microenvironment in the development of tumours. They proposed tumours as a 
complex tissue composed of multiple cell types that interact with one another in an 
active way. The stromal cells, including fibroblasts, mesenchymal, endothelial and 
inflammatory cells, contribute to the development and expression of some of the cancer 
hallmarks. Table 1.1 presents a brief summary of these cancer traits and the underlying 
mechanisms.  
1.4.2 The host defences against cancer 
An important aspect deducted from the hallmarks of cancer presented in the previous 
section is the existence of multiple regulatory mechanisms (intra and extracellular) that 
prevent the emergence of cancer cells.  
In this sense, the first line of defence from malignant cell alteration includes the 
mechanisms controlling cell cycle and DNA stability. A variety of intrinsic tumour-
suppressor mechanisms including p53, sense the activity of oncogenes and initiate the 
programmed cell death machinery (apoptosis) or senescence. Similarly, cellular stress, 
injury, or lack of survival signals and alterations in mitochondria integrity trigger 
apoptosis. Cell-surface death receptors, such as tumour necrosis factor receptor (TNFR), 
can also activate cell death pathways (Vesely et al., 2011). As seen in Table 1.1, 
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alternative cell death pathways such as necrosis and autophagy may also intervene in 
the transformation process. In summary, both senescence and apoptosis prevent the 
acquired capacity of cells to proliferate without environmental control and act as a 
barrier to the further development of neoplastic cells. 
 
Table 1.1 The hallmarks of cancer. Capabilities of the cancer cells acquired during the development of 
tumours.  
Cancer hallmark* Mechanisms 
Sustaining proliferative signalling Chronic proliferation by deregulating the signals that 
control cell cycle and cell growth 
Evading growth suppressors 
Inactivation/circumvention of pathways controlled by 
tumour suppressors genes such as RB (retinoblastoma-
associated) and p53  
Abolishing the mechanisms of cell-to-cell contact 
inhibition 
Evasion of the anti-proliferative effects of TGF-β 
Resisting cell death 
Evasion or limited apoptosis by damage of suppressor 
sensors such as p53 or increasing the expression of anti-
apoptotic regulators 
Deregulation of the process of autophagy 
Necrosis having the potential of being pro-inflammatory 
and tumour promoting 
Enabling replicative immortality Protecting the telomeres at the ends of the chromosomes 
which provides capability for unlimited proliferation  
Inducing angiogenesis Permanently activating and controlling the angiogenesis 
signalling  
Activating invasion and metastasis Developing alterations in the cell shape and the 
attachment to other cells and the extracellular matrix 
Reprogramming of energy metabolism Adjustment of energy metabolism in order to fuel cell 
growth and division 
Evading immune destruction Evasion of antitumor mechanisms** 
* Reviewed in (Hanahan and Weinberg, 2000, Hanahan and Weinberg, 2011). ** These mechanisms are 
further described in the next section. 
 
Extrinsic tumour-suppressor mechanisms include those that prevent cancer cells from 
invading and spreading to other tissues (Vesely et al., 2011). One of these mechanisms 
involves adhesion molecules such as integrins, which are proteins that facilitate the 
anchorage of cells to other cells or the extracellular matrix (ECM). These molecules 
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also mediate cytosolic events that influence cell proliferation, survival and motility and 
therefore can control processes such as angiogenesis, tumour growth and metastases 
(Stupack, 2007).  
Another extrinsic factor involves the immune mechanisms that limit the transformation 
or tumour growth. Swann (2007), proposed three primary roles of the immune system in 
the prevention of cancer. First, it can protect the host from virus-induced tumours by 
controlling viral infections. Second, the prompt elimination of pathogens aids in the 
resolution of inflammation that could favour tumourigenesis. Finally, the immune 
system can specifically identify and eliminate tumour cells based on the expression of 
tumour-associated antigens (TAAs). The immune system identifies transformed cells 
that have escaped cell-intrinsic tumour-suppressor mechanisms and eliminates them 
before they can establish malignancy. This process is referred as immune surveillance 
and will be discussed in more detail in the following section.  
The concept of immunosurveillance 
In the late 1950s, Burnet and Thomas formulated the hypothesis that the immune 
system can recognise and destroy nascent transformed cells (Burnet, 1957a, Burnet, 
1957b). The theory proposed that mutated tumour cells have distinctive structures 
(tumour specific antigens) that can be recognised by cells of the immune system. The 
concept was supported by the rejection of transplanted tumours induced by chemical 
carcinogens or virus in syngeneic mice. Thus, the immune surveillance suggested that 
lymphocytes act as sentinels recognising and eliminating continuously arising, nascent 
transformed cells (Burnet, 1970).  
Following its introduction, the cancer immunosurveillance concept was highly debated 
and challenged (reviewed in Dunn et al., 2002). Initial studies in mice with induced 
immunodeficiencies showed inconsistent results in relation to the susceptibility of these 
mice to spontaneous or chemically induced tumours (Stutman, 1975). Furthermore, 
studies with athymic nude mice in the 1970s showed no statistical differences in the 
incidence of chemically induced tumours in the nude mice compared to the wild type 
(Stutman, 1979).  
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In the 1990’s, studies with inbred mouse lines that carried targeted mutations affecting 
specific components of the immune system contributed to the renaissance of the cancer 
immunosurveillance theory. Not only did these studies support the importance of the 
immune system to control tumour formation but also suggested the involvement of both 
the innate and adaptive immune systems. Functional removal of NKT cells, αβ and γδ T 
cells, NK cells, IFN-γ or interleukin 12 (IL-12) all led to increased susceptibility of the 
host to tumours. Vesely et al. (2011) presented a comprehensive compilation and review 
of these studies. 
The cancer immunoediting concept 
The immunosurveillance concept proposed that the immune system plays a vital role in 
the development of tumours. The theory, however, does not explain why tumours still 
develop in individuals with a functional immune system. Studies from the last decade 
suggest that immunosurveillance only represents one dimension of the complex 
relationship between the immune system and cancer (Dunn et al., 2004a). An important 
study by Shankaran et al. (2001) reported that immune deficient mice lacking either 
lymphocytes or IFN-γ functionality, developed more spontaneous neoplasms and were 
more susceptible to carcinogen-induced tumours compare to wild type mice. In 
addition, transplantation experiments showed that tumours formed in the absence of an 
intact immune system are more immunogenic than tumours developed in 
immunocompetent hosts. These results showed that the immune system functions as an 
effective extrinsic tumour-suppressor system but also leads to the immunoselection of 
tumour cells. 
Dunn et al. (2002), proposed the new term “cancer immunoediting” to describe the dual 
host-protective and tumour-sculpting actions of the immunity in developing tumours. 
The tumour immunoediting concept, known as the “three Es model” involves three 
phases. The following description of the three phases was extracted from the reviews by 
Dunn et al. (2004b), Schreiber et al. (2011) and Swann and Smyth (2007).  
Elimination. This phase is an update of the process described in the initial theory of 
tumour immunosurveillance. The innate and adaptive immune systems work together to 
detect and eliminate tumour cells that are developing because the intrinsic tumour 
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suppressor mechanisms failed. The immune system detects “danger signals” such a 
Type I IFN that activates dendritic cells and promote the induction of adaptive anti-
tumour immune responses. Other signals include damage-associated molecular pattern 
molecules (DAMP) because they are released directly from dying tumour cells or from 
damage tissues. A third potential mechanism may involve stress ligands that are 
frequently expressed on the surface of tumour cells. These include RAE-1 and H60 in 
mice or MICA/B in humans. These ligands bind to activating receptors on innate 
immune cells, leading to the release of pro-inflammatory and immunomodulatory 
cytokines that facilitates the development of a tumour-specific adaptive immune 
response. In most systems, effective responses require the additional expression of 
tumour antigens capable of propagating the expansion of effector CD4+ and CD8+ T 
cells. If all tumour cells are cleared the elimination phase represents the endpoint of the 
cancer immunoediting process. 
Equilibrium. Rare tumour cell variants may survive the elimination phase and enter the 
equilibrium phase. In this phase, the adaptive immune system prevents tumour cell 
outgrowth and sculpts the immunogenicity of the tumour cells. The equilibrium could 
extend through the life of the host and it may represent a second stable endpoint of 
cancer immunoediting. Equilibrium represents a type of tumour dormancy specifically 
controlled by the immune system. During this period, the tumour cells could also 
continue to evolve and accumulate further changes such as DNA mutations or changes 
in gene expression. As this process continues, the immune system applies a selective 
pressure by eliminating susceptible tumours. Studies with mouse models showed that 
only the adaptive immunity, specifically interleukin-12 (IL12), INF-γ, CD4+ and CD8+ 
T cells, are responsible for maintaining the tumour cells in equilibrium (Koebel et al., 
2007).  
Escape. If the immune system fails to eliminate the tumour, the process results in the 
selection of tumour cell variants that are able to resist, avoid, or suppress the anti-
tumour immune response, leading to the escape phase. The immune system is no longer 
able to contain tumour growth and tumour cells emerge as visible tumours. Progression 
from equilibrium to the escape phase can occur because: i, the tumour cell populations 
change in response to the immune system’s editing functions; ii, the host immune 
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system changes in response to increased tumour-induced immunosuppression or iii, 
immune system deterioration.  
Recent studies in mice with broad immunodeficiency or specific antigenic tolerance 
showed that that recognition of tumour-specific antigens by lymphocytes is critical for 
immunoediting against sarcomas (Dupage et al., 2012). The study also found that 
primary sarcomas were edited to become less immunogenic through the selective 
outgrowth of cells that were able to escape T lymphocyte attack. Thus, loss of tumour 
antigen expression or presentation on major histocompatibility complex I was necessary 
and sufficient for this immunoediting process to occur. Section 1.5 discusses the 
immune escape mechanisms in more detail. 
The theory of tumour immune complexity 
Supporters of the cancer immunoediting concept acknowledge that immunosurveillance 
is a heterogeneous process requiring the actions of different immune effectors in a 
manner that is dependent on the tumour’s cell type of origin, mechanisms of 
transformation, anatomical localization and mechanisms of immunologic recognition 
(Dunn et al., 2002). This heterogeneity somehow explains the subtle differences on the 
results of the many independent groups that support the role of the immune system in 
the protection against cancer.  
However, results from a recent study have challenged again this concept. Ciampricotti 
et at. (2011) investigated the functional role of the adaptive immune system as a 
regulator of spontaneous HER2+ breast tumour genes and pulmonary metastasis 
formation using a  mouse mammary tumour virus (MMTV)-NeuT mouse model. In this 
model, mammary carcinogenesis is induced by transgenic expression of the activated 
HER2/neu oncogene driven by the MMTV promotor. To investigate the modulatory 
role of the adaptive immune system, MMTV-NeuT mice were intercrossed with 
recombination-activating gene-2 homozygous null (Rag-2-/-) mice which are deficient 
for mature T and B lymphocytes. They found that the absence of the adaptive immune 
system did not modified tumour progression. Similarly, the phenotype, behaviour 
(growth, multiplicity, and immunogenicity) and inflammatory microenvironment of 
primary breast tumours arising in the immune deficient mice were identical to those in 
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the immune proficient mice. Additionally, they demonstrated that pulmonary metastasis 
formation is not dependent on the adaptive system. Therefore, they suggested that 
spontaneous tumourigenesis and metastasis formation of HER2+ breast cancer are not 
suppressed by the immunosurveillance mechanisms or promoted by the adaptive 
immune system.  
Manjili (2011) has proposed a new model to explain the conflicting results that question 
the role of the immune system in the development of tumours. Manjili considers that the 
contradictory results imply the existence of different pathways, which may be 
complementary rather than conflicting. Thus, the model proposes that the tumour cells 
and the immune system interact in a complex network that is not simply “a one-way 
road”. The different interactions between tumour cells and the immune system relates to 
the heterogeneous nature of tumours and their genetic instability. According to the 
model, dangerous clones of tumours elicit an immune response and may trigger tumour 
immunosurveillance and immunoediting mechanisms. Non-dangerous clones fail to 
elicit a response and may induce immune tolerance. The new extended model proposes 
10 possible pathways used by the tumour cells to survive under the monitoring of the 
immune system. 
1.5 Mechanism of immune evasion in cancer 
Tumour cell escape can occur through many different mechanisms and involve the 
tumour, the tumour microenvironment and various components of the innate and 
adaptive immune systems. This section will focus on the mechanisms at the tumour 
level, as these are particularly relevant for the present research.  
1.5.1 Generating an immunosuppressive tumour microenvironment 
Cancer cells can develop an immunosuppressive state within the tumour 
microenvironment by various mechanisms: 
 Producing immunosuppressive cytokines such as vascular endothelial growth factor 
(VEGF), transforming growth factor-β (TGF-β), galectin, indoleamine 2,3-
dioxygenase (IDO) or interleukin-10 (IL10) (Zou, 2005). These factors are released 
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after activation of Stat3 and Braf signalling and can induce inhibition of both the 
innate and adaptive anti-tumour immunity (Drake et al., 2006). 
 Recruiting regulatory immune cells that function as the effectors of 
immunosuppression. Regulatory T cells (Treg cells) and myeloid-derived suppressor 
cells (MDSC) are two major types of immunosuppressive leukocyte populations that 
play key roles in inhibiting host-protective antitumour responses. Treg cells are CD4
+ 
that express CD25 and the transcription factor Foxp3. When stimulated they inhibit 
the function of tumour specific T lymphocytes by producing the immunosuppressive 
cytokines IL-10 and TGF-β. Treg cells also express the negative co-stimulatory 
molecules CTLA-4, PD-1 and PD-L1. They also consume IL-2, a cytokine that is 
critical for maintaining CTL function. MDSC are a heterogeneous group of myeloid 
progenitor cells. These cells produce TGF-β that induce Treg cells which inhibit 
lymphocyte function. MDC cells can sequestrate or deplete the amino acids 
arginine, tryptophan, or cysteine, which are required for T cell function. MDC cells 
can also block T cell receptors or chemokine receptors on tumour-specific T cells 
(Drake et al., 2006, Zou, 2005). 
1.5.2 Tumour cell modifications to evade immune detection and destruction 
At the cellular level, tumour outgrowth is promoted by alterations that reduce immune 
recognition or increase resistance to the cytotoxic effects of immune cells. These 
alterations are produced by the combination of the genetic instability of the tumour cells 
and the process of immune selection. The result is the generation via a “Darwinian 
selection process” of poorly immune-genetic cell variants that become invisible to the 
immune system and acquire the capacity to grow progressively (Schreiber et al., 2011).  
Tumour cells can become resistant to cytotoxic effects through the induction of anti-
apoptotic mechanisms. However, the reduction of the tumour immunogenicity is 
perhaps one of the most common and best-studied mechanisms of tumour evasion. The 
section below describes the roles of the MHC in the processes of antigen presentation 
and transplantation. This will follow by the presentation of the mechanisms by which 
tumours reduce immunogenicity.  
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Major histocompatibility complex (MHC) and antigen presentation  
Major histocompatibility complex (MHC) molecules are the foundations of the self and 
non-self discrimination in vertebrates. The name of these highly polymorphic proteins 
relates to their function as being the major barrier for allogeneic transplantation 
(Kumanovics et al., 2003). The MHC loci are grouped into three classes of genes called 
Class I (MHC-I), Class II (MHC-II) and Class III (MHC-III). The three classes are 
distinguished based on both structure and function of their encoded proteins. MHC-I 
molecules are expressed in virtually all cells and present cytosol-derived peptides to CD8+ 
T cells. MHC-I molecules are also important for the immune regulatory activity of NK cells 
(Ljunggren and Karre, 1990). MHC-II molecules are expressed in antigen-presenting cells 
such as dendritic cells and typically present exogenous derived peptides to CD4+ T cells. 
The MHC-III genes encode a variety of immune and non-immune system related molecules, 
most of which are not involved in antigen presentation, and include cytokines and 
components of the complement system (Belov et al., 2006). 
MHC-I molecules are heterotrimers consisting of a 45-kDa glycosylated transmembrane 
heavy chain, a soluble 12 kDa subunit beta-2 microglobulin (B2M) and an 8-10 residue 
peptide ligand (Germain and Margulies, 1993). In humans, the heavy chain is encoded by 
genes located within the MHC region in chromosome 6, whereas B2M is encoded in 
chromosome 17. MHC-I can divided into classical and non-classical molecules. The 
classical class I molecules are expressed on the surface of most mammalian cells with only 
few exceptions. Most glandular or squamous epithelia, as the surrounding connective tissue, 
express MHC-I antigens. However, the intensity of expression varies between different 
locations. For instance, skeletal, smooth muscle, gastric mucosa and the central and 
peripheral nervous system are weakly positive. The non-classical MHC-I have a much more 
limited degree of polymorphism and a more restricted tissue distribution and often perform 
other functions than antigen presentation (Garcia-Lora et al., 2003). 
MHC-I molecules bind peptide fragments of intracellular proteins and display them at the 
cell surface where they function to report the presence of virus or tumours to CD8+ cells. 
These antigens peptides are generated from degraded endogenous proteins (tumour-
associated antigens TAAs in the case of tumour cells) by the antigen presenting machinery. 
This process is known as antigen processing and requires four major steps: i, the generation 
of antigenic peptides by a large multicatalytic protease complex called proteasome and 
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other cytosolic proteases. ii, the transport of these peptides from the cytosol into the lumen 
of the endoplasmic reticulum (ER) by the transporter associated with antigen processing-1 
and -2 (TAP1 and TAP2). iii, the assembly of the peptides with MHC-I molecules. This 
depends on the association of the MHC-I heavy chain, first with B2M, and then with the 
peptide. The process involves components of the general glycoprotein quality control and 
MHC-I specific components including the chaperone tapasin (Zhang and Williams, 2006). 
iv. the exit of the tri-molecular complex (MHC-I heavy chain, B2M and peptide) from the 
ER through the Golgi secretory pathway and display on the cell surface for presentation to 
CD8+ T cells (Solheim, 1999). The binding of high affinity peptide is crucial for the release 
and efficient transport of class I molecules from the ER – Golgi compartments and for class 
I stability on the cell surface at the physiological temperature (Donaldson and Williams, 
2009). Any defect of these processes will lead to non-expression of MHC-I molecules on 
the cell surface (Garcia-Lora et al., 2003). 
The interaction of cells displaying MHC-I with the T cell receptor (TCR) on CD8+ T cells 
triggers a cascade of T signalling events that ultimately lead to cell proliferation, cytokine 
production and lysis of the target cell. MHC-I antigens also regulate the lytic activity of NK 
cells which is related to their ability to kill target cells lacking MHC-I expression. Although 
NK cells do not express the TCR, the detection of targets by NK cells is mediated by two 
major families of receptor molecules belonging to the killer immunoglobulin-like receptor 
and to the C-type lectin superfamily (Garcia-Lora et al., 2003). 
Role of the major histocompatibility complex in transplantation  
As mentioned before, MHC molecules are the foundations of the self and non-self 
discrimination in vertebrates and therefore are mainly responsible for graft rejection. T cells 
constitute the principal effector arm of allorecognition in vivo and in vitro (in mixed 
lymphocyte reactions). In contrast to the low frequency of T cells that recognise 
conventional antigens, as many as 10% of T cells respond to an alloantigen (Sherman and 
Chattopadhyay, 1993). The donor MHC antigens present in the allogeneic tissue are the 
main targets of the cellular immune response against the allograft. The recognition of 
mismatched donor histocompatibility antigens is the primary event that ultimately leads to 
allograft rejection (Sherman and Chattopadhyay, 1993).  
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Allorecognition occurs through two unique but not mutually exclusive pathways called 
direct and indirect pathways of antigen presentation. The direct pathway results from the 
recognition of intact foreign major histocompatibility molecules on the surface of donor 
cells. Indirect allorecognition occurs in the normal way by which the immune system 
normally recognises antigens. Donor histocompatibility molecules are internalised, 
processed, and presented as peptides by host antigen presenting cells (APC) (Game and 
Lechler, 2002). Both CD4+ (which recognise donor MHC-II) and CD8+ T cells (which 
recognise donor MHC-I) can mediate direct and indirect allorecognition (Bharat and 
Mohanakumar, 2007). 
Additionally to MHC antigens, minor histocompatibility antigens can also activate the 
immune system against the allograft. These antigens are coded by non-MHC genes and are 
able of binding to both MHC-I and MHC-II molecules. In this way, these molecules can 
induce CD4+ and CD8+ T cell responses. Minor histocompatibility antigens generally relate 
to a polymorphism of any protein between donor and recipient. These proteins can be 
processed and presented on self MHC and potentially elicit graft rejection (Ingulli, 2010).  
In addition to antigen recognition, the inflammation and stress produced by the organ 
transplantation can activate the recipient immune response. Studies in mice models showed 
that induction of several neutrophil and macrophage chemo-attractants were required for 
optimal recruitment of T cells into the graft (Morita et al., 2001). Similarly, Bharat et al., 
(2007) demonstrated that the early release of cytokines plays a crucial role in the 
development of alloimmunity and human lung allograft rejection. 
In summary, the rejection of allografts is the result of complex coordination between both 
the innate and adaptive immune system. T cells are central to the process as they are able to 
recognise donor derived antigens presented by MHC molecules. Once the T cells become 
activated, they undergo clonal expansion and differentiation into effector cells. Then these 
cells migrate into the graft where they promote tissue destruction. In addition, help B cells 
produce alloantibodies increasing the response (Ingulli, 2010).  
Expression of MHC-I in the nervous system 
The ability of cells within the CNS and PNS to express MHC-I molecules has been debated 
for many years. Contributing to this debate is the widely accepted concept that the brain is 
an immunologically privileged organ and therefore it was considered that neurons would 
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not express MHC-I genes. However, research is producing evidence that neurons in the 
CNS and the Schwann cells in the PNS express MHC-I molecules.  
Different studies have provided strong evidence that neurons and Schwann cells increase 
the levels MHC-I under special conditions or treatments. For instance, neurons express high 
levels of MHC-I protein after axotomy  (Maehlen et al., 1988), nerve injury (Cullheim and 
Thams, 2010), viral infection (Chevalier et al., 2011, Redwine et al., 2001)  and exposure to 
cytokines (Fujimaki et al., 1996, Neumann et al., 1997). Similarly, Schwann cells express 
MHC-I molecules under pro-inflammatory conditions (Armati et al., 1990, Lilje and 
Armati, 1997) and in neuropathies such as the Guillain–Barré syndrome (GBS) (Wanschitz 
et al., 2003).  
Under normal conditions the in vivo expression of MHC-I protein in the nervous system is 
still controversial. Boulanger et al. (2004) argued that the inconsistences in the detection of 
MHC-I expression in neurons of the CNS could be due to technical issues. These include 
the lack of specific antibodies for use in fixed tissues compared to flow cytometry analyses 
performed in live cells, lack of antibodies cross-reacting to the whole population of MHC-I 
molecules, and biological factors including the development stage and subset of neurons 
analysed. Despite the controversial nature of the data in this area, there is still a consensus 
that MHC-I expression in neurons is low compared with the levels observed in other tissues 
such as spleen (Corriveau et al., 1998) and the endothelial cells that line CNS blood vessels 
(Boulanger and Shatz, 2004). Like the CNS, many reports of in vivo MHC-I expression in 
Schwann cells relate to neuropathies and exposure to cytokines (Lilje and Armati, 1997). 
The data under normal conditions is more complex. Flow cytometry studies of mouse 
Schwann cells showed that the cells express MHC-I at basal conditions (Meyer zu Horste et 
al., 2010), while immunohistochemistry studies did not found expression in myelin sheaths 
compared to blood vessels and endoneurial macrophages (Wanschitz et al., 2003). Thus, the 
presence and changes of MHC-I expression in the peripheral nerve system is not completely 
understood.  
 Loss of tumour antigenicity 
Changes in the expression and/or function of the MHC-I antigens is one of the best 
documented mechanisms of tumour immune evasion in human cancers. MHC-I alterations 
occur through different mechanisms that include downregulation or total loss of MHC-I 
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molecules or other molecules of the antigen processing machinery (Seliger et al., 2002). 
These defects contribute to the immune evasion via resistance of tumour cells to killing by 
activated immune cells (Dunn et al., 2002). Studies revealed that 63% of melanoma, 88% of 
breast carcinoma, 77% of laryngeal, 74% of colorectal, 82% of prostate, and 77% of 
bladder tumours have various types of abnormal MHC-I expression (reviewed in Aptsiauri 
et al., 2007).  
The molecular mechanisms leading to alteration in MHC-I expression are not well 
understood and can occur at any step required for MHC-I synthesis, assembly, transport or 
expression at the cell surface (Mendez et al., 2008). Additionally, these defects can occur at 
the genetic, epigenetic, transcriptional and post-transcriptional levels. Garrido et al. (2010), 
classified the MHC alterations into two main groups: reversible defects (regulatory or 
“soft”) including those abnormalities that can be recovered with cytokine treatment, and 
irreversible defects (structural or “hard”) including the structural abnormalities that cannot 
be reversed (Table 1.2). Both reversible and irreversible structural defects have been 
described in tumour cell lines, animal models and in primary tumours and metastases 
obtained from cancer patients (Garrido et al., 2010).  
The understanding of the processes of loss of tumour immunogenicity has been useful for 
the evaluation of immune-therapeutic approaches into the clinic and a number of strategies 
are investigated in clinical trials. For instance, studies have shown that by silencing HER2, 
an oncogene normally expressed in breast and other cancers, tumour cell lines increased the 
expression of MHC-I molecules (Choudhury et al., 2004). Additionally, experimental 
models have shown that HER2 vaccines can induce tumour protection in vivo (Scardino et 
al., 2007). The general assumption of these studies is that vaccination methods that enhance 
the avidity of MHC-I restricted T cells can overcome the relatively poor antigen 
presentation in tumours (Ladjemi et al., 2010).  
The interaction between the tumour cells and the immune cells is a highly complex system. 
This is reflected in the variability of the responses on cancer patients to immunotherapy. 
There is a unanimous call to incorporate a more holistic approach for the development of 
immune therapies. Approaches should consider the molecular make-up of the tumour as 
well as the tumour microenvironment. The aim is to combine tumour therapies that trigger a 
multifaceted immune response involving humoral, cellular and innate immunity (Garrido et 
al., 2010, Poschke et al., 2011, Zou, 2005).  
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Table 1.2 Molecular defects leading to MHC-I altered expression in tumours.  
Irreversible structural defects 
MHC gene 
Loss of heterozygosity (haplotype loss) 
Mutations of MHC-I heavy chain (allelic loss) 
B2M gene 
Loss of heterozygosity 
Mutations/deletions 
IFN transduction pathway Blockade of the Jack-STAT pathway 
Reversible regulatory defects 
Transcriptional downregulation 
Coordinated downregulation of heavy chain, β2m 
and APM molecules 
Hypermethylation MHC-I genes 
Oncogene activation (c-myc, HER-2/neu, 
oncogenic adenovirus 12) 
Downregulation of MHC-I and APM genes 
Inhibition of the post-transcriptional processing of 
MHC-I mRNA 
APM: antigen processing machinery (adapted from Garrido et al., 2010). 
 
1.6 Tumour antigens and immunotherapy 
1.6.1 Tumour antigens 
Section 1.4 introduced the concepts of immune surveillance and cancer immunoediting. 
Evidence for this response is demonstrated in part by the identification of antibodies 
against a number of intracellular and surface antigens detectable in sera from patients 
with different cancer types (Gnjatic et al., 2003, Jager et al., 2000). Molecular studies 
revealed that tumour-associated antigens (TAAs) are the consequence of genetic and 
epigenetic alterations in cancer cells or the products of genes encoding viral proteins 
(Pardoll, 2003, Schreiber et al., 2011). The reason for spontaneous humoral responses in 
cancer patients are not known but may include an overabundance of antigen or its 
immunogenicity in the malignant setting (Vesely et al., 2011). 
MAGE-1 (melanoma antigen) was the first gene reported to code for human tumour 
antigen recognised by autologous T cells (van der Bruggen et al., 1991). Different 
proteomic and immunologic approaches have revealed hundreds of different antigens 
from several human tumours (reviewed in Novellino et al., 2005, Reuschenbach et al., 
2009). Initially, tumour antigens were classified as tumour-specific antigens (TSAs) 
including those antigens expressed only by tumour cells, and tumour-associated 
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antigens (TAAs) including the mutated counterparts of proteins expressed in normal 
cells. The current classification only includes TAAs, which are divided into shared and 
unique TAAs.  
Reuschenbach at al. (2009) performed a systematic literature review of TAAs eliciting 
humoral responses in cancer patients and found more than 100 antigens. The majority of 
these antigens were related to overexpressed or mutated proteins. Most of the antigens 
represented cytoplasmic proteins (42%), 26% were expressed predominantly in the 
nucleus (transcription factors, cell cycle regulators), 21% were membrane bound 
proteins (receptors, cell adhesion proteins) and 10% were extracellular proteins 
(extracellular matrix proteins, secreted proteins). The most frequently analysed antigens 
were p53, MUC1, NY-ESO-1, c-myc, survivin, p62, cyclin B1 and HER-2/neu. 
Antibodies against these antigens were frequently detected in cancer patients, while for 
most of antigens, antibodies were rarely found in healthy individuals. The most 
frequently analysed tumour sites were breast, colorectal, liver and lung.  
 A similar review listed all the available TAAs recognised by T cells (either CD8+ or 
CD4+) (Novellino et al., 2005). These antigens were classified into four different 
groups. The best characterized are shared antigens called cancer-testis (CT) antigens 
because of their expression in different human tumours and, among normal tissues in 
spermatocytes of testis and occasionally placenta. CT antigens result from the 
reactivation of genes that are silent in normal tissues. They include the MAGE, BAGE 
and GAGE gene families. The second group are differentiation antigens shared between 
tumour and normal tissue from which the tumour arose. These TAAs are mostly found 
in melanomas and normal melanocytes and are normally involved in the biosynthesis of 
melanin. The third group include widely occurring and overexpressed TAAs. These 
antigens are present in histologically different types of tumours as well as in many 
normal tissues, generally with low level of expression. It is possible that these 
overexpressed antigens trigger an anti-cancer response by breaking previously 
established tolerance. Among these TAAs are the anti-apoptotic proteins livin and 
survivin, hTERT and the tumour suppressor protein p53. The final group include unique 
TAAs that arise from point mutations of normal genes such as β-Catenin, caspase-8 and 
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CDK-4. Unique TAAs are considered the most specific targets for cancer 
immunotherapy in humans.  
1.6.2 Identification of TAAs 
Immunoproteomics, which defines the subset of proteins involved in the immune 
response, is the most common method to identify humoral responses in cancer patients. 
This method allows the individual screening of sera from a large number of patients. 
Immunoproteomics also permits the determination of relevant autoantigens eliciting 
immune responses and the distinction of isoforms. More importantly, the technique is 
useful for the detection of antibodies against post-translational modifications or specific 
targets (Mou et al., 2009). Desmetz et al. (2009), reviewed the advantages and 
drawbacks of the current proteomic approaches used for the study of humoral responses. 
Table 1.3 presents a summary of this information. 
1.6.3 Cancer immunotherapy using TAAs 
Research into the identification of TAAs that elicit immune responses is constantly 
increasing. TAAs have been useful for screening, prognosis and diagnosis in different 
human cancers. For instance, higher titters of HER-2/neu are detected in early stages of 
breast cancers (Disis et al., 1997). Overexpression of MUC1 and HER-2/neu are also 
associated with aggressive behaviour of the tumour and poor disease outcome (Menard 
et al., 2004, Yonezawa et al., 2008). NY-ESO has been found frequently in advanced 
tumour stages of oesophageal cancer (Akcakanat et al., 2004). Poor survival has been 
demonstrate for p53-antibody positive patients in various type of cancers (Abendstein et 
al., 2000, Lai et al., 1998, Tang et al., 2001).  
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Table 1.3 Proteomics techniques for the screening and validation of tumour associated antigens.  
Technique Description Sensitivity Throughput Advantages Disadvantages 
SERPA 
Tumour proteins are separated by 
2-DE followed by identification by 
MS  
Moderate Moderate 
Identification of TAAs in vivo  
Identification of post-
translational modifications and 
isoforms 
Identification of low-abundance TAAs 
limited 
Identification of transmembrane TAAs 
limited 
SEREX 
Tumour proteins are expressed by 
phage bank 
Moderate Moderate 
Identification of TAAs in vivo TAAs’ post-translational modifications 
impossible to detect if using phages 
Complex 
False-positive 
Protein 
array 
Purified proteins or phage clones 
(each expressing a specific tumour 
protein) or fractioned tumour cell 
lysates are printed on slides 
High High 
High throughput allowing 
autoantibody profiling  
Laboratory efficient 
Expensive 
Requires protein synthesis at high 
quality 
Antibody 
array 
High quality antibodies are printed 
on slides and are incubated with 
whole proteins extracts 
High High 
High throughput allowing 
autoantibody profiling 
TAAs are immobilized into their 
native configuration  
Direct information is provided 
on the TAAs 
Expensive 
Require highly specific and affine 
antibodies 
ELISA 
Known antigens are coated on 96-
well plates 
Highest Moderate 
Robust 
Well-established use in clinical 
assays 
Requires well-characterized protein 
and antibody for detection and 
extensive validation 
SERPA, Serological proteome analysis; SEREX: Serological identification of recombinant expressed clones. 2DE, Two-dimensional electrophoresis; MS, mass 
spectrometry. Adapted from Desmetz et al. (2009). 
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The identification of TAAs has also been useful for the development of immunotherapy 
strategies. Current approaches can be passive or active. Antibody based immunotherapy 
(passive) is limited as it can target only cell surface or secreted proteins. However is has 
been effective in breast carcinoma with antibodies against the transmembrane protein 
ERB2 (HER2) (Baselga and Swain, 2009) and the T-lymphocyte antigen-4 (CTLA-4) in 
melanoma (Eggermont et al., 2010). On the other hand, active therapy has mainly 
focused on strategies that efficiently activate cytotoxic T lymphocytes (CTL). This is 
because CTL can recognise antigenic peptides derived from endogenously expressed 
proteins. Thus, CTL can recognise potentially all tumour-associated antigens (Hirohashi 
et al., 2009). Additionally, CTL are the only cell type that can directly kill target cells in 
a highly and efficient manner (Poschke et al., 2011). 
There are numerous cancer vaccine clinical trials performed with vaccines based on 
peptides derived from known TAAs (Table 1.4). Although the immunization trials 
induce a high frequency of specific T cells, the clinical outcomes have been limited 
(Rosenberg et al., 2004). Several reasons may account for the lack of effectiveness in 
these trials: i, tumour evasion from immune recognition. This include selection of 
resistant tumour variants, antigen loss and induced immune tolerance induced by shared 
TAAs; ii, inefficient induction of high affinity adaptive immunity and iii, tumour-
induced immunosuppression (Buonaguro et al., 2011).  
As mentioned before it has become apparent that successful immunotherapy of tumours 
will require a better understanding of the natural relationship between the tumour and 
the immune system. The new strategies aim to use a combination of approaches that 
target each of the key elements in anti-tumour immunity. The objective is to efficiently 
trigger both the innate and adaptive (humoral and cellular) immune system. This will 
elicit an adequate level of effector cells and establish immunological memory 
(Buonaguro et al., 2011, Reuschenbach et al., 2009). 
Some of the approaches already adopted include immunisation with whole tumour 
proteins containing multiple and relevant antigenic epitopes that increase the chance of 
polyvalent B and T cell activation (Jager et al., 2001). Similarly, cytokines used as 
adjuvants not only increased T cell activation but also helped to control regulatory T 
cells (which induce T cell tolerance) (Hara et al., 2000, Litzinger et al., 2007). 
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Furthermore, dendritic cells loaded with peptides or proteins in vitro, or transduced with 
the relevant genes represent one of the most promising strategies (Osada et al., 2006).  
Table 1.4 TAAs-based cancer vaccines for most relevant tumours. 
Tumour Antigen (# of clinical trials registered) Phase 
Acute myelocytic 
leukaemia 
WT1 (5), PR (5) 
I/II 
Breast E75 (2); p53 (2); HER-2/neu (9) I/II 
Colorectal Ras (5); CEA (4) I/II 
Lung URCL10 (6); ras (4); HER-2 (2); VEGFR1 and 2 (3); mutant p53 
(2) 
I/II 
Melanoma MAGE (13); gp100 (54); MART-1 (36); Tyrosinase (32); NY-ESO-
1 (4) 
I/II 
Ovarian p53 (4); NY-ES0-1 (3); HER-2 (3)  I/II 
Uterine HPV16 E7 (4); Survivin (1); mutant p53 (1) I/II 
Pancreas ras (4); VEGFR1 and 2 (3); MUC-1 (1); Survivin (1)  I/II 
Adapted from Buonaguro et al. (2011). 
Our group is conducting an immunisation program in order to trigger an immune 
response against devil facial tumour cells. Preliminary immunisation trials with 
non-viable DFTD cell lines revealed that Tasmanian devils are able to produce a 
humoral (antibody) response against the cancer cells. Based on the human model, the 
identification of the DFTD antigens eliciting these humoral responses it is significant 
for the development of immune targeted therapies or a vaccination approach that would 
contribute to the conservation of the species. 
1.7 Summary 
The review presented in the previous pages highlighted the major advances in our 
understanding of the interactions between cancer cells and the immune system. 
Potentially, one of the most important progresses is the accepted scientific consensus on 
the participation of the immune system in the control of tumour development. Evidence 
for this is the inclusion of immune evasion as a “hallmark” of cancer. It is also accepted 
that the immune system plays a paradoxical role in this process. It participates in the 
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control of emerging cancer cells but can also promote tumour progression and 
development. Research from different groups shows that the interaction between cancer 
cell-immune system is multifactorial and highly complex. The trend is to change the 
“one single way” approach and adopt a more holistic one that also includes the tumour 
microenvironment as an important factor mediating both tumour initiation and 
progression.  
Similarly, substantial efforts have been made to understand the mechanisms of 
transmission of the fatal cancer that is threatening the Tasmanian devil with extinction. 
Karyotyping and genetic analysis confirmed allotransplantation of DFTD cancer cells as 
the means of transmission. Sequencing analyses indicate that Tasmanian devils have 
limited diversity at the major histocompatibility complex (MHC) loci and this was 
postulated as the main reason why devils do not reject the cancer cells. Recent evidence 
showed that the limited MHC diversity is enough to cause rejection of allogeneic skin 
grafts and adequate to mount high responses in mixed lymphocyte reactions. Therefore, 
more research is needed to understand the nature of the tumour and the lack of immune 
response to the transfer of allogeneic cancer cells.  
Investigation of the immune system of the Tasmanian devil and DFTD has been 
hindered for the lack of cross-reacting reagents. However, the recent sequencing of the 
devil and DFTD genome and transcriptome has facilitated and opened new 
opportunities of study.  
Using these new tools, the present research focuses on three specific areas of interest. i, 
the understanding of the nature of DFTD and the exploration of biological markers that 
could be useful for diagnosis of the disease. ii, the understanding of the mechanisms 
that favour DFTD immune evasion and iii, identification of DFTD tumour associated 
antigens.  
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1.8 Research aims 
Aim one: To determine the nature of DFTD and identify tumour markers that could 
be used for the development of diagnostic tools. 
DFTD is a transmissible fatal cancer. Our knowledge about the biology of this tumour 
and the immune response of Tasmanian devils is very limited. Understanding the nature 
of the tumour could lead to the discovery of specific diagnostic markers for the disease 
and will provide insights into the mechanisms used by DFTD to escape the devil’s 
immune system. 
Chapter 2 presents an analysis of the histogenesis of DFTD based on previous 
immunohistochemistry studies and the devil transcriptome. 
Chapter 3 evaluates the utility of the expression of proteins in DFTD as diagnostic 
markers for the disease.  
Aim two: To evaluate MHC-I expression in DFTD as a mechanism used to escape the 
immune system. 
Immunisation trials with DFTD cells showed that some Tasmanian devils can produce 
an immune response against DFTD. However, this immune response is unlikely to be 
protective. In order to produce an effective response, endogenous antigens (such as 
those produced by cancer cells) need to be transported and displayed at the surface of 
the cell. MHC-I molecules are essential components of this process. Genetics studies 
indicate that DFTD tumour cells express MHC-I molecules. However, these molecules 
have not been detected at the protein level. 
Chapter 4 presents and evaluation of the expression, at the protein level, of MHC-I 
molecules in DFTD. 
Aim three: To identify the DFTD tumour specific antigens that bind to antibodies in 
DFTD immunised devils.  
Chapter 5 presents an analysis of the reactivity of the serum of immunised Tasmanian 
devils in order to identify DFTD tumour associated antigens. 
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2.1 Introduction 
Devil facial tumour disease (DFTD) emerged around 1996 in north-east Tasmania. The 
disease is a contagious cancer that has already spread in more than 60% of the geographical 
extension of the species. Some local devil populations have declined by more than 80% 
(Hawkins et al., 2006). Cytogenetic and molecular studies confirmed that the infectious 
agent is the cancer cell itself (Pearse and Swift, 2006, Siddle et al., 2007a). However, our 
knowledge about the nature and biology of this tumour is limited. 
In this context, the first systematic study of cell type and classification of DFTD was 
undertaken by Loh and colleagues (2006a) using standard pathological techniques such as 
cytology, histology and transmission electronic microscopy. Their results described the 
tumour masses as a malignant undifferentiated soft tissue neoplasm. Further 
immunohistochemistry analysis of DFTD tumour cells conducted by the same group 
concluded that the neoplasm was of neuroectodermal origin and consistent with a malignant 
neuroendocrine tumour (Loh et al., 2006b). 
Recently, Murchison and collaborators performed a large-scale genetic analysis of DFTD 
tumours and devil tissues that included deep sequencing of the tumour transcriptome. This 
study revealed that DFTD expresses a set of genes related to the myelination pathway in the 
peripheral nervous system (PNS). Components of this molecular network included 
transcription factors (SOX10, SOX2, POU5F1, and Jun) and structural myelin genes such 
as protein zero (MPZ), periaxin (PRX), myelin basic protein (MBP) and peripheral myelin 
protein 22 (PMP22) (Murchison et al., 2010). 
The genetic studies on the transcriptome support the neuroectodermal origin of DFTD. 
However, although both the myelinating cells in the PNS and neuroendocrine cells derive 
from the neural crest, they develop from two different cellular lineages. Therefore, 
confirmation of the protein expression of the peripheral nerve markers is required to clarify 
the nature of the tumour. To achieve this, this chapter examined the expression of myelin 
and other neuronal proteins on tumour tissues using immunohistochemical techniques. 
Additionally, the expression of PNS markers in DFTD cell lines was evaluated using flow 
cytometry. Results of this study have been published in Murchison et al., (2010) and Tovar 
et al., (2011).  
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2.2 Methods 
2.2.1 Tissue samples 
A total of 20 primary DFTD tumours and 10 DFTD metastases were used in this study. 
The samples were supplied by the tissue bank held at the Menzies Research Institute 
Tasmania, University of Tasmania, and the Mount Pleasant Laboratories from the 
Tasmanian Department of Primary Industry, Parks, Water and Environment (DPIPWE). 
2.2.2 Histology and Immunohistochemistry 
Three-micrometre thick paraffin sections were prepared from DFTD tumour and normal 
devil tissues previously fixed in 10% buffered formalin and placed onto 3-
aminotriethoxysilane-coated slides. Standard hematoxylin and eosin (H&E) staining 
was performed at the Anatomical Pathology Department of the Royal Hobart Hospital. 
For immunohistochemistry, sections were initially deparaffinised in a histology oven at 
60 °C for 15 minutes followed by two five minutes washes in xylene, then rehydrated 
through successive graded ethanol solutions, and washed for five minutes in distilled 
water. Heat-induced antigen retrieval was performed in citrate buffer, pH 6 (Dako, 
Carpinteria, CA) using an electric pressure cooker at medium heat for 10 minutes, 
followed by a 20 minutes cooling period at room temperature. A complete list of 
reagents is presented in Appendix 2. 
The slides were preincubated with serum-free blocking solution (Dako) for 30 minutes 
and then incubated with the primary antibody for 1 hour (see Table 2.1 for a complete 
list of antibodies). Endogenous peroxidase activity was then quenched by treating the 
slides in 3% hydrogen peroxide in phosphate-buffered saline (PBS) for 10 minutes at 
room temperature. Signal detection was carried out using the anti-mouse (K4007) or 
anti-rabbit (K4003) Dako EnVision+ System, HRP, (Dako) and the DAB Substrate-
Chromogen system (Dako) which yields a brown reaction end-product at the site of the 
target antigen (positive staining). The sections were counterstained with hematoxylin for 
40 seconds and mounted. 
The specificity of the primary antibodies was validated with recognized positive 
controls using appropriate normal devil tissues and negative controls by omitting the 
primary antibody for each immunohistochemistry run. Peripheral nerves bundles, 
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usually located in tissues adjacent to tumour nests, were used as a positive control for 
MBP, NGFR, NSE, PMP22, periaxin and S100; spinal cord was used as control for 
nestin and pituitary gland for CGA.  
2.2.3 Interpretation of protein expression in tissues 
A light microscope (Olympus-BX50) coupled with a camera (Leica-DFC320) was used 
for visualization and acquisition of the images. Immunoreactivity (i.e. protein 
expression) was considered positive when more than 10% of DFTD tumour cells within 
the tissue section were labelled with the antibody. Labelling reactions were analyzed 
semi-quantitatively by the principal author and a trained veterinary pathologist. 
2.2.4 Flow cytometry 
A DFTD cell line (C5065) was provided by the Mount Pleasant Laboratories from the 
DPIPWE. The cells were incubated to semi-confluence at 37 °C and 5% CO2 in T25 
cm2 culture flasks in RPMI medium (RPMI 1640, Gibco, Auckland, New Zealand), 
10% foetal calf serum (FCS), 2 mM of L-glutamine (Sigma, St Louis, MO) and 40 
mg/ml of gentamicin (Pfizer, Sydney, Australia). Cell surface or intracellular expression 
of eight neuronal markers was tested in non-permeabilized or permeabilized cells 
respectively. For cell surface labelling, approximately 5 × 106 cells (number estimated  
using a Neubauer chamber) were transferred to microcentrifuge tubes and resuspended 
in 200 µl of PBS + 10% FCS (PBS-FCS) containing the primary antibody at the 
recommended concentration (Table 3.2). The tubes were mixed gently and incubated for 
30 minutes on ice. The cells were washed three times with PBS-FCS by centrifugation 
at 10000 × g for 30 seconds. The final pellet was resuspended in 200 µl of PBS-FCS 
containing the secondary antibody goat anti-rabbit or goat anti-mouse Alexa Fluor 488 
(Invitrogen). The cells were incubated for 30 minutes on ice and then washed 3 times as 
indicated above. Following the final wash, the cells were resuspended in 200 µl of PBS-
FCS and transferred to flow cytometry tubes. For intracellular labelling, 5 × 106 DFTD 
cells were first permeabilized with Fix and Perm Cell Permeabilization Reagents 
GAS003 (Invitrogen, Carlsbad, CA) according to the manufacturer's protocol. Labelling 
was then performed as described above but replacing the PBS with the washing buffer 
provided with the kit. Isotype controls and negative controls experiments (by omitting 
the primary antibody) were run in parallel for both permeabilized and non-
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permeabilized cells. Fluorescence detection was performed in a BD FACS Canto II flow 
cytometer and analysed using BD CellQuest Pro v5.2.1 software. 
Table 2.1 List of antibodies tested by immunohistochemistry (IHC) and flow cytometry (FC) 
Antibody 
Official 
symbol 
(aliases)* 
Species 
IHC/FC 
Concentration 
Company/Catalogue 
Chromogranin A 
CHGA 
(CGA) 
Mouse IgG2b 1/50 - IHC 
ABR Affinity Bioreagents/ 
MA1-37447 
Myelin basic protein MBP Mouse IgG2b 1/400 - IHC 
ABR Affinity Bioreagents/ 
MA1-10837 
Nerve growth factor receptor 
NGFR 
(p75NTR) 
Rabbit IgG 
1/100 - IHC 
1/500 - FC 
Abcam/ab8874 
Nestin NES Mouse IgG1 
1/250 - IH 
1/200 - FC  
BD Bioscience/611658 
Neuron specific enolase/ 
enolase 2 gamma 
ENO2 
(NSE) 
Mouse IgG1 1/50 - IHC AbD serotec/MCA1764T 
Periaxin PRX Rabbit IgG 
1/300 - IHC 
1/500 - FC 
Sigma/HPA 001868 
Peripheral myelin protein 22 PMP22 Rabbit IgG 
1/100 - IHC 
1/500 - FC 
Abcam/ab61220 
S100 calcium binding protein S100 Rabbit IgG 1/300 - IHC Dako/Z 0311 
Myelin protein zero MPZ Rabbit IgG 1/500 - FC Abbiotec 250762 
Alexa Fluor 488 goat 
anti-rabbit IgG 
- Goat  1/1000 IF Invitrogen/A11034 
Alexa Fluor 488 goat 
anti-mouse IgG 
- Goat  1/1000 IF Invitrogen/A11029 
* Official symbol according to the HUGO Gene Nomenclature Committee – HGNC.  
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2.3 Results 
2.3.1 Histological features of DFTD tumours 
The histological appearance of DFTD tumours was identical to previous descriptions in 
both primary tumours and metastases (Loh et al., 2006a). Briefly, tumour cells formed 
large nodular aggregates, often within a thin, fibrous pseudo-capsule and composed 
predominantly of neoplastic cells supported by minimal fibrovascular stroma. Cells 
could also be arranged in bundles, cords or streams separated by fine strands of collagen 
fibres. Cells were polygonal to round with a high nuclear to cytoplasm ratio (Figure 
2.1.A-B). Mitotic figures were commonly observed with up to seven figures per high 
power field (40X) in some cases. Most of the large tumour masses contained central 
areas of necrosis. Inflammatory cells were rare and when present were mostly confined 
to the periphery of the tumour. 
2.3.2 Protein expression of myelin and neuronal markers in DFTD tumours 
This study evaluated the protein expression of the structural myelin proteins periaxin 
(PRX), peripheral protein myelin 22 (PMP22), and myelin basic protein (MBP). 
Peripheral neuronal markers included protein S100, nestin (NES) and nerve growth 
factor receptor (NGFR). Additionally, the neuroendocrine markers neuron-specific 
enolase (NSE) and chromogranin A (CGA) were also examined. Expression was 
considered positive for samples that showed immunolabelling in more than 10% of the 
tumour cells. Average labelling intensity was considered weak, moderate, or strong 
compared to that of the positive control (Table 2.2). 
Periaxin, a protein that participates in the membrane-protein interactions that are 
required to stabilize the mature myelin sheath in peripheral nerves, was strongly 
expressed in 100% of DFTD primary tumours (n = 20) and 100% of DFTD metastases 
(n=10). Peripheral nerves surrounding the tumours were also clearly identified by their 
strong and specific immunoreactivity for periaxin (Figure 2.1.C-D). 
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Table 2.2 Expression of myelin and neuronal markers in primary DFTD tumours and metastases 
Sample 
Marker 
PRX S100 PMP22 NGFR NES NSE MBP CGA 
Primary 
tumours 
10/10 10/10 19/20 13/20 9/20 3/20 2/20 0/20 
Metastases 10/10 10/10 9/10 8/10 4/10 1/10 0/9 0/9 
Total positive 30/30 30/30 28/30 21/30 13/30 4/30 2/29 0/29 
Labelling Strong Moderate 
- weak 
Moderate 
- Strong 
Weak -
moderate 
Weak Weak - 
moderate 
Weak None 
DFTD, devil facial tumour disease; PRX, periaxin; PMP22, peripheral myelin protein 22; NGFR, nerve growth 
factor receptor; NES, nestin; NSE, neuron specific enolase; MBP, myelin basic protein; CGA, chromogranin A. 
The table indicates the number of samples showing positive immunoreactivity for the marker in more than 10% 
of the viable-looking cells. 
S100 are calcium-binding proteins commonly used as markers for neuronal cells, 
Schwann cells and tumours of neuronal origin. S100 expression was observed in all 
primary tumour samples (n = 20) and metastases (n = 10). Peripheral nerves also 
showed strong immunoreactivity for S100 (Figure 2.1.E-F).  
PMP22 is an integral membrane protein that is a major component of myelin in the 
peripheral nervous system. Moderate PMP22 expression was detected in 95% of 
primary tumours (19/20) and 90% of metastases (9/10). Peripheral nerves bundles 
showed strong immunoreactivity for PMP22 (Figure 2.1.G-H). 
NGFR, also called p75 (NTR), is expressed by both neuronal and glial cell types. NGFR 
expression in Schwann cells is important for the remyelination process after peripheral 
nerve injury (Tomita et al., 2007). NGFR expression was observed in 65% of primary 
DFTD tumours (13/20) and 80% of metastases (8/10). Peripheral nerve bundles showed 
strong immunoreactivity for NGFR (Figure 2.1.I-J).  
Nestin is an intermediate filament expressed during the development of the nervous 
system in both neuronal and glial cells. In DFTD cells, immunoreactivity for nestin was 
found in less than 50% of the primary tumour samples (9/20) and DFTD metastases 
(4/10). Devil’s spinal cord tissue showed cells strongly labelled with nestin antibody 
(Figure 2.1.K-L). 
 Chapter 2. Histogenesis of DFTD 
 51 
Weak to moderate labelling for neuron specific enolase (NSE), a protein commonly 
found in neuronal and neuroendocrine cells, was only observed in 3/20 primary tumours 
and 1/10 metastasis. Immunoreactivity for NSE was detected in peripheral nerves 
(Figure 2.1.M-N) and spinal cord.  
The protein encoded by the MBP gene is a major constituent of the myelin sheath of 
oligodendrocytes and Schwann cells in the nervous system. MBP protein expression 
was only observed in 2/20 primary DFTD tumours. MBP was not detected in DFTD 
metastases. Although peripheral nerve bundles labelled positively with MBP, the 
interpretation of the results was difficult due the high background observed in the 
surrounding connective tissue (Figure 2.1.O-P). 
Chromogranin A (CGA) belongs to a family of proteins found in the secretory granules 
of neuroendocrine cells. No immunoreactivity was found for CGA in DFTD tumour 
cells. However, strong granular and cytoplasmic immunoreactivity was observed in 
pituitary gland (Figure 2.1.Q-R) and cells of the islets of Langerhans in the pancreas. 
2.3.3 Protein expression of myelin and neuronal markers in DFTD cell lines 
A DFTD cell line was also evaluated for their expression of neuronal and peripheral 
nerve markers using flow cytometry. Cell surface or cytoplasmic expression was 
investigated in intact or permeabilized cells respectively. Cytoplasmic expression was 
clearly detected for periaxin, NGFR and nestin. Myelin protein zero (MPZ), which is a 
major integral membrane protein of the peripheral nervous system was also detected in 
permeabilized cells. Less conclusive cytoplasmic expression was observed with PMP22 
and CGA. No surface expression was detected with any of the antibodies (Figure 2.2). 
NSE and MBP were not detected in permeabilized or non-permeabilized DFTD cells.  
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Figure 2.1 Expression of neuronal and peripheral nerve markers in DFTD and devil tissues. Left panels show labelling in 
primary DFTD tumour cells (arrows). Right panels show peripheral nerve tissue as a control (indicated with arrowheads) 
except for nestin (NES) and chromogranin A (CGA) in which positive control are spinal cord and pituitary gland 
respectively. A-B, DFTD tumours form dense aggregates arising in the dermis and propagate through the connective 
tissue. C-D. Strong and specific immunolabelling of DFTD tumour cells and peripheral nerve bundles with periaxin 
(PRX). E-F, Immunolabelling of DFTD tumour cells with S100 protein. Peripheral nerves (F) show strong S100 
immunoreactivity. G-H, Strong peripheral myelin protein (PMP22) expression in DFTD tumour cells and peripheral 
nerves. I-J, Granular immunolabelling of DFTD tumour cells and peripheral nerve with nerve growth factor receptor 
(NGFR). 
A B
C D
E F
G H
I J
H&E
PRX
S100
PMP22
NGFR
DFTD tumour cells Positive control
 Chapter 2. Histogenesis of DFTD 
 53 
 
Figure 2.1(continued), K, Few cells within the tumour nest show nestin expression. L, Strong nestin labelling was 
detected in neuronal cells within the spinal cord. M, Immunoreactivity of neuron specific enolase (NSE) in DFTD tumour 
cells. N, Strong NSE labelling in peripheral nerves. O, Granular immunolabelling with myelin basic protein (MBP). High 
levels of non-specific labelling are observed in connective tissue. P, Moderate MBP labelling in peripheral nerves. Q, 
CGA immunoreactivity was not detected in any of the DFTD samples. R, CGA expression was observed in cells of the 
devil’s anterior pituitary gland. A-B, hematoxylin and eosin staining. C-R immunohistochemical detection with 
EnVision+ system (Dako) with hematoxylin counterstain.  
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Figure 2.2 Expression of peripheral nerve and myelin markers in DFTD cell lines. Flow cytometry histograms 
representing surface expression (labelling in non-permeabilized cells) or cytoplasmic expression (permeabilized 
cells). Positive immunolabelling is represented by a shift to the right in fluorescence intensity (X-axis) compared 
to that of the negative or isotype control. No cell surface expression was detected with any of the antibodies. 
Cytoplasmic expression was detected in DFTD cells labelled with periaxin (PRX), myelin protein zero (MPZ) 
and nerve growth factor receptor (NGFR). Less conclusive evidence of cytoplasmic expression was observed for 
peripheral myelin protein 22 (PMP22). 
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Figure 2.2 (Continued), cytoplasmic expression was detected for nestin (NES). Less conclusive evidence of 
cytoplasmic expression was detected for chromogranin A (CGA). Neuron specific enolase (NSE) and myelin 
basic protein (MBP) were not detected in the surface or in the cytoplasm. 
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2.4 Discussion 
Recent studies on the Tasmanian devil transcriptome revealed that devil facial tumour 
cells express a set of genes related to the myelination pathway in the peripheral nervous 
system (PNS) (Murchison et al., 2010). The immunohistochemistry and flow cytometry 
studies confirmed the protein expression of a number of markers found throughout the 
neuronal system in DFTD. These included the neuronal markers protein S100, neuronal 
specific enolase (NSE), nestin (NES) and myelin basic protein (MBP). Notably, DFTD 
tumour cells expressed structural proteins exclusively found in myelinating Schwann cells 
in the peripheral nervous system. These included peripheral myelin protein 22 (MP22), 
myelin protein zero (MPZ), and the recently described periaxin (PRX). Nerve growth 
factor receptor (NGFR), which is involved in the differentiation of Schwann cells, was 
also detected in DFTD tumour cells. Based on these combined results, this thesis proposes 
that DFTD is a peripheral nerve sheath tumour of Schwann cell origin. 
The first immunohistological study of DFTD revealed labelling characteristics consistent 
with cells of neuroendocrine origin (Loh et al., 2006b). The neural crest, which arises 
from the neuroectoderm, gives rise to a number of cell types during vertebrate 
embryogenesis. These neural crest derived cells include neurons and glial cells from the 
peripheral nervous system, pigment cells in the skin (melanocytes); endocrine cells, and a 
variety of mesenchymal cell types (Dupin et al., 2007, Joseph et al., 2004, Le Douarin et 
al., 2008). This thesis provided additional support to the neuroectodermal origin of DFTD 
by detecting immunoreactivity to nestin and NGFR, proteins found in neuronal cells and 
neuronal neoplasias (Hoshi et al., 1994, Shimada et al., 2007). However, chromogranin A 
(CGA), a glycoprotein that is found in secretory vesicles of neurons and endocrine cells 
(Hendy et al., 1995), was not detected in DFTD tumours. The presence of Schwann cell 
markers in DFTD and the lack of CGA expression indicate that DFTD tumours originated 
from cells of the peripheral nervous system lineage rather than neuroendocrine as 
originally proposed.  
Differences with the previous study can be attributed to improvements in the technique 
used. Applying immunohistochemistry to the study of protein expression in marsupials 
tissues have been challenging (Canfield and Hemsley, 2000, Loh et al., 2006b). One of 
the major constraints is the limited availability of commercial antibodies targeted to 
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marsupial tissues. This is especially relevant for antibodies against antigens that are not 
widely studied, such as myelin proteins. In this current study of devil tissue, it was found 
that some antibodies, in particular polyclonal antibodies, could produce relatively high 
levels of non-specific labelling in connective and other tissues. Moreover, secondary 
avidin or biotin conjugated antibodies produced high background and interpretation of 
results was difficult. This non-specific labelling was notably reduced with a biotin-free 
visualisation system and by selecting monoclonal antibodies.  
The major difference to the original immunohistochemical characterization of DFTD was 
the detection of CGA. The Loh et al. study detected CGA in all the samples and was 
described as “low intensity positivity in the cytoplasm”. In this thesis, a monoclonal anti-
CGA was used rather than a polyclonal antibody and detection was achieved using the 
EnVision+ system (Dako) which is an avidin-biotin free system. With this method, strong 
CGA expression was observed in samples of pituitary gland and pancreas. However, none 
of the DFTD samples showed CGA expression. The polyclonal anti-CGA antibody used 
in Loh et al. study was re-tested in eight tumour samples used in this chapter and devil 
tissues using the avidin-biotin free system. Although CGA was detected in pituitary gland 
and pancreas, none of the eight samples showed CGA expression (Appendix 3). The first 
study used tissue samples collected from 2001 to 2004. It could be speculated that 
evolution of the tumour could account for the difference as the earliest samples used in 
the current research were from 2006. Testing this hypothesis would have required 
analysing early tumour samples; however, the samples were not available for the current 
study.  
The flow cytometry analysis clearly detected periaxin, NGFR, nestin and MPZ within the 
cytoplasm of DFTD cells in culture, but not the other markers. None of the markers was 
detected on the cell surface. However, as there are not available appropriate cultured devil 
cells that can be used as positive controls, precaution needs to be taken for the 
interpretation of these results. It is possible that the cells in culture do not express the 
markers but is also possible that the antibodies are simply not suitable for use in flow 
cytometry. The current study was able to establish a primary culture of devil’ Schwann 
cells and fibroblasts suitable for immunofluorescence studies (see Chapter 4). However, 
flow cytometry requires a large number of cells that remain viable in cell suspension. 
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Refinement of the cell culture is an ongoing process and this could make available control 
devil cells for use in flow cytometry in the future.   
Cytoplasmic expression (in permeabilized cells) was clearly detected for periaxin, NGFR 
and nestin. Myelin protein zero (MPZ), which is a major integral membrane protein of the 
peripheral nervous system was also detected in permeabilized cells. Less conclusive 
cytoplasmic expression was observed with PMP22 and CGA. No surface expression was 
detected with any of the antibodies (Figure 2.2). NSE and MBP were not detected in 
permeabilized or non-permeabilized DFTD cells. However, there are not available 
appropriate devil cells that can be used as positive control for these two markers. 
Therefore is still possible that the antibodies are simply not suitable for use in flow 
cytometry.  
Tumours of the PNS have been described in humans, dogs, cattle and other animals 
(Bundza et al., 1986, Chijiwa et al., 2004, Nielsen et al., 2007, Schoniger and Summers, 
2009, Schulman et al., 2009). Furthermore, the Schwann cell is thought to be the major 
contributor to the formation of both benign and malignant peripheral nerve sheath 
tumours neoplasms (Carroll and Ratner, 2008, Gupta et al., 2008, Zhu et al., 2002). 
Tumours of the PNS can occur sporadically but the majority arise in individuals affected 
with neurofibromatosis type 1 (NF1) and type 2 (NF2) (Ferner, 2010, Stemmer-
Rachamimov et al., 2004). NF1 and NF2 are autosomal dominant tumour-suppressor 
gene syndromes and evidence provided by mouse models indicates that loss of NF1 or 
NF2 functionality in the Schwann cell lineage is sufficient to generate tumours (Carroll 
and Ratner, 2008, Le et al., 2011, Zheng et al., 2008, Zhu et al., 2002). The expression of 
these cancer genes in DFTD requires further investigation. 
Evidence from human cancers indicates that tumours have a phenotypic and functional 
heterogeneous composition of cells. It has also been noted that the cell that acquires the 
first cancer-promoting mutations (cell-of-origin) is not necessarily related to the cancer 
stem cell (CSC), the cellular subset within the tumour that sustains malignant growth 
(Visvader, 2011). In this context, it is remarkable that DFTD tumours consistently express 
markers of highly differentiated Schwann cells. As DFTD propagates as a clone, it is 
likely that these differentiated cells reflect both, the cell of origin and the cancer 
propagating cells. A similar mechanism has been described in mouse models of 
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neurofibromas and peripheral malignant nerve sheath tumours (MPNST), where tumours 
developed from fully differentiated glial cells in adult sciatic nerves (Zheng et al., 2008). 
Biting has been proposed as the most likely mean of DFTD transmission (Obendorf and 
McGlashan, 2008). It could be speculated that the origin of DFTD also relates to the 
characteristic biting behaviour of Tasmanian devils during mating and feeding. Frequent 
injury and infection are common in the face in areas highly innervated such as the devils' 
vibrissae. Chronic inflammation, a common feature of infections, has been associated 
with cancer due to the generation of free radicals, prostaglandins, cytokines and other 
mediators that participate in the inflammatory response. Prolonged exposure to these 
mediators leads to increased cell proliferation, mutagenesis, oncogene activation, and 
angiogenesis (Shacter and Weitzman, 2002). These factors could particularly affect tissue 
stem cells that participate in tissue regeneration and it is increasingly accepted that 
carcinogenesis develops by misappropriating homeostatic mechanisms that govern tissue 
repair and stem cell-renewal (Beachy et al., 2004). Mature Schwann cells are able to 
dedifferentiate and actively participate in nerve repair after injury (Dahlin, 2008). 
Schwann cells also modulate local immune reactions in the peripheral nervous system 
(Gold et al., 1999). Interestingly, nestin a marker of stem cells (Lendahl et al., 1990) was 
also detected in DFTD tumour cells. Therefore, the plasticity and immunocompetence of 
Schwann cells may be significant in the origin and evolution of DFTD as a transmissible 
cancer. 
In summary, the results of this chapter confirmed the protein expression of genes involved 
in the myelination pathway within the peripheral nervous system. Thus, the combined 
data of the previous genetic studies and the protein profile presented here indicate that 
DFTD tumour cells are from the peripheral nervous system lineage and most likely to be 
of Schwann cell origin.  
A correct classification of the cells of origin of tumours is important for the biological 
understanding of carcinogenesis and to tailor new approaches for the prevention and 
treatment of tumours (Waldum et al., 2008). The finding that DFTD originated from 
Schwann cells in the peripheral nervous system clearly raises new opportunities for the 
investigation of diagnostic markers for the disease and the understanding of the immune 
evasion of this transmissible cancer.  
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3.1 Introduction 
Diagnosis of devil facial tumour disease (DFTD) is currently based on histopathology, 
clinical appearance of the disease in affected animals and cytogenetics. Karyotyping is 
the most accurate method for tumour diagnosis. This classical analysis requires 
chromosomal banding and collection of fresh tumour biopsies for establishment of cell 
cultures in vitro. This is not only time-consuming but also labour intensive. As 
Tasmanian devils are also susceptible to other types of neoplasias (Canfield and 
Cunningham, 1993, Griner, 1979) , a specific diagnostic test that can be carried out 
rapidly on fixed samples is required to differentiate DFTD tumours from other cancers 
of similar morphological appearance (Jones et al., 2007). 
The previous chapter showed that DFTD tumours consistently express a set of proteins 
related to the myelination pathway in the peripheral nervous system (PNS). Based on 
the results it was proposed that DFTD is of Schwann cell origin. The aim of this chapter 
was to evaluate the utility of the neuronal and peripheral nerve proteins as diagnostic 
markers of DFTD. To achieve this, a thorough semi-quantitative assessment of the 
pattern of immunohistochemical expression of these markers was performed on DFTD 
and non-DFTD tumours, and Tasmanian devil tissues. 
Additionally, the utility of the markers was evaluated in alternative models of the 
disease such as murine xenografted DFTD tumours, DFTD cell lines and devil Schwann 
cells in primary culture. Results of this chapter have been published in Tovar et al., 
(2011) and Kreiss et al., (2011b). 
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3.2 Methods 
3.2.1 Immunohistochemistry 
Devil tissues, DFTD tumours and non-DFTD tumour samples were supplied by the tissue 
bank held at the Menzies Research Institute Tasmania, University of Tasmania, and the 
Mount Pleasant Laboratories from the Tasmanian Department of Primary Industry, Parks, 
Water and Environment (DPIPWE). Samples from primary DFTD tumours, DFTD 
metastases and normal devil tissues were evaluated by immunohistochemistry for the 
expression of periaxin, S100 protein, peripheral myelin protein 22, nerve growth factor 
receptor, nestin, neuron specific enolase, myelin basic protein and chromogranin A. Tissue 
sections preparation and immunohistochemistry protocols were as described in Chapter 2.2.  
3.2.2 Annotation and interpretation of protein expression in tissues 
A light microscope (Olympus-BX50) coupled with a camera (Leica-DFC320) was used for 
visualization and acquisition of the images. Labelling reactions, analyzed semi-
quantitatively by the principal author and a trained veterinary pathologist, were assessed 
according to the following criteria: i) immuno-labelling intensity (negative, weak, moderate 
or strong) compared with that of the positive control; positive labelling was defined by the 
presence of 10% or more immunoreactive cells in tumour sections; ii) the fraction of 
tumour cells labelled was defined as 10-25%, 25-50%, 50-75%, or >75%; and iii) sub-
cellular localization (nucleus, cytoplasmic or associated with the cell membrane) combined 
with parameters describing the labelling characteristics (i.e. smooth, granular, or fine 
granular). 
3.2.3 Primary Schwann cell culture 
The following protocol was modified from Mauritz et al., (2004). Sciatic nerves were 
collected into Dulbecco’s modified Eagle medium (DMEM; Gibco, Auckland, New 
Zealand) during autopsy of an adult male devil, and the epineurium was dissected with 
micro-scissors and forceps. The epineurium-free tissue was incubated for 14 days at 37 °C 
and 5% CO2 in DMEM containing 10% fetal calf serum (FCS; Gibco), 1% 
penicillin/streptomycin and 2 µM forskolin (Sigma, St Louis, MO). Nerve fascicles were 
washed gently with DMEM and then incubated with DMEM containing 10% FCS, 50 U of 
penicillin, 50 µg of streptomycin (penicillin-streptomycin liquid, Sigma) and an enzyme 
mixture consisting of 0.15 U/ml collagenase and 0.24 U/ml dispase (Invitrogen, Carlsbad, 
CA) at 37 °C and 5% CO2 for 20 hours. After dissociation through glass pipettes, the 
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homogenous cell suspension was centrifuged at 250 × g for five minutes at 21 °C. 
Following resuspension, the cells were filtered through 70-µm cell strainer to remove 
undigested tissue. The cell filtrate was plated into a tissue culture flask and incubated at 37 
°C and 5% CO2 in DMEM culture media containing 2 µM forskolin, 10 ng/ml fibroblast 
growth factor (Promega, Madison, WI), 5 µg/ml bovine pituitary extract (Sigma) and 1% 
penicillin-streptomycin liquid (Invitrogen). Two weeks later the cells were harvested for 
immunofluorescence analysis.  
3.2.4 Immunofluorescence 
Cultured DFTD tumour cells and primary cultured devil Schwann cells were plated onto 
Poly-L-Lysine (Sigma)-coated coverslips and incubated to semi-confluence at 37 °C and 
5% CO2. DFTD tumour cells were incubated in complete RPMI medium (RPMI 1640, 
Gibco) containing 10% FCS, 2 mM L-glutamine (Sigma) and 40 mg/ml gentamicin (Pfizer, 
Sydney, Australia). Schwann cells were incubated in the DMEM culture medium described 
above. The cells were fixed in 4% paraformaldehyde-glucose (Sigma) for 30 minutes 
followed by three washes with PBS. Cells were then incubated in 10% BSA for an hour to 
block non-specific binding. Primary antibody was incubated in 0.3% Triton X100 overnight 
at 4 °C. After washing with PBS the cells were incubated in the dark with a fluorescently 
labeled secondary antibody (Alexa Fluor 594 goat anti-rabbit IgG; Invitrogen) in PBS for an 
hour at room temperature. Actin stain (Alexa Fluor 488 phalloidin; Invitrogen) was added 
and incubated for 30 minutes. The coverslips were washed with PBS and rinsed with 
distilled water prior to mounting onto glass slides using fluorescent mounting medium 
(Dako). Labelling was visualized under a confocal microscope (Zeiss LSM 510 Meta). 
Isotype and negative (omitting the primary antibodies) controls were also performed in 
parallel.  
3.2.5 Murine xenografted DFTD tumours 
A DFTD xenograft model in immuno-compromised NOD/SCID mice was already 
described (Kreiss et al., 2011b) In brief, NOD/SCID mice were injected subcutaneously 
with viable DFTD tumour cells. All inoculated mice developed tumours. Additionally, cells 
derived from these tumours were successfully passaged into other NOD/SCID mice.  
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3.3 Results 
3.3.1 Patterns of expression of Schwann cell markers in DFTD and devil tissues 
The previous chapter demonstrated that DFTD expresses a number of Schwann cell 
markers. These include periaxin (PRX), S100 protein, peripheral myelin protein 22 
(PMP22), nerve growth factor receptor (NGFR), nestin (NES), neuron specific enolase 
(NSE) and myelin basic protein (MBP). This chapter presents a thorough examination of 
the immunohistochemical labelling patterns of these markers in DFTD. The semi-
quantitative evaluation of the labelling included the fraction of labelled cells, cellular 
localization and description of the characteristics of the stain (Table 3.1). This chapter also 
presents the pattern of expression of the markers in normal devil tissues (Table 3.2). The 
results for positive control were already reported in the previous chapter and therefore they 
are not included here.  
Of the eight markers assessed, periaxin, a marker of myelinating Schwann cells (Gillespie et 
al., 1994), gave the most consistent labelling of tumour cells. In all cases, the labelling was 
moderate to strong, cytoplasmic and observed in more than 75% of the tumour cells. The 
periaxin expression was observed in all DFTD primary tumours and metastases. Although 
75% was used as the criteria for reporting the fraction of labelled cells, it was observed that 
periaxin consistently labelled almost 100% of the tumour cells in all the samples. Stronger 
immunoreactivity was occasionally observed at the edges of the tumour fascicles. One 
particular feature of periaxin was its strong specificity for DFTD tumour cells and the lack 
of background labelling in other tissues (Figure 3.1.A). Peripheral nerves within these 
DFTD tumour sections were also clearly identified by their strong and specific 
immunoreactivity for periaxin. 
S100 protein is a commonly used marker for peripheral nerve sheath tumours (Coindre, 
2003). S100 was observed in all DFTD samples. However, the intensity of the labelling was 
variable between samples and within a sample; background labelling was also observed in 
other tissues (Tables 3.1 and 3.2). In DFTD tumour cells, labelling with S100 was 
consistently granular and located in both cytoplasmic and nuclear compartments (Figure 
3.1.B). Similar to periaxin, the level of S100 expression varied across tumour nodules (i.e. 
the cells at the periphery of the tumour exhibited stronger immunoreactivity compared to 
cells in the centre). Strong S100 immunoreactivity was also observed in peripheral nerves 
and in the nucleus of neurons and oligodendrocytes located in devil spinal cord. 
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Table 3.1 Patterns of expression of myelin and neuronal markers in DFTD primary tumours and metastases 
 PRX S100 PMP22 NGFR NES NSE MBP CGA 
PT M PT M PT M PT M PT M PT M PT M PT M 
Intensity 
Strong:  
Moderate:  
Weak:  
Negative: 
Total positive: 
% positive: 
 
15/20 
5/20 
0/20 
0/20 
20/20 
100% 
 
7/10 
2/10 
1/10 
0/10 
10/10 
100% 
 
4/20 
8/20 
8/20 
0/20 
20/20 
100% 
 
1/10 
6/10 
3/10 
0/10 
10/10 
100% 
 
5/20 
6/20 
8/20 
1/20 
19/20 
95% 
 
0/10 
1/10 
8/10 
1/10 
9/10 
90% 
 
1/20 
5/20 
7/20 
7/20 
13/20 
65% 
 
0/10 
1/10 
7/10 
2/10 
8/10 
80% 
 
0/20 
2/20 
7/20 
11/20 
9/20 
45% 
 
0/10 
1/10 
3/10 
6/10 
4/10 
40% 
 
0/20 
1/20 
2/20 
17/20 
3/20 
15% 
 
0/10 
0/10 
1/10 
9/10 
1/10 
10% 
 
0/20 
0/20 
2/20 
18/20 
2/20 
10% 
 
0/9 
0/9 
0/9 
0/9 
0/9 
0% 
 
0/20 
0/20 
0/20 
20/20 
0/20 
0% 
 
0/9 
0/9 
0/9 
9/9 
0/9 
0% 
Fraction of positive 
cells 
>75%:  
75-50%:  
50-25%:  
25-10% 
 
20/20 
0/20 
0/20 
0/20 
 
10/10 
0/10 
0/10 
0/10 
 
1/20 
5/20 
7/20 
7/20 
 
1/10 
1/10 
5/10 
3/10 
 
11/19 
3/19 
4/19 
1/19 
 
3/9 
4/9 
1/9 
1/9 
 
1/13 
7/13 
2/13 
3/13 
 
2/8 
4/8 
1/8 
1/8 
 
1/9 
2/9 
2/9 
4/9 
 
0/4 
2/4 
0/4 
2/4 
 
0/3 
0/3 
1/3 
2/3 
 
0/1 
0/1 
0/1 
1/1 
 
1/2 
1/2 
0/2 
0/2 
 
0/0 
0/0 
0/0 
0/0 
 
0/0 
0/0 
0/0 
0/0 
 
0/0 
0/0 
0/0 
0/0 
Labelling 
Smooth:  
Fine granular:  
Granular: 
 
20/20 
0/20 
0/20 
 
10/10 
0/10 
0/10 
 
4/20 
0/20 
16/20 
 
3/10 
0/10 
7/10 
 
8/19 
2/19 
9/19 
 
4/9 
4/9 
1/9 
 
0/13 
0/13 
13/13 
 
0/8 
0/8 
8/8 
 
0/9 
2/9 
7/9 
 
0/4 
1/4 
3/4 
 
0/3 
1/3 
2/3 
 
0/1 
0/1 
1/1 
 
0/2 
0/2 
2/2 
 
0/0 
0/0 
0/0 
 
0/0 
0/0 
0/0 
 
0/0 
0/0 
0/0 
Localization 
Memb. association:  
Cytoplasm:  
Cyto.-nucleus: 
 
2/20 
18/20 
0/20 
 
0/10 
8/10 
2/10 
 
0/20 
7/20 
13/20 
 
0/10 
1/10 
9/10 
 
11/19 
8/19 
0/19 
 
4/9 
5/9 
0/9 
 
0/13 
13/13 
0/13 
 
0/8 
8/8 
0/8 
 
0/9 
9/9 
0/9 
 
0/4 
4/4 
0/4 
 
0/3 
3/3 
0/3 
 
0/1 
1/1 
0/1 
 
0/2 
2/2 
0/2 
 
0/0 
0/0 
0/0 
 
0/0 
0/0 
0/0 
 
0/0 
0/0 
0/0 
DFTD, devil facial tumour disease; PRX, periaxin; S100, S100 protein; PMP22, peripheral myelin protein 22; NGFR, nerve growth factor receptor; NES, nestin; NSE, neuron 
specific enolase; MBP, myelin basic protein; CGA, chromogranin A; PT: primary tumours; M: metastases.  
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Table 3.2 Pattern of expression of selected markers in normal devil tissues. 
 
PRX S100 PMP22 NGFR NES NSE MBP CGA 
Epithelium - - - - - - ++ - 
Connective tissue - + ++ + - + +++ - 
Sebaceous glands - - - - + - - + 
Hair follicles - + - - - + - + 
Endothelium - + - - - - - - 
Skeletal muscle - ++ - - +++ - - + 
Peripheral nerves +++ +++ +++ +++ - +++ ++ - 
Anterior pituitary gland  - + ++ ++ ++ + + +++ 
Posterior pituitary gland  - +++ + + - ++ + - 
Lymphoid tissue – 
leukocytes 
- - + + - - - - 
Spinal Cord  - ++ + +++ +++ ++ + - 
Kidney  + ++ - + - - - - 
Pancreas ND ND ND ND ND ND ND +++ 
PRX, periaxin; PMP22, peripheral myelin protein 22; S100, S100 protein; NGFR, nerve growth factor receptor; NES, nestin; NSE, neuron specific enolase; MBP, myelin 
basic protein; CGA, chromogranin A; ND not done; - negative; + low intensity; ++ moderate; +++ high intensity.  
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Figure 3.1 Pattern of expression of neuronal and myelin markers in DFTD tumour cells. 
Immunoreactivity was assessed semiquantitatively including intensity, fraction of positive cells, and 
localization and characteristic of the labelling. 
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C. Peripheral Myelin Protein 22 (PMP22)
Overall positivity: 28/30 (93%) 
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D. Nerve Growth Factor Receptor (NGFR)
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Figures 3.1 (continued) Right panels show immunoreactivity for each marker in DFTD tumour cells at 
100× magnification. PT, primary tumour; M, metastases.  
H. Chromogranin A (CGA)
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F. Neuron Specific Enolase (NSE)
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G. Myelin Basic Protein (MBP)
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E. Nestin (NES) 
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Strong immunoreactivity for PMP22, a major component of myelin in the peripheral 
nervous system, was observed at the outer margins of the tumour nodules and in 
neoplastic cells at the advancing edge of the tumour. PMP22 expression was smooth to 
fine granular. The labelling was predominantly cytoplasmic and frequently enhanced at 
the cell membrane (Figure 3.1.C). Although most of the samples were positive, labelling 
within a single sample, as indicated by the fraction of labelled cells, was highly variable 
((table 3.1). Peripheral nerve bundles were also positive for PMP22. Intense non-specific 
background of the connective tissue was also frequently observed. 
The labelling pattern for the nerve growth factor receptor (NGFR) was cytoplasmic and 
granular and it was observed in more than 50% of the DFTD tumour cells (Figure 3.1.D). 
Some populations of cells, usually located to the edges of the tumour fascicles, were 
strongly positive for NGFR. Immunoreactivity to NGFR was also observed in peripheral 
nerves, spinal cord and anterior and posterior pituitary gland. Occasional non-specific 
labelling was observed in connective tissues and in renal tubular epithelium (Table 3.2). 
The labelling expression of nestin was weak to moderate and variable. Positive cells 
showed granular cytoplasmic labelling. A particular feature of nestin labelling (not 
observed with the other markers) was its tendency to form coarse granules or clusters 
within the cytoplasm of the cell (Figure 3.1.E). Skeletal muscle cells were also strongly 
positive for nestin whereas sebaceous glands showed weak immunoreactivity (Table 3.2). 
Weak to moderate granular and cytoplasmic labelling for neuron specific enolase (NSE) 
was observed in 13% of samples (4/30) with less than 50% of cells in each sample being 
positive (Figure 3.1.F). Notably, cells at the periphery of the tumour nests showed 
stronger immunoreactivity. Immunoreactivity for NSE was also detected in peripheral 
nerves, spinal cord and pituitary gland. Weak background labelling was also observed in 
connective tissues and hair follicles. 
Positivity for myelin basic protein (MBP) was only observed in 2/20 DFTD primary 
tumours. In these two samples more than 50% of the cells showed immunoreactivity. The 
labelling pattern was diffuse, granular and cytoplasmic (Figure 3.1.G). MBP expression 
was also observed in peripheral nerves. Significant patchy background labelling was 
present in many samples making overall interpretation difficult. For instance, non-specific 
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and strong labelling was observed in connective tissues, epidermis and dermis. Necrotic 
foci within the tumour also showed non-specific immunoreactivity. 
No immunoreactivity was detected for chromogranin A (CGA) in DFTD viable tumour 
cells (Figure 3.1.H). However, strong granular and cytoplasmic immunoreactivity for this 
protein, which is normally found in endocrine cells (Hendy et al., 1995), was observed in 
pituitary gland and cells of the islets of Langerhans in the pancreas. Background labelling 
was observed in hair follicles and muscle cells. 
3.3.2 Periaxin expression in xenografted tumours, non-DFTD tumours and 
cultured Schwann cells 
The results above showed that periaxin consistently gave the strongest and most specific 
labelling of DFTD tumour cells. Periaxin immunoreactivity was also detected in almost 
100% of the tumour cells in both primary tumour and metastases (Table 3.1. Figures 
3.2.A-D). These results suggested that periaxin could be a reliable and potential marker 
for DFTD.  
To further evaluate the diagnostic utility of this candidate, periaxin labelling was also 
tested in non-DFTD Tasmanian devil tumours and alternative models of the disease such 
as murine xenografted DFTD tumours, DFTD cell lines and devil Schwann cells in 
primary culture. Nine non-DFTD tumours were evaluated for the expression of periaxin. 
Samples included three mammary adenocarcinomas, three histiocytomas, one cystic 
papillary adenocarcinoma, one squamous cell carcinoma and one hepatic fibrosarcoma. 
None of the non-DFTD tumours were positive for periaxin (Figures 3.2.E-F). On the 
other hand, strong periaxin labelling was observed in all neoplastic cells within 
xenografted DFTD tumours (Figure 3.2.G-H). The periaxin labelling was maintained in 
tumours from over two passages. 
Finally, immunofluorescence techniques were used to confirm the expression of periaxin 
in primary cultured Schwann cells from an adult Tasmanian devil and DFTD cultured cell 
lines. Periaxin expression was conserved in normal Schwann cells and was a useful 
marker to differentiate these cells from co-cultured fibroblasts (Figure 3.3.A-C). Periaxin 
also consistently labelled all DFTD tumour cells obtained from tissue culture (Figure 
3.3.D-F).  
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Figure 3.2 Periaxin expression in DFTD and non-DFTD tumours. A, DFTD primary tumours cells in the dermis. B, 
Strong and specific labelling of DFTD cells with periaxin. C, H&E staining showing the presence of a secondary 
DFTD tumour (dense cell aggregates) within the liver. D, DFTD tumour cells show strong immunohistochemical 
labelling for periaxin, which allows differentiation from the surrounding normal liver tissue. E, Devils are prone to a 
variety of neoplastic processes. This H&E staining shows adenocarcinoma cells (dense cell aggregates) in the dermis. 
F, Adenocarcinoma cells did not showed immunoreactivity for periaxin. However, periaxin labelled peripheral nerves 
in the tissue sample (insert). G, DFTD tumour induced in NOD/SCID mice by inoculation of DFTD cultured cells. 
Histological features are similar to DFTD tumours. H, Periaxin expression is present in all xenografted DFTD tumour 
cells. Left panels H&E staining. Right panels immunohistochemistry with EnVision+ system (Dako) detection and 
hematoxylin counterstain.  
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Figure 3.3 Expression of periaxin in primary cell culture of adult devil Schwann cells and DFTD cell lines. A, 
Primary Schwann cell cultures are normally contaminated by fibroblasts. Both Schwann cells (arrows) and 
fibroblasts (arrowhead) were detected with actin (green). B, Schwann cells in culture expressed periaxin (red), 
which allowed them to be differentiated from fibroblasts. C, Images A and B merged. DFTD cells in culture 
were dual labelled with actin (green, panel D) and periaxin antibody (red – panel E). As shown in the merged 
panel F, all DFTD tumour cells were positive for periaxin.  
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3.4 Discussion 
The previous chapter showed evidence indicating that the devil facial tumour disease 
(DFTD) is a peripheral nerve sheath tumour (PNST) that arose from a Schwann cell. In 
this study, eight neuronal and peripheral nerve proteins were evaluated for their utility 
as diagnostic markers for DFTD. Proteins evaluated included periaxin, S100 protein, 
peripheral myelin protein 22, nerve growth factor receptor, nestin, neuron specific 
enolase, chromogranin A, and myelin basic protein. Of these, periaxin was confirmed as 
the most sensitive and specific marker, labelling the majority of DFTD cells in all 
primary DFTD tumours and DFTD metastases. In normal tissues, periaxin showed 
specificity for Schwann cells in peripheral nerve bundles. Periaxin expression was also 
maintained in cultured devil Schwann cells, DFTD cell lines, and xenografted DFTD 
tumours validating its utility as a diagnostic marker for the disease. 
PNST tumours have been described in humans and in several animal models (Bundza et 
al., 1986, Chijiwa et al., 2004, Nielsen et al., 2007, Schoniger and Summers, 2009, 
Schulman et al., 2009). Diagnosis of these tumours still remains a diagnostic challenge 
due to the lack of specific immunohistochemical markers of neural differentiation 
(Sandberg, 2008). Although labelling for S100 protein (S100) shows some non-specific 
activity, it is the most commonly used marker to identify PNST of various types 
(Coindre, 2003, Wu and Montgomery, 2008). In this study, S100 expression was 
observed in all DFTD tumour samples. The intensity of labelling and fraction of 
immunoreactive cells varied considerably among samples. This is a common finding 
with other studies (Nonaka et al., 2008, Stasik and Tawfik, 2006). S100 labelling was 
also observed in other tissues such as endothelium, skeletal muscle, hair follicles, 
kidney and connective tissue, and therefore is not a cell-specific marker. 
Other markers normally tested in PNST with different levels of reliability include 
myelin basic protein (MBP), nerve growth factor receptor (NGFR) and nestin (Chijiwa 
et al., 2004, Hoshi et al., 1994, Shimada et al., 2007, Stasik and Tawfik, 2006). NGFR 
positivity was found in 70% of the DFTD tumour samples. However, intensity of 
labelling was highly variable. Nestin and MBP stained only a small fraction of samples. 
Interpretation of results was also difficult due to the high level of non-specific labelling 
with MBP. 
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This study also tested periaxin, a marker of Schwann cell lineage (Gillespie et al., 1994) 
that was found to be expressed in the devil transcriptome (Murchison et al., 2010). The 
labelling for periaxin was intense and specific in DFTD tumours. Periaxin strongly 
labelled almost 100% of the neoplastic cells in all DFTD primary tumours with minimal 
non-specific labelling.  
Remarkably, the high levels of periaxin protein expression were maintained in all 
DFTD metastases. Protein expression was also preserved after the xeno-transplantation 
and passage of DFTD tumour cells into NOD-SCID mice, including tumours from the 
second generation. Similarly, cultured devil Schwann cells and DFTD tumour cell lines 
were all positive for periaxin. These results provide evidence for the genetic stability of 
periaxin in vivo and in vitro and reinforce the value of the protein as a diagnostic marker 
in a wide range of DFTD models.  
In contrast, non-DFTD tumours did not show periaxin expression. Consequently, 
periaxin expression is useful for the differentiation of DFTD tumours from other 
cancers of similar appearance. Similarly, periaxin can be a useful marker for identifying 
tumour cells in early DFTD tumours. These small tumours can be difficult to 
distinguish from the lacerations and scars often observed in the face of the animals, 
which are produced by the common biting behaviour in devils (Hamede et al., 2008). 
Fixed sample from small punch biopsies are useful for this purpose.  
Given the clonal and stable characteristics of the DFTD karyotype (Deakin et al., 2012), 
current gold standard for tumour identification is cytogenetics. The distinctive 
karyotype is specific for devil facial tumour cells and is an important tool for diagnosis 
and monitoring the evolution of the disease (Deakin et al., 2012, Pearse and Swift, 
2006). One of the major disadvantages is the need for fresh tumour samples for 
establishment of cell cultures under sterile conditions before chromosome analysis 
(Sandberg and Meloni-Ehrig, 2010). This is time consuming and labour intensive. 
Periaxin offer a reliable and quicker alternative.  
Therefore, this thesis proposes periaxin as a reliable, sensitive and specific marker for 
DFTD. It has been suggested that the most valuable immunohistologic markers are 
those that are linked to the cell of origin or those that reflect the genetic signature of the 
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tumour (Natkunam and Mason, 2006). As shown here, periaxin certainly meets these 
two criteria.  
The diagnostic of PNST in humans relies in S100 expression plus a range of other 
unreliable markers (Coindre, 2003). This thesis showed that periaxin was consistent and 
specifically expressed in DFTD, which is a PNST. The study of DFTD may have 
relevance for human cancer by identifying a reliable diagnostic marker.  
An interesting aspect of the findings is that despite their similar morphology, the tumour 
cells surrounding the tumour nests have higher levels of protein expression, especially 
in the areas where the cells are in close contact with the surrounding normal connective 
tissue. The role of the tumour microenvironment in tumour growth and invasion has 
been widely investigated (Albini and Sporn, 2007, Bierie and Moses, 2006). It is 
probable that the interactions between the cancer cells at the periphery of the tumour 
nest and the surrounding stromal cells induce differential protein expression compared 
to that of the internal tumour cells. The variability of expression of the markers 
between, and within, tumours could also reflect different stages of tumour development. 
This could be revealed in the current study by the pattern of growth of the tumour 
fascicles or nodules, which is clearly concentric and layered with centralized areas of 
tumour cell necrosis. The interaction of DFTD tumour cells with the extracellular 
matrix and its function for tumour progression is an important aspect that will require 
further investigation.  
In conclusion, this study presents periaxin as a new sensitive marker for DFTD that will 
greatly facilitate the diagnosis of the disease in histological and cytological samples. 
Periaxin expression is maintained in DFTD metastases, xenografted tumours and cell 
lines supporting its importance as a biomarker for the disease. Using 
immunohistochemistry techniques for diagnosis of DFTD in fixed tissue samples has 
evident advantages compared to the current cytogenetics methods. Periaxin could also 
be a potential marker for the diagnosis of neoplasias of Schwann cell origin in other 
species. Thus, the improvement of the diagnosis of DFTD and the finding that over 
expressed genes in the tumour (Murchison et al., 2010) can be recognized with specific 
markers open new opportunities for the understanding and management of this unusual 
disease.
  
 
4 Analysis of MHC class I expression in DFTD 
 Chapter 4. MHC-I expression in DFTD 
 78 
Table of Contents 
4.1 Introduction ................................................................................................................. 79 
4.2 Methods....................................................................................................................... 81 
4.2.1 Flow Cytometry ........................................................................................ 81 
4.2.2 Western blot .............................................................................................. 82 
4.2.3 Immunohistochemistry .............................................................................. 84 
4.2.4 Immunofluorescence ................................................................................. 84 
4.3 Results ......................................................................................................................... 86 
4.3.1 Screening the reactivity of readily available anti-MHC-I antibodies ....... 86 
4.3.2 Assessing the reactivity of custom-designed monoclonal anti-devil MHC-I 
antibodies ................................................................................................................ 90 
4.3.3 Analysis of MHC-I expression in devil tissues and DFTD: Western blot 
analyses  ................................................................................................................... 92 
4.3.4 Analysis of MHC-I expression in devil tissues and DFTD tumours: 
Immunohistochemistry analyses ............................................................................. 97 
4.3.5 Analysis of MHC-I expression in cultured devil fibroblasts and devil 
facial tumour cells: Immunofluorescence studies ................................................. 103 
4.4 Discussion ................................................................................................................. 107 
 
 Chapter 4. MHC-I expression in DFTD 
 79 
4.1 Introduction 
Devil facial tumour cells spread between unrelated individuals without evoking an 
immune response despite the devils having a competent immune system (Kreiss et al., 
2008, Kreiss, 2009, Kreiss et al., 2009, Woods et al., 2007). Affected animals die within 
months of tumour appearance and the species could face extinction within 25 years 
(Hawkins et al., 2006).  
Initial sequencing analyses showed that devils have low levels of genetic diversity at the 
major histocompatibility complex (MHC) (Siddle et al., 2007b) and devils from eastern 
Tasmania showed weak responses to allogeneic mixed lymphocyte reactions (MLR) in 
culture (Woods et al., 2007). This combined data suggested that DFTD tumour cells and 
the host might be identical at the MHC loci allowing the tumour to spread without 
encountering any histocompatibility barriers (Siddle et al., 2007a, Siddle et al., 2007b).  
Experimental transplantation of skin grafts and MLR between unrelated devils provided 
evidence that the devils are capable of allogeneic responses (Kreiss et al., 2011a). 
Devils rejected the skin grafts regardless of the MHC type and the strongest MLR 
responses occurred when mixing lymphocytes from eastern Tasmanian devils with 
lymphocytes from western Tasmanian animals. Therefore, it is likely that DFTD 
evolved special adaptive mechanisms that allow allotransplantation of tumour cells 
without immune recognition.  
Downregulation of MHC class I (MHC-I) expression is very common in cancer 
(Aptsiauri et al., 2007). This particular mechanism allows successful allotransplantation 
of cancer cells in the canine transmissible venereal tumour (CTVT), the only other 
naturally occurring contagious cancer (Cohen et al., 1984). However, MHC-I 
expression in devil facial tumour cells has only been studied at the genetic level. Thus, 
this chapter investigated the protein expression of MHC-I to determine if this 
mechanism may explain the lack of immune response to DFTD cells.  
As specific anti-devil reagents were not available, cross-reactivity of a range of 
commercial anti-MHC antibodies were initially evaluated. Anti-human, anti-mouse and 
anti- short-tailed opossum (Monodelphis domestica) antibodies developed and provided 
by research collaborators, were also evaluated. An anti-devil MHC-I antibody recently 
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developed by collaborators in UK was also tested in this current study. A wide range of 
techniques were used to evaluate MHC-I protein expression. These included flow 
cytometry of DFTD cell lines and immunofluorescence performed on DFTD cell lines 
and devil primary cultured fibroblasts. DFTD primary tumours and metastases were 
also evaluated using immunohistochemistry. Western blot was performed using protein 
extraction from primary tumours, devil tissues and cell lines.  
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4.2 Methods 
4.2.1 Flow Cytometry 
Human, Tasmanian devil and opossum leukocytes isolated from peripheral blood were 
used to test the suitability and cross-reactivity of readily available anti-MHC class I 
antibodies.   
Approximately 10 ml of blood was taken from the jugular vein from anaesthetised 
Tasmanian devils (permit # A0009215 from the University of Tasmania Animal Ethics 
Committee) following standard veterinary procedures previously described (Brown et 
al., 2011). Approximately 5 ml of blood was collected during autopsy of captive 
opossums (held at Melbourne University). Approximately 10 ml of human blood 
samples were taken from volunteer donors (permit # H0011494 from the University of 
Tasmania Human Research Ethics Committee). Blood samples were collected in 
heparin tubes and kept at room temperature. Under sterile conditions, each sample was 
diluted 1:1 with PBS. In 15 ml centrifuge tubes, the diluted blood samples were layered 
onto a Histopaque 1077 gradient (Sigma, USA) and then centrifuged at 400 × g for 30 
minutes. The mononuclear cell layer was collected from each sample into a separate 
centrifuge tube, 10 ml PBS added and centrifuged at 250 × g for 10 minutes to wash. 
The wash step was then repeated. Samples were then resuspended in PBS containing 
10% foetal calf serum. Appendix 2 provides a complete list of reagents.  
MHC-I expression was assessed with flow cytometry using a wide range of readily 
available anti-MHC class I antibodies in order to examine potential inter-species cross-
reactivity (Table 4.1). All assays were run in triplicate. The flow cytometry protocol 
was as described in chapter 2.2.4. Briefly, cell surface MHC-I expression was assessed 
in intact (non-permeabilized) leukocytes labelled with primary antibody and an Alexa 
Fluor 488-conjugated secondary antibody (Invitrogen, Carlsbad, CA). Fluorescence 
intensity was detected in a BD FACS canto II flow cytometer and analysed using BD 
CellQuest Pro v5.2.1 software. For analysis of MHC-I intracellular expression, the 
leukocytes were first fixed and permeabilized, using Fix and Perm Cell 
Permeabilization Reagents GAS003 (Invitrogen, Carlsbad, CA) according to the 
manufacturer’s protocol.  
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4.2.2 Western blot  
Protein samples 
Samples of primary DFTD tumours, normal devil tissues and murine xenografted DFTD 
tumours were supplied by the tissue bank held at the Menzies Research Institute Tasmania, 
University of Tasmania. Tissues samples were kept at -80 oC. DFTD cell lines were 
provided by the Department of Primary Industry, Parks, Water and Environment 
(DPIPWE), Tasmania. 
Table 4.1 List of anti-MHC-I antibodies tested against devil peripheral blood mononuclear cells 
Antibody Species Reactivity Antibody Species Reactivity 
Commercial 
MHC-I 2G5 
AbD Serotec 
MCA2189 
Mouse 
IgG2b 
Rat, Guinea pig, 
sheep, bovine, 
pig, human, 
hamster 
MHC-I EH-144*  Mouse Mouse 
Commercial 
B2MAbcam 
ab27588 
Mouse 
IgG2a 
Human, pig MHC-I Y-3* Mouse Mouse 
MHC-I 
W6/32* 
Mouse Human MHC-I 34.7.23* Mouse Mouse 
MHC-I Y25* Mouse Mouse MHC-I MKD6* Mouse Mouse 
MHC-I 5FI* Mouse Mouse MHC-I 20.8.4* Mouse Mouse 
MHC-I 16.12* Mouse Mouse MHC-I 28.11.5* Mouse Mouse 
MHC-I BW4* Mouse Human MHC-I 3.4.2.12* Mouse Mouse 
MHC-I 2.28* Mouse Human MHC-I B721* Mouse Human 
MHC-I BB7.7* Mouse Human MHC Modo UA** Rabbit Opossum 
MHC-I B27* Mouse Human MHC Modo UG** Rabbit Opossum 
MHC-I 20C3* Mouse Human MHC Modo UJ** Rabbit Opossum 
MHC-I 3E12* Mouse Human 
MHC-I(TD5, 
TD26, TD35, 
TD50)*** 
Mouse Devil 
MHC-I 20F2* Mouse Human    
Commercial antibodies were used at 1/200 dilution. *Culture supernatant provided by J. McCluskey 
(University of Melbourne) were used at 1/3 dilution. **Antibodies (purified rabbit serum) developed and 
provided by M. Baker (University of New Mexico, USA) and used at 1/100 dilution. ***Antibodies 
(supernatant) developed and provided by H. Siddle and J. Kaufman (University of Cambridge, UK). TD5, 
TD26, TD35 and TD50 represent four clones against the synthetic peptide (GGKGGDYVPAAGN) 
representing the cytoplasmic tail of devil MHC-I; each clone was used at 1/50 dilution.  
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Total protein was extracted from devil tissues, DFTD tumours, leukocytes and cell lines 
using 1 ml of ice-cold RIPA buffer (Thermo Scientific, Rockford, IL) containing 10 µl 
of Halt™ protease inhibitor cocktail (Thermo Scientific) for approximately 40 mg of 
tissue sample or cell pellet. Sample homogenization was performed in 2 ml screw-cap 
vials containing 1 mm zirconia/silica beads (BioSpec Products, Bartlesville, OK) and 
extraction buffer. Total disruption of the tissue was obtained in 4-5 shaking cycles of 1 
minute in a Mini-bead beater model 607 (BioSpec Products). The sample was then 
centrifuged at 14,000 × g for 30 minutes at room temperature and the supernatant 
transferred to a new tube for protein concentration quantification using the DC-protein 
assay (Bio-Rad, Hercules, CA) following manufacturer’s specifications.  
SDS-electrophoresis 
Electrophoresis was performed using the NuPAGE® system and the XCell SureLock™ 
mini cell (Invitrogen, Carlsbad, CA). 
40 µg of protein sample was added to NuPAGE® LDS sample buffer (4X) and 
NuPAGE® reducing agent (10X) with the remaining volume made up by Milli-Q water 
to either 10 µl or 20 µl depending on the protein concentration. The samples were 
vortexed, centrifuged briefly and heated at 70 oC for 10.  
Samples were loaded on 4-12% NuPAGE® Bis-Tris mini-gels. One of the lanes was 
loaded with a molecular weight marker (Spectra Multicolor Broad Range Protein 
Ladder – Thermo Scientific). The inner buffer chamber of the mini-cell was filled with 
200 ml of NuPAGE® SDS MOPS running buffer containing 500 µl of NuPAGE® 
antioxidant. The outer buffer chamber was filled with 600 ml of NuPAGE® SDS 
MOPS running buffer. The gel was run at 200 V for 50 minutes.  
Protein transfer 
Electroblotting of proteins from the gel to a nitrocellulose membrane, 0.45 µm (Bio-
Rad, Germany) was performed using the XCell II™ Blot Module system (Invitrogen). 
Blotting was performed using 1XNuPAGE® transfer buffer with 10% methanol 
overnight at 4 oC and 25 V.  
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Immunodetection 
Membranes were blocked in TBSTM (TBS buffer, 0.1% Tween 20, 5% skim milk) for 
1 hour at room temperature. The membrane was then incubated with the primary 
antibody diluted in TBSTM for 2 hours at room temperature, quickly washed twice with 
TBST (TBS, 0.1% Tween 20) and then 4 × 5 minutes with TBST at room temperature. 
The membranes were then incubated with the horseradish peroxidase (HRP)-conjugated 
anti-rabbit (NIF 824) or anti-mouse (NIF 825) secondary antibody (Amersham 
Biosciences, Piscataway, NJ) diluted in TBSTM for one hour and again washed as 
described above.  Chemiluminescent detection was performed following membrane 
immersion with Immobilon™ Western HRP substrate (Millipore, Billerica, MA) for 5 
minutes at room temperature using a Chemi-Smart 5000 digital camera (Vilber 
Lourmat, EEC).  Amersham 
(Piscataway, NJ) 
4.2.3 Immunohistochemistry 
Samples from primary DFTD tumours, DFTD metastases and normal tissues were 
evaluated by immunohistochemistry for the expression of MHC-I. Serial sections were 
used to identify DFTD cells and tumour nests by their labelling with the anti-periaxin 
antibody (Sigma/HPA 001868). Tissue section preparations and immunohistochemistry 
protocols were as described in Chapter 2.2. Optimal concentration of the anti-devil 
MHC-I antibody was initially determined by serial dilution. The preferred concentration 
for each clone was 1/50.  
4.2.4 Immunofluorescence 
Cell lines 
DFTD cell lines provided by the DPIPWE were plated onto Poly-L-Lysine (Sigma)-
coated coverslips and incubated to semi-confluence at 37 oC and 5% CO2 in complete 
RPMI medium (RPMI 1640, Gibco, New Zealand) containing 10% foetal calf serum, 
2 mM of L-glutamine (Sigma) and 40 mg/ml of gentamicin (Pfizer, Australia).  
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Primary fibroblasts cell culture 
In order to compare the MHC-I expression of DFTD tumour cells with that of normal 
cells, a primary culture of fibroblast was established. Samples of ovary and uterus tissue 
were taken during the autopsy of an adult devil. The tissue was dissociated with a sterile 
scalpel in PBS containing 0.25% trypsin (Sigma) and incubated overnight at 4 oC. The 
tissue was then diluted with 3 ml of complete RPMI medium and washed through a 70 
µm cell strainer (BD Falcon, Franklin Lakes, NJ) with 3 ml of complete RPMI medium. 
The filtrate was centrifuged at 500 × g for 3 minutes and the supernatant discarded. The 
cell pellet was resuspended in 8 ml of complete RPMI medium, plated onto Poly-L-
Lysine-coated coverslips and incubated to semi-confluence at 37 oC and 5% CO2.  
Primary DFTD cells culture  
One to two needle aspiration biopsies (approximately 200 ul each) were taken from a 
primary DFTD tumour and collected in complete RPMI medium. The cell suspension 
was washed through a 70 µm cell strainer and the filtrate centrifuged at 500 × g for 3 
minutes. The cell pellet was resuspended in 8 ml of complete RPMI medium, plated 
onto Poly-L-Lysine-coated coverslips and incubated to semi-confluence at 37 oC and 
5% CO2. The same procedure was repeated with at least three tumours from different 
individuals and the best culture selected for further analysis.  
Immunofluorescence 
Immunofluorescence protocol was as described in section 3.2.4. Briefly, cells growing 
on coverslips were fixed with paraformaldehyde before labelling with the primary 
antibodies (mouse anti-devil MHC-I and rabbit anti-periaxin) and secondary antibodies 
(Alexa Fluor 488 goat anti-mouse, Alexa Fluor 633 goat anti-rabbit [Invitrogen]). Actin 
stain (Alexa Fluor 546 phalloidin, Invitrogen) was also added to the cells as a 
counterstain and to visualise all the cells. A confocal microscope was used for 
visualization and imaging of the labelling.  
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4.3 Results 
Flow cytometry, western blotting, immunohistochemistry and immunofluorescence 
techniques were used to study the expression of MHC molecules in devil tissues and 
DFTD cells. Due to the lack of specific antibodies against devil MHC molecules, a 
significant part of the research involved testing a broad range of commercial reagents 
and in house designed reagents provided by research collaborators. This section also 
presents a summary of these screening studies. 
4.3.1 Screening the reactivity of readily available anti-MHC-I antibodies 
Flow cytometry was used to screen and test the reactivity of commercial and other 
available antibodies against MHC-I molecules on devil peripheral blood mononuclear 
cells. These included antibodies widely used such as the clone W6/32 which is 
conformationally dependent on the expression of both MHC-heavy chain and beta-2-
microglobulin (B2M); the clone 2G5, a conformationally dependent antibody that 
recognises an MHC-I epitope phylogenetically conserved, and an antibody against the 
highly conserved B2M. In total 19 different antibodies against human and mouse 
MHC-I donated by colleagues at the University of Melbourne (Australia) were tested. 
All antibodies were tested in triplicate.  
This section presents representative results showing only three of the antibodies tested, 
the three that were most likely to display cross-reactivity with devil MHC-I (i.e. the 
clones W6/32, 2G5 and B2M). MHC-I expression at the cell surface (intact cells) and 
intracellular (permeabilized cells) was clearly detected in the human leukocytes used as 
positive control. However, no cross-reactivity was observed with the three antibodies 
tested in devil leukocytes (Figure 4.1). All the remaining 18 antibodies were also 
negative with devil leukocytes.  
Colleagues at the University of New Mexico (USA) developed polyclonal antibodies 
against published classical (Modo UA) and non-classical (Modo UG, Modo UJ) MHC-I 
sequences of the grey, short-tailed opossum (Monodelphis domestica), a South 
American marsupial (Baker et al., 2009, Gouin et al., 2006, Miska and Miller, 1999). 
The specificity of these antibodies was assessed for the first time in both opossum and 
Tasmanian devil leukocytes. The antibodies were tested in permeabilized and non-
 Chapter 4. MHC-I expression in DFTD 
 87 
permeabilized cells using flow cytometry (Figure 4.2). Unfortunately, these antibodies 
failed to detect MHC-I in the intact opossum leukocytes that were used as a positive 
control. Modo UG (a non-classical MHC-I molecule) was detected in permeabilized 
opossum leukocytes although high background was also observed with the isotype 
control. The non-classical Modo UJ was also detected but at the same level as the 
isotype. Therefore, the reactivity of these antibodies for detection of devil MHC-I was 
difficult to interpret and they were not considered useful for further analyses.  
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Figure 4.1 Studies of tissue cross-reactivity of readily available MHC-I antibodies on Tasmanian devil leukocytes. Two antibodies against MHC-I (clone 2G5 and clone W6/32) 
and one antibody against beta-2-microglobulin (B2M) were tested on human and devil leukocytes isolated from peripheral blood. Cell surface or intracellular MHC-I expression 
was investigated in non-permeabilized or permeabilized cells respectively using flow cytometry. Cell surface MHC-I expression was clearly observed in the non-permeabilized 
human leukocytes used as a positive control (left panels). Intracellular expression was also detected with the clone W6/32 and the B2M antibody in human leukocytes. In 
contrast, these antibodies failed to detect surface or intracellular MHC-I expression in devil leukocytes (right panels). Isotype and negative controls (omitting the primary 
antibody) are also shown.  
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Figure 4.2 Studies of tissue cross-reactivity of anti-opossum MHC-I antibodies on opossum and Tasmanian devil leukocytes. Three anti-opossum MHC-I antibodies 
against classical (modo UA) and non-classical molecules (modo UG and modo UJ) were tested on opossum and devil leukocytes isolated from peripheral blood using flow 
cytometry. Cell surface or intracellular MHC-I expression was investigated in non-permeabilized or permeabilized cells respectively. No cell surface expression was 
detected in opossum leukocytes used as positive control. High levels of background (as determined by the isotype control) were also observed in the permeabilized 
opossum leukocytes (left panels). The lack of surface reactivity and high levels of background in the positive controls make the interpretation of the results in the devil 
leukocytes difficult and uncertain (right panels). Thus, the antibodies were not considered suitable for further studies.  
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4.3.2 Assessing the reactivity of custom-designed monoclonal anti-devil MHC-I 
antibodies 
During the course of this research, H. Siddle and J. Kaufman, collaborators from the 
University of Cambridge (UK), developed the first monoclonal antibodies against a 
synthetic peptide (GGKGGDYVPAAGN) representing the cytoplasmic region of a devil 
MHC-I sequence (Siddle et al., 2007b). The antibodies included four clones (from the 
same exon) designated as TD5, TD26, TD35 and TD50. Western blot analyses were used 
to test the specificity and suitability of these antibodies for detection of MHC-I in proteins 
isolated from tissue samples. Testing the clones individually, MHC-I was detected in 
proteins extracted from devil spleen, kidney and leukocytes. Specificity was demonstrated 
by detection of a single band of approximately 40 kDa (the molecular weight expected for 
the MHC-I molecule) in the three tissue samples. Results were consistent for the four 
antibodies (Figure 4.3.A). Spleen and leukocytes showed similar levels of expression and 
therefore these tissues were selected as positive controls for further experiments.  
Specificity of the antibodies was also confirmed using mouse IgG as an isotype control 
and omitting the primary antibody as a negative control. In this experiment the four 
MHC-I clones were combined as an antibody cocktail without altering the results 
previously observed (Figure 4.3.B). This preparation (combining the four clones) was 
then used for further experiments.  
Finally, commercial antibodies against the cytoskeleton protein actin (beta actin 
polyclonal antibody ab729, Abcam, Cambridge, UK), the microtubule protein tubulin 
(alpha tubulin monoclonal antibody ab8227, Abcam) and the glycolytic enzyme 
phosphoglycerate kinase 1 (PGK1 monoclonal antibody ab67335, Abcam) were tested as 
loading controls for the western blot analyses. Cross-reactivity of these antibodies was 
assessed in proteins isolated from devil spleen tissue and primary devil facial tumours. 
DFTD tumour showed higher levels of expression of PGK1 and tubulin compared to 
spleen. The level of expression of actin was similar in both tissues (Figure 4.3.C) and thus 
it was selected as the loading control. Actin has a close molecular weight to that of the 
MHC-I (around 40 kDa) making it difficult to detect both proteins in one single lane. 
Therefore, actin controls were loaded in a separated lane and run in parallel under the 
same conditions.  
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Figure 4.3 Testing the suitability of anti-devil MHC-I antibodies for protein expression analyses in devil 
tissues using western blotting. A, Total protein (40 µg) extracted from devil spleen (S), kidney (K) and 
leukocytes (L) was separated using gel electrophoresis and transferred onto nitrocellulose membranes for 
immune detection using custom antibodies against devil MHC-I (clones TD5, TD26, TD50, TD35). A single 
band was detected in the three tissues at 40 kDa, the molecular weight expected for the MHC-I molecule. B, 
Specificity of the custom antibodies was confirmed in protein extractions of devil spleen (S) and leukocytes 
isolated from peripheral blood (L). The membranes were probed with MHC-I antibody (a combination of the 
four clones), and isotype control (mouse IgG) or omitting the primary antibody (negative control). C, Three 
commercial loading controls were tested on proteins extracted from primary DFTD tumour (T) and devil 
spleen (S). Actin showed a more similar level of expression in both tissues compared to that of the 
phosphoglycerate kinase 1 (PGK1) and tubulin. Signal detection was achieved using a chemiluminescence 
substrate (Millipore) and images taken with a Chemi-Smart 5000 digital camera (Vilber Lourmat). Scale 
(molecular weight) at the right of the panels is in kDa. 
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4.3.3 Analysis of MHC-I expression in devil tissues and DFTD: Western blot 
analyses 
MHC-I expression in normal tissue and primary DFTD tumours 
The level of expression of MHC-I in normal devil tissue and primary DFTD tumours 
was assessed using western blot analysis as described previously. MHC-I expression 
was clear and consistently detected in all samples (10/10) of normal devil spleen. Four 
spleen samples had particularly high levels of expression (Figure 4.4). The devil spleen 
is a structurally complex organ with a capsule rich in blood vessels and a white pulp 
rich in lymphoid tissue. Random small tissue samples (around 0.5 cm3) were taken 
during autopsy and it is likely that differences in MHC-I expression simply reflect the 
heterogeneity of the tissue.  
MHC-I expression was clearly detected in seven of the fourteen DFTD tumour samples. 
Levels of expression in the positive samples were similar to that of the spleen. No 
expression, or low level of expression, was observed in the other seven DFTD samples. 
Additionally, some non-specific bands (approximately 60 kDa), not previously observed 
in normal tissues (kidney, spleen or leukocytes), were apparent in some of the tumour 
samples (Figure 4.4).  
The loading control actin showed similar levels of expression in all samples of devil 
spleen and most DFTD tumours. This reinforced the observation that the levels of 
MHC-I expression are characteristic of the tissues and not due to different amounts of 
protein loaded for each sample.  
MHC-I expression in DFTD cell lines and mouse xenografted DFTD tumours 
MHC-I expression was weakly detected in proteins extracted from only one of the six 
DFTD cell lines. However, the level of MHC-I expression was lower compared to that 
of the spleen or the level of expression previously observed in isolated leukocytes 
(Figure 4.5). No bands were detected at the expected molecular weight for MHC-I in the 
other five DFTD cell lines. Instead, a band was detected at a molecular weight of 
approximately 60 kDa, similar to the additional band observed in proteins from primary 
DFTD tumours. Likewise, a band of similar size was detected in proteins extracted from 
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the cell line K562, a human leukaemia cell line that lacks MHC-I expression (Figure 
4.5).  
MHC-I expression was also assessed in proteins extracted from DFTD tumours that 
were xenografted onto NOD/SCID mice. MHC-I expression was not detected in any of 
the samples (9/9). The devil spleen sample loaded as a positive control showed the 
expected band (40 KDa) for MHC-I. Similar to the cell lines and primary DFTD 
tumours, a band around 60 kDa was detected in seven of the DFTD xenografts (Figure 
4.5).  
MHC-I expression in devil peripheral nerve tissue  
Devil peripheral nerve, a tissue enriched with Schwann cells, was used to study the 
levels of MHC-I expression in these cells. After removal of the gross epineurial 
connective tissue whole cell proteins were extracted from adult devil peripheral nerves 
and analysed by western blot. No MHC-I expression was observed in any of the seven 
peripheral nerve protein samples analysed (Figure 4.6).  
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Figure 4.4 MHC-I expression in normal devil tissues and DFTD primary tumours. Western blots of total proteins (40 µg) from devil spleen (S1-S10) and DFTD primary tumours (T1-T14) probed with 
a cocktail of anti-devil MHC-I antibodies (clones TD5, TD26, TD35 and TD50). MHC-I was detected in all spleen samples as a unique band at 40 kDa (left panel). MHC-I was only clearly detected in 
seven of fourteen samples of DFTD primary tumours. An additional band at approximately 60 kDa was also observed in some of the tumour samples. Loading control actin is showed at the bottom of 
the panels. Signal detection was achieved using a chemiluminescence substrate (Millipore) and images taken with a Chemi-Smart 5000 digital camera (Vilber Lourmat). Scale (molecular weight) at the 
right of the panels is in kDa.  
- 225
- 115
- 80
- 65
- 50
- 35
- 30
- 25
- 15
- 10
- 50
- 35
S1          S2       S3           S4          S5         S6          S7        S 8       S9        S10         T1       T2   T3        T4        T5        T6         T7         T8        T9      T10     T11       T12      T13        T14   
MHC-I
Actin
Devil spleen tissue DFTD primary tumours
 Chapter 4. MHC-I expression in DFTD 
 95 
 
 
Figure 4.5 MHC-I expression in DFTD cell lines and murine xenografted DFTD tumours. Western blots of proteins extracted from DFTD cell lines (C1-C6) and xenografted 
DFTD tumours (X1-X9) probed with a cocktail of anti-devil MHC-I antibodies (clones TD5, TD26, TD35 and TD50). MHC-I was detected in only one cell line (left panel). None 
of the xenografted DFTD tumours showed MHC-I expression at the correct molecular weight. MHC-I was detected in the spleen sample (S) used as positive control. A band around 
60 kDa was observed in most of the DFTD cell lines and xenografted tumours. A similar band was detected in the human leukaemia cell line K562 (HC in the left panel). Loading 
control actin is shown at the bottom of the panels. Signal detection was achieved using a chemiluminescence substrate (Millipore) and images taken with a Chemi-Smart 5000 
digital camera (Vilber Lourmat). Scale (molecular weight) at the right of the membranes is in kDa. 
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Figure 4.6 MHC-I expression in peripheral nerve. Western blot of proteins extracted 
from devil peripheral nerve samples (PN1-PN7) probed with a cocktail of MHC-I 
antibodies (clones TD5, TD26, TD35 and TD50). None of the samples (O/7) showed 
MHC-I expression. The protein from spleen tissue (S) used as a positive control shows 
the MHC-I band at 40kDa. Actin (blue bands) as loading control is showed under the 
main panel. Signal detection was achieved using a chemiluminescence substrate 
(Millipore) and images taken with a Chemi-Smart 5000 digital camera (Vilber 
Lourmat). Scale (molecular weight) at the right of the membranes is in kDa.  
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4.3.4 Analysis of MHC-I expression in devil tissues and DFTD tumours: 
Immunohistochemistry analyses 
The western blot analyses showed in the previous section indicated that a range of 
primary DFTD tumours express variable levels of MHC-I. Expression ranged from no 
detectable expression to levels similar to that of the normal control tissues such as 
spleen or leukocytes. Primary DFTD tumours normally grow within the dermis as 
aggregated nests or cords surrounded by connective tissue. Angiogenesis is also 
common. Consequently, protein preparations from samples of primary tumours that 
contain only tumour cells were difficult to obtain. Immunohistochemistry of tissue 
sections was used to investigate if the variability in the levels of MHC-I expression in 
DFTD observed by western blot analysis was related to the heterogeneous cell 
composition of the tumour sample or truly reflected the altered expression in the cancer 
cells.  
Tissue sections of 28 primary tumours and 13 metastases were labelled with the 
anti-devil MHC-I antibodies cocktail. Observation of the labelling of normal tissue 
surrounding the tumours was used to compare the levels of expression between different 
types of cells. Strong MHC-I labelling was observed in epithelial cells within the skin. 
This labelling was both cytoplasmic and associated with the cell nucleus, and was 
observed in virtually all the skin cells (Figure 4.7). Fibroblasts in the underlying dermis 
and those in the connective tissue surrounding the tumours also showed cytoplasmic 
labelling (Figure 4.7). In some samples, the epithelial cells showed clear MHC-I 
labelling associated with the cell membrane (Figure 4.8). Positive cytoplasmic 
expression was also observed in endothelial cells (Figure 4.8) and lymphoid cells in the 
spleen and lymph nodes.  
In general, the intensity of the labelling in primary DFTD tumour cells was lower than 
that of cells of surrounding normal tissue. In tumours forming dense nodules, the cancer 
cells at the periphery of the tumour nest and close to the surrounding normal/connective 
tissue showed stronger labelling compared to that of the cancer cells towards the centre 
of the nest (Figure 4.7). In a few tumour samples some of the tumour cells showed 
strong MHC-I labelling. Regardless of the intensity, labelling in tumour cells in all 
samples was primarily associated with the cell nucleus and in some cases cytoplasmic. 
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Significantly, no MHC-I labelling appeared to be associated with the cell membrane of 
the tumour cells (Figure 4.8).  
Similarly, negative to moderate MHC-I labelling was observed in the tumour cells of 
the DFTD metastases. Immunoreactivity was mainly peri-nuclear or cytoplasmic and 
never associated with the membrane (Figure 4.9).  
A semi-quantitative assessment of the MHC-I immunolabelling indicated that 86% of 
the primary tumour samples (24/28) showed negative to weak labelling in more than 
50% of the tumour cells. In 11% of the samples (3/28) there was moderate MHC-I 
labelling, while only one sample labelled strongly in more than 50% of the tumour cells. 
Likewise, 85% of the DFTD metastases (11/13) were negative or labelled weakly in 
more than 50% of the tumour cells. Labelling of the rest of the samples (2/13) was 
moderate. Strong labelling was not observed in DFTD metastases.  
Finally, tissue sections of peripheral nerves within the skin were analysed for the 
expression of MHC-I. The immunohistochemistry studies supported the western blot 
analyses. Schwann cells within peripheral nerve bundles showed negative MHC-I 
labelling compared to that of the supporting cells within the bundle or the surrounding 
stromal tissue (Figure 4.10). 
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Figure 4.7 MHC-I expression in devil skin and DFTD tumour cells. A, Immunohistochemistry labelling of a section 
of devil skin containing a DFTD tumour nest (arrows) using a cocktail of anti-devil MHC-I antibodies (clones TD5, 
TD26, TD35 and TD50). DFTD cells show lower MHC-I expression compared to that of epithelial cells in the 
epidermis and normal cells within the dermis. Right panels: Magnification of the areas indicated with boxes in the left 
panel. B, Epithelial cells showing strong cytoplasmic and nuclear MHC-I labelling. Fibroblasts (arrowheads) and 
other cells in the dermis also show strong cytoplasmic labelling. C, Magnification of the area of contact between 
tumour cells (tumour nest periphery) and the surrounding stromal tissue. Tumour cells (arrows) show weak to 
moderate MHC-I labelling compared to that of the surrounding fibroblasts (arrowheads). D, DFTD tumours cells at 
the centre of the tumour nest showing negative MHC-I expression. Immunohistochemical detection with EnVision+ 
system (Dako) with hematoxylin counterstain.  
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Figure 4.8 Patterns of MHC-I expression in normal devil tissues and devil facial tumours. A, Immunohistochemistry 
labelling of a section of normal epidermal tissues. Epithelial cells (arrows) show clear cytoplasmic MHC-I labelling 
associated with the cell membrane. Fibroblasts, endothelial cells, and leukocytes cells within blood vessel also show 
MHC-I labelling. B, DFTD tumour cells (arrows) show MHC-I labelling associated with the nucleus. Labelling 
intensity is similar to that of the surrounding normal cells (arrowheads). C-D, Variable MHC-I labelling of DFTD 
tumour cells (arrows). Normal cells (arrowheads) showing cytoplasmic MHC-I labelling. Immunohistochemical 
detection with EnVision+ system (Dako) with hematoxylin counterstain. 
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Figure 4.9 MHC-I expression in DFTD metastases. A-C, DFTD metastases in lymph nodes. A, 
Immunohistochemical labelling with periaxin antibody allows the detection of the tumour nests (arrows) within the 
normal lymph tissue (arrowhead). B, Same tissue section immunolabelled with MHC-I antibody. Normal connective 
and lymphoid tissue (arrowhead) shows MHC-I expression. DFTD metastases (arrows) show negative to very weak 
MHC-I labelling. C, Magnification of the area indicated by the box in the previous panel. Normal cells (arrowhead) 
show high intensity MHC-I labelling. DFTD cells (arrow) show weak cytoplasmic MHC-I expression. D-F, DFTD 
metastases in the lungs. D. Periaxin labelling that allows the detection of the tumour nests (arrows) within the normal 
lung tissue. E, DFTD cells (arrow) show very weak MHC-I labelling compared to that of the normal surrounding 
lung tissue (arrowheads). F, Magnification of the area indicated by the bottom box in the previous panel. DFTD 
tumour cells show weak cytoplasmic MHC-I labelling. The insert corresponds to the top box in panel E. Epithelial 
cells in a bronchiole show strong cytoplasmic MHC-I labelling that extends to the borders of the cell membrane. 
Immunohistochemical detection with EnVision+ system (Dako) with hematoxylin counterstain.  
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Figure 4.10 MHC-I expression in devil peripheral nerve. Left panels show immunohistochemistry labelling of a 
peripheral nerve bundle with periaxin antibody. Schwann cells within the bundle (arrow) show strong and specific 
periaxin labelling which is not observed in the surrounding tissue (arrowheads). The bottom left panel is a 
magnification of the area indicated in the top panel. Schwann cells (arrow) but not supporting cells show periaxin 
labelling. Right panels: the same tissue section labelled with a cocktail of MHC-I antibodies (TD5, TD26, TD35 and 
TD50). Stromal cells (arrowheads) show strong MHC-I immunolabelling. In contrast, most Schwann cells within the 
peripheral nerve bundle show no MHC-I expression. The bottom right panel is a magnification of the area in the box. 
Schwann cells within the bundle (arrow) express very weak levels of MHC-I protein. Supporting connective tissue 
cells within and surrounding the nerve bundle (arrowheads) show strong MHC-I labelling. Immunohistochemical 
detection with EnVision+ system (Dako) with hematoxylin counterstain.  
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4.3.5 Analysis of MHC-I expression in cultured devil fibroblasts and devil facial 
tumour cells: Immunofluorescence studies 
Cells from devil ovary, uterus tissue and needle aspiration biopsies taken from devil 
facial primary tumours were plated onto coverslips and cultured for 8 days for 
immunohistochemical visualisation of MHC-I expression using confocal microscopy.  
The primary cultured fibroblasts from devil ovary and uterus showed diffuse and 
punctate MHC-I labelling throughout the whole cytoplasm. MHC-I was colocalized 
with actin in the borders of the cells suggesting membrane expression (Figure 4.11). 
In the cultures of primary devil facial tumours MHC-I labelling was detected in both 
fibroblast and tumour cells. However, the subcellular localization was different. 
Fibroblasts showed diffuse MHC-I labelling that colocalized with actin in the borders of 
the cells. In contrast, MHC-I did not colocalized with actin in the membrane extensions 
of the DFTD cells and labelling was mainly focused around the cell nucleus (Figure 
4.12). 
MHC-I labelling of tumour cell lines was restricted to the cell nucleus and peri-nuclear 
regions, similar to the labelling observed in the primary cultured tumour cells. There 
was no evident localization of the labelling at the outer borders or extensions of the 
DFTD cells (Figure 4.13).  
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Figure 4.11 Cellular MHC-I localization in cultured devil fibroblasts. Confocal immunofluorescent microscopy analysis of MHC-I in 
primary cultures of devil fibroblasts extracted from ovary tissue (A-C) and fibroblasts extracted from devil uterus (D-F). A,D, Actin 
(red) staining. B,E, MHC-I labelling (green) is punctate and extends through the whole cell. C,F, Actin and MHC-I images merged. 
MHC-I colocalizes with actin at the periphery of the cell.  
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Figure 4.12 MHC-I colocalizes with actin in cell membrane extensions of fibroblasts but not in DFTD cells. Confocal immunofluorescent microscopy analysis of the cellular 
localization of MHC-I in primary cultured DFTD cells. Cells from needle aspiration biopsies from primary DFTD tumours were plated onto coverslips and immunolabelled 
with a cocktail of anti-devil MHC-I antibodies (TD5, TD26, TD35 and TD50), double labelled with periaxin and counterstained with actin (phalloidin). A, Actin staining (red) 
of DFTD cells and contaminating fibroblasts (arrows). B, Periaxin (cyan) only labels DFTD cells allowing them to be differentiated from fibroblasts. C, MHC-I labelling 
(green) is detected in fibroblast and DFTD cells. D, Images A, B and C merged. In DFTD cells MHC-I colocalizes with periaxin and actin mainly in the perinuclear area. E, 
Detail of the area indicated by the box in panel D. Actin (red) and MHC-I (green) are shown. In fibroblasts (arrows) MHC-I diffuses through the cytoplasm and colocalizes 
with actin at the membrane extensions of the cell. In DFTD cells (arrowheads) MHC-I labelling is perinuclear and does not extend to the cell membrane.  
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Figure 4.13 Cellular MHC-I localization in DFTD cell lines. Representative detail of the MHC-I labelling pattern in a DFTD cell using confocal immunofluorescent 
microscopy. A, Actin (red) staining. B, Periaxin (cyan) labels the cell through the whole cell surface. C, MHC-I labelling (green) is associated with the nucleus and the 
perinuclear region. D, Images A, B and C merged. E, Magnification of the cell showing only the actin (red) and MHC-I labelling (green). MHC-I does not colocalize with 
actin at the cell membrane.  
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4.4 Discussion 
The mechanisms that allow transplantation of devil facial tumour cells across major 
histocompatibility (MHC) barriers are not clearly understood. The absence of an 
immune response to tumour establishment and growth was initially attributed to the lack 
of genetic diversity at the MHC loci (Siddle et al., 2007a). However, recent studies 
showed that despite the limited allelic diversity, devils are capable of rejecting skin 
grafts and producing strong mixed lymphocyte reactions between individuals from 
different regions in Tasmania (Kreiss et al., 2011a). The tumour has also spread to devil 
populations that were predicted to be resistant due to a greater MHC diversity (Hamede 
et al., 2012). These lines of evidence suggest that the low MHC diversity alone cannot 
satisfactorily explain the lack of an immunological rejection to transferred tumour cells. 
This Chapter presents an integrated approach for the analysis of MHC-I protein 
expression in normal devil tissues and DFTD. Flow cytometry, western blot analyses, 
immunohistochemistry and confocal microscopy techniques were used to evaluate 
MHC-I expression in a variety of normal tissues, including leukocytes isolated from 
peripheral blood, primary devil facial tumours, metastases, and cultured devil 
fibroblasts and tumour cells. The combined results indicate that tumour cells have low 
levels and inappropriate localisation of MHC-I expression compared to that of normal 
tissues, such as epithelial, connective, endothelial and lymphoid tissue. This evidence 
provides an opportunity to consider other mechanisms of immune evasion that allow for 
the successful allotransplantation of tumour cells between devils in wild populations.  
Immune evasion by downregulation of MHC molecules is common in cancer (Aptsiauri 
et al., 2007). This particular mechanism explains the transplantation ability of 
neoplastic cells in the canine transmissible venereal tumour (CTVT), the only other 
naturally occurring contagious cancer (Cohen et al., 1984). However, a similar analysis 
of the expression of MHC proteins in devils was hindered by the lack of cross-reacting 
reagents. In this study, 24 different antibodies against MHC molecules were initially 
screened for specificity against the devil MHC-I. These included widely utilised 
antibodies such as the clones MHC-2G5, MHC-W6/32 and beta-2-microglobulin, and 
antibodies against MHC-I molecules of the grey-short tailed opossum, a South 
American marsupial. Unfortunately, none of the antibodies were able to detect devil 
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MHC-I proteins. Recently, collaborators from the University of Cambridge (UK) 
developed the first anti-devil MHC-I antibodies raised against a synthetic peptide 
(GGKGGDYVPAAGN) representing the cytoplasmic tail of a known published devil 
MHC-I sequence (Siddle et al., 2007b). These antibodies were used in this thesis to 
compare the expression of MHC-I in normal devil tissues and facial tumours.  
The specificity of the anti-devil MHC-I antibodies was validated in this thesis by 
detection of a unique band of approximately 40 kDa (expected mass for MHC-I 
proteins) by western analysis of normal tissue proteins. Our collaborators in Cambridge 
also confirmed the specificity of the antibodies by western analysis of proteins isolated 
from cultured devil fibroblasts. In their experiments, the specific MHC-I band also 
disappeared after blocking with a synthetic MHC-I peptide (H. Siddle, personal 
communication, November 2011) further validating the specificity of the antibodies. 
However, as indicated previously, this thesis identified by western analysis an 
additional band (of approximately 60 kDa) present in most of the DFTD protein 
samples (i.e. primary tumours, cell lines and xenografted DFTD tumours). This band 
persisted in western analysis even following strong conditions of reduction and 
denaturation (data not shown). Furthermore, a band of similar molecular weight was 
also observed in the human cell line K562 (with the anti-devil antibodies) that lacks 
MHC-I. This band was not observed in normal devil tissue proteins. Therefore, it is 
unlikely that the detected protein is MHC related. It is possible that the antibody is 
binding non-specifically to an unusual protein characteristic of the cancer cell proteome. 
An attempt was made to separate the protein using SDS-gel electrophoresis and to 
identify the protein using mass spectrometry. Several proteins were identified within the 
predicted molecular weight but they were not MHC-I related (Appendix 4).  
The additional band detected in the western blots should not affect the analysis derived 
from the immunohistochemistry studies. Four of the tumours samples were tested with 
both western blots and immunohistochemistry. One sample showed a weak band in the 
western blot analysis at both the correct (40 kDa) and additional 60 kDa bands. The 
other three samples only showed a weak band at 60 kDa, suggesting a lack of MHC-I 
expression. The immunohistochemistry for MHC-I was weakly positive, indicating that 
the non-specific binding was not detrimentally influencing these findings. As indicated 
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above, the extra 60 kDa band was only observed in tumour samples and not in normal 
tissues. At most, this low level of background in the immunohistochemistry of tumours 
might contribute to the “weak expression”. This would be an overestimate of the actual 
labelling and further support the concept that MHC-I is downregulated. It is highly 
unlikely that it would account entirely for the stronger staining patterns.  
MHC-I expression was first evaluated in normal devil tissues. Western blot analyses 
confirmed that MHC-I proteins are strongly expressed in kidney, spleen and leukocytes 
isolated from peripheral blood. Following this, the pattern of expression of MHC-I in 
situ was evaluated using immunohistochemistry. Strong MHC-I expression was 
observed in most cells within the skin including epidermal cells, fibroblasts and 
endothelial cells. Immune cells in lymph nodes expressed high levels of MHC-I protein. 
MHC-I expression was generally detected in the peri-nuclear region and diffusing 
throughout the cytoplasm. Clear MHC-I labelling associated with the cell membrane 
was observed in leukocytes, epithelial cells of the skin and epithelial cells in 
bronchioles. These combined results confirmed the synthesis of MHC-I proteins by 
normal devil cells. Detection of MHC-I associated with the cell membrane suggests that 
the underlying mechanisms and cellular components that regulate MHC-I translation, 
assembly and transport to the cell surface, are functional in Tasmanian devils.  
The results from the western blot analyses indicated that MHC-I protein expression in 
tumours is vastly different to that of normal devil tissues. MHC-I protein was only 
detected in half of the protein samples from DFTD primary tumours. Although some 
tumours showed high levels of MHC-I protein expression, it is possible that this was 
due to contaminating stromal cells (e.g. connective tissue and blood cells) in a 
heterogeneous tumour sample.  
In order to validate the western blot analyses, immunohistochemistry was used to study 
the in situ MHC-I expression in tumour sections. MHC-I protein was detected in DFTD 
cells of primary tumours. However, the levels of expression were always lower than that 
observed in normal cells such as epithelial cells, fibroblasts and leukocytes. Also the 
pattern of MHC-I expression in DFTD cells was atypical with most expression 
primarily perinuclear and in some cases cytoplasmic, but it was never observed to be 
associated with the cell membrane. These findings indicate that MHC-I protein 
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synthesis does occur in devil facial tumour cells. However, the immunohistochemistry 
suggests that these proteins are not transported to the cell surface.  
Confocal microscopy was then used to increase the resolution and visualization of 
MHC-I expression patterns in normal and cultured DFTD cells. Cultured normal devil 
fibroblasts showed diffuse cytoplasmic MHC-I expression that also colocalized with 
actin at the cell membrane. MHC-I was also detected in primary and long term cultures 
of DFTD cells. However, as observed with immunohistochemistry, the expression in 
tumour cells was restricted to the perinuclear region. These results confirmed that 
although MHC-I is produced in DFTD cells, the molecules are not transported to the 
cell surface.  
Thus, it is unlikely that MHC-I molecules in DFTD are immunologically functional. 
This relates to the capacity of MHC-I molecules of binding peptide fragments of 
intracellular proteins (antigens) and displaying them at the cell surface for antigen 
presentation to CD8+ T cells (Donaldson and Williams, 2009). Low levels or lack of 
membrane MHC-I expression reduces cancer cell immunogenicity and would confer a 
survival advantage for DFTD cells. Low MHC-I surface expression would explain why 
devil facial tumour cells establish and grow undetected by the devil’s immune system. 
The cytoplasmic and perinuclear localization of MHC-I in devil facial tumour cells 
strongly suggest that MHC-I molecules are retained within the ER compartment and not 
exported to the cell surface. The antigen presenting machinery (APM) plays a crucial 
role in mediating immune responses by the generation and expression of the trimeric 
MHC-I, beta-2-microglobulin (B2M) and peptide complex (Seliger, 2012 ). 
Components of the APM include the catalytic beta subunit of the proteasome, the 
transporter associated with antigen processing (TAP-1 and TAP-2) and various 
endoplasmic reticulum (ER) chaperones (Donaldson and Williams, 2009). Therefore, it 
is probable that deregulation of APM components is also occurring in DFTD. 
Under normal circumstances, the levels of MHC-I and APM components expression are 
transcriptionally and epigenetically regulated. Different cells and tissues can 
constitutively express widely different levels of MHC molecules. For instance, MHC 
expression is highest in the cells of the immune system whereas MHC is usually 
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undetectable in the cells of the central nervous system and myocardial cells 
(Hutchinson, 2010). Furthermore, MHC transcription in a given tissue can change in 
response to hormonal or cytokine stimuli (Lee et al., 2010). This Chapter showed that 
normal devil tissues, such as epithelial cells within the skin and lung, and cells of 
immune organs, express high levels of MHC-I. On the contrary, Schwann cells within 
peripheral nerves bundles showed low or no MHC-I expression. MHC-I was not 
detected in samples of protein extracted from adult peripheral nerves. The fact that 
DFTD cells and Schwann cells showed low levels of MHC expression strongly suggests 
that the trait relates to the cell of origin rather than acquired after cell transformation.  
In normal cells the epigenetic and transcriptional modulation of MHC-I expression 
involves the existence of underlying regulatory mechanisms that control and modulate 
gene expression. Mechanisms include DNA methylation, post-translational 
modifications of histones, transcription factors, and microRNA patterns among others 
(Esteller, 2008, Seliger, 2012 ).  
A differential expression pattern of MHC-I was observed in the different DFTD models 
investigated in this thesis suggesting the occurrence of these modulatory mechanisms. 
Evidence for this includes: 
 Different levels of MHC-I expression among primary DFTD tumours from different 
animals. 
 Different levels of expression within a single tumour with cells at periphery of the 
tumour nest showing more intense MHC-I immunolabelling.  
 Lower MHC-I expression in DFTD metastases than primary tumours.  
 Differential expression of MHC-I among cell lines, with protein detected only in 
one cell line.  
 No MHC-I expression detected in the DFTD tumours xenografted onto mice. 
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Low levels of MHC-I expression in DFTD cells would reduce immune recognition. 
This is comparable to the frequent strategy employed by tumours to evade immune 
detection. This is, the deregulation of these modulatory mechanisms, which in turn alter 
MHC-I expression (Cabrera et al., 2003). MHC-I deficiencies have been described in 
human cancers such as cervical carcinoma, colorectal carcinomas, breast carcinoma, 
melanoma and bladder carcinoma (Aptsiauri et al., 2007, Ferrone and Marincola, 1995, 
Koopman et al., 2000) and the canine transmissible venereal tumour (CTVT) (Cohen et 
al., 1984). Various mechanisms are responsible for these alterations and involve 
structural changes (genetic mutations or deletions), deregulation of the expression of 
components of the antigen presenting machinery (APM) or epigenetic changes in the 
DNA (Seliger et al., 2002). What are the leading mechanisms that control MHC-I 
expression in DFTD cells is an area that requires further investigation.  
In summary, this chapter showed that MHC-I proteins are expressed in DFTD tumour 
although at lower levels than normal tissues. More importantly, MHC-I is not expressed 
at the cell surface suggesting that impaired expression of associated components of the 
antigen processing machinery is also involved. Alteration of MHC-I surface expression 
reduces the immunogenicity of DFTD cells and therefore plays a significant role in the 
lack of immune recognition to transferred DFTD cells. Thus, this information provides 
new insights into the mechanisms of immune evasion that allow allotransplantation of 
devil facial tumour cells. It also opens new areas of research for the development of 
management strategies for the conservation of the species such as immunotherapy and 
vaccination. 
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5.1 Introduction 
Results from the previous chapter indicated that downregulation of MHC-I proteins at the 
cell surface may impede immune recognition of devil facial tumour cells. These findings 
imply that DFTD cancer cells are unlikely to encounter natural immunohistocompatibility 
barriers. Despite the immune system of devils being able to recognise and reject allogeneic 
transplants (Kreiss et al., 2011a), it would be unlikely to find animals that are resistant to 
DFTD in the wild. Vaccination would provide a potential strategy for the conservation of 
the species should a suitable antigen be identified.  
Recent immunisations of devils with non-viable DFTD cells performed by our research 
group induced antibody responses. This type of humoral response against tumour cells is 
common. In humans, it is well established that antibodies against tumour antigens can occur 
in cancer patients (Reuschenbach et al., 2009). The tumour antigens eliciting an immune 
response are collectively called tumour-associated antigens (TAAs). 
Molecular studies revealed that TAAs are the consequence of the genetic and epigenetic 
alterations in cancer cells or the products of genes encoding viral proteins (Matsushita et al., 
2012, Pardoll, 2003, Schreiber et al., 2011). The reason for spontaneous humoral responses 
in cancer are not known but may include new epitopes in expressed proteins, altered post-
translational modifications with immunological relevance (e.g. underglycosylation), altered 
tissue specific expression patterns or over-abundance of the antigen (Fonseca and Dranoff, 
2008, Houghton, 1994, Vesely et al., 2011). 
Different strategies are currently available for the identification of TAAs and more than one 
hundred have been described from human tumours. The detection of antibodies against 
TAAs in cancer patients has been a useful tool for early cancer diagnosis, prognosis and 
targeted immune therapy (Buonaguro et al., 2011, Jager et al., 2001). TAAs have also 
contributed to the understanding of the tumourigenesis process and cancer biology (Bortner 
et al., 2009, Cappello et al., 2003b, Ciocca and Calderwood, 2005).  
The identification of the DFTD antigens eliciting humoral responses in Tasmanian devils 
may provide valuable information about this emerging disease and contribute to the 
development of a vaccine. Consequently, this chapter presents an immunoproteomic 
approach to investigate tumour-associated antigens in DFTD.  
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5.2 Methods 
5.2.1 Experimental approach 
Immunoproteomics, which describes the subset of proteins involved in the humoral 
response, has been a potential tool for the discovery of serological markers (Imafuku et 
al., 2004). This section describes the development of an immunoproteomic approach for 
the identification of cognate DFTD antigens eliciting humoral responses in immunized 
Tasmanian devils. In this strategy, tumour proteins are first separated on replicate gels 
using two-dimensional gel electrophoresis (2DE), transferred to nitrocellulose 
membrane and probed with pre-immune devil sera, immune devil’s or control 
antibodies. A replicate gel is also stained with coomassie blue. Immunoblots detected 
with sera from immunized animals are then compared to those of the controls (pre-
immune sera), differentially expressed spots are then located on the coomassie-stained 
gel and excised. Excides proteins are subjected to trypsin digestion and finally identified 
by mass spectrometry (Figure 5.1) 
5.2.2 Tasmanian devil immunisations 
Experiments involving the use of Tasmanian devils were conducted under the approval 
of the University of Tasmania Animal Ethics Committee (permit number A0009215).  
A DFTD cell line (C5065) was kindly provided by the Tasmanian Department of 
Primary Industries, Parks, Wildlife and Environment (DPIPWE). The cells were 
maintained in RPMI culture medium (RPMI 1640 – Gibco, New Zealand) containing 
10% foetal calf serum, 2 mM of L-glutamine (Sigma, USA) and 40 mg/ml of 
gentamicin (Pfizer, Australia) at 35 °C in a humidified atmosphere of 5% CO2. To 
generate cells for immunisations, DFTD cells were frozen in 1 ml aliquots at a 
concentration of 1 × 108 cells/ml in sterile PBS. On the day of immunisation cells were 
thawed and sonicated for four cycles of 60 seconds at input 6 (out power 6 watts), with 
60 second intervals on ice using a Microson™ Ultrasonic Cell Disruptor (XL 2000, 
Qsonica, Newtown, CT). The suspensions were centrifuged at 960 x g and the cell 
pellets were resuspended in 1 ml of sterile PBS. The cell suspension was mixed with 
400 µl each of Montanide ISA 71 MVG adjuvant (Seppic, Puteaux, France) and CpG 
1668 (450µg).  
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Figure 5.1 Schematic illustration of the immunoproteomic approach for identification of devil facial tumour associated antigens. 
 
 
 Chapter 5. DFTD TAAs 
 118 
Two anaesthetised healthy male Tasmanian devils were injected sub-cutaneously in the 
shoulder with the cell suspensions at monthly intervals (three times) and blood samples 
collected every 14 days post- injection in clot-activating tubes (approximately 10 ml of 
blood was taken from the jugular from the anaesthetised devil as described in section 
4.2.1). Approximately 8 ml of blood (from a 10 ml sample) was injected into a lithium-
heparin tube for isolation of leukocytes and the remaining volume of the sample was 
used for extraction of serum. The blood samples were centrifuged at 1100 × g for 10 
minutes and serum harvested. Clot removed and the process repeated. Serum was 
aliquoted into 200 µl samples and stored at -20 oC.  
5.2.3 Preliminary screening of serum samples 
An initial screening of the devil’s serum from immunised and healthy animals was 
performed using standard denaturing one-dimensional gel electrophoresis (1D-SDS-
PAGE). Optimization of the concentrations of antibodies for immune detection (i.e. 
devil serum, polyclonal rabbit anti-devil immunoglobulin and horseradish peroxidase 
(HRP)-conjugated anti-rabbit IgG) was performed using the Mini-PROTEAN II 
Multiscreen apparatus (Bio-Rad, USA). This system allowed the simultaneous 
screening of multiple samples by western analyses using minimal amount of reagents. 
The conditions of electrophoresis, protein transfer and immunodetection (including 
details of antibodies) are explained below.  
SDS-electrophoresis 
Total DFTD proteins from cell lines were extracted with RIPA buffer (Thermo 
Scientific, Rockford, IL) as described in section 4.2.2. 400-500 µg of protein in loading 
sample buffer (3X) was heated at 95 oC for 10 minutes prior to loading on a single-well 
7% polyacrylamide gel using the Xcell SureLock™ mini-cell (Invitrogen, Carlsbad, 
CA) and running buffer (see Appendix 2 for a list of reagents). The gels were run at 100 
V until the line of the dye reached the bottom of the gel.  
Protein transfer 
Transfer of proteins from gels to a nitrocellulose membrane (0.45 µm, Bio-Rad, 
Germany) was performed using the XCell II™ Blot Module system (Invitrogen). 
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Blotting was performed using 1XNuPAGE® (Invitrogen) transfer buffer with 10% 
methanol overnight at 4 oC and 25 V.  
Immunodetection 
Immunodetection was performed using a Mini-PROTEAN II Multiscreen apparatus 
following the instructions of the manufacturer. Devil serum was applied at a dilution of 
1/2000 in TBS buffer containing 0.1% tween 20 and 5% skim milk (TBSTM). After 
four washes with TBST, the secondary antibody (polyclonal rabbit anti-devil 
immunoglobulin) was applied at a dilution of 1/2000 in TBSTM. Production of this 
secondary antibody was previously described in Kreiss (2009). Briefly, rabbits were 
immunised with devil immunoglobulins that were previously purified by precipitation 
with ammonium sulphate from whole devil’s serum. The rabbit IgG fraction was then 
purified using a protein A antibody purification kit.  
Sera from naïve devils and the pre-immune sera from the immunised devils were used 
as controls. Two negative controls were run. One omitting the primary antibody (devil’s 
serum) and another control omitting both primary and secondary antibodies. A 
commercial antibody against the cytoskeleton protein actin (beta actin polyclonal 
antibody ab729, Abcam) was used as loading controls for the western blot analyses. 
The membrane was finally incubated with a donkey horseradish peroxidase (HRP)-
conjugated anti-rabbit IgG tertiary antibody (NIF 824, Amersham Biosciences, 
Piscataway, NJ) at a dilution of 1/5000 in TBSTM. Chemiluminescent detection was 
performed following membrane immersion with Immobilon™ Western HRP substrate 
(Millipore, Billerica, MA) for 5 minutes at room temperature using a Chemi-Smart 
5000 digital camera (Vilber Lourmat, EEC).  
5.2.4 Two-dimensional electrophoresis (2DE) 
2DE was performed using the ZOOM® IPGRunner™ System and the Xcell 
SureLock™ mini cell (Invitrogen, Carlsbad, USA) following the instructions of the 
manufacturer. A summary of the protocol is presented here. Complete instructions can 
be found in the manual of the system (ZOOM® IPGRunner™ System – Manual 
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MAN0000256 – Invitrogen, see Appendix 5). Appendix 2 includes a comprehensive list 
of reagents.  
Sample preparation 
A 950 µl aliquot of chilled lysis buffer containing ZOOM® 2D protein solubilizer, 1 M 
tris-base, protease inhibitor cocktail and 2 M DTT, were added to 50 µl of pelleted 
DFTD cells and the sample sonicated. The lysate was then alkylated with N,N-
dimethylacrylamide (DMA) and excess DMA quenched with 2 M DTT, centrifuged, 
and the supernatant transferred to a new microcentrifuge tube.  
A 12 µl aliquot of lysate containing ~15 µg of protein was diluted with sample 
rehydration buffer containing 1X ZOOM® 2D protein solubilizer, 2 M DTT, ZOOM® 
carrier ampholytes and bromophenol blue.  
First dimension – isoelectric focusing (IEF) 
155 µl of the protein in sample rehydration buffer was used to rehydrate each ZOOM® 
strip pH 3-10NL overnight using the ZOOM® IPGRunner™ cassettes.  
After rehydration, isoelectric focusing was performed using the ZOOM® IPGRunner™ 
and the XCell SureLock™ mini-cell. Electrofocusing conditions were 200 V for 20 
minutes, 450 V for 15 minutes, 750 V for 15 minutes and finally 2,000 V for 4 hours.  
Second dimension SDS-PAGE 
IEF strips were equilibrated with NuPAGE® LDS sample buffer and NuPAGE® 
sample reducing agent and then alkylated with alkylation solution containing 
NuPAGE® LDS sample buffer and iodoacetamide.  
The equilibrated strips were then applied to second dimension gels (Nu NuPAGE® 
Novex® 4-12% Bis-Tris ZOOM® gels). SDS-PAGE gel-electrophoresis was performed 
at 200 V for 40-50 minutes using the NuPAGE® system and the XCell SureLock™ 
mini cell (Invitrogen, Carlsbad, CA). 
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Protein Transfer 
Electroblotting of proteins from the gel to nitrocellulose membrane was performed 
using the iBlot® dry blotting system (Invitrogen). Blotting was performed using 20 V 
for 8 minutes.  
Immunodetection 
Immunodetection was performed as described in section 5.2.3 with the following 
antibody concentrations: Tasmanian devil serum (primary antibody) at 1/2000; 
secondary rabbit anti-devil immunoglobulin at 1/7500 and the HRP-conjugated 
anti-rabbit at 1/5000. Pre-immune sera from the immunised devils were used as a 
control. A negative control omitting the primary antibody (devil’s serum) was also run.  
5.2.5 Mass spectrometry analysis and selection of proteins 
 In-gel digestion 
2DE gels were stained with GelCode™ Blue Safe Protein Stain (Thermo Scientific, 
Rockford, IL) according to the manufacturer’s instructions. Matched immunospots were 
identified in the gel, excised with a scalpel and transferred to microcentrifuge tubes. In-
gel trypsin digestion was performed using the In-Gel Tryptic Digestion Kit (Thermo 
Scientific, Rockford, IL, USA). 
Mass spectrometry and analysis of data  
Digested samples were processed and analysed by the Central Science Laboratory at the 
University of Tasmania using multidimensional protein identification technology 
(MudPIT) and a tandem mass spectrometer (LTQ Orbitrap, Thermo Scientific, San 
Jose, CA).  
Mass spectra data were searched against a database consisting of semi-tryptic digestion 
of marsupial proteins (Metatheria - NCBI) using X!Tandem v2007.07.01 software. 
Positive protein identification required two or more unique matching peptides 
(Kocharunchitt et al., 2012). Where multiple proteins were reported (e.g. tubulin 
isoforms) peptides were assigned to satisfy the principal of parsimony.  
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5.3 Results 
5.3.1 One-dimensional gel-electrophoresis 
A preliminary screening using the sera of two devils that had been immunized with 
DFTD cells showed several unique bands that were not detected when using pre-
immune sera. The pattern of bands using the pre-immune sera was similar to that of the 
sera from four naïve devils (D1-D4). However, the resolution and visualization of the 
bands, particularly in the lower molecular weight range, was not very clear due to use 
7% polyacrylamide gels for protein separation and immune detection through a mini-
multi screen apparatus (Figure 5.2). The system proved useful for both screening 
multiple samples and optimization of antibody concentrations.  
 
Figure 5.2 Screening of Tasmanian devils’ serum for detection of antibodies against 
DFTD proteins using western blot analysis. Total DFTD proteins from cells in culture 
were separated by regular one-dimensional gel-electrophoresis (7% polyacrylamide) 
and blotted to nitrocellulose membrane. Membranes were probed with sera from four 
naïve devils (D1-D4) or sera (I1-I4) from two immunised devils. Pre-immune sera 
samples (PI) for each devil were run in parallel. Devil immunoglobulins were detected 
using polyclonal rabbit anti-devil and HRP-conjugated anti-rabbit IgG antibodies. 
Chemiluminescence was used for signal detection. Red squares indicate unique bands 
not detected in the sera of naïve devils or the pre-immune sera. Lane A, actin control 
To increase resolution, DFTD proteins were separated using precast gradient gels 
(4-12%). This system facilitated the detection of clear bands in the serum of the two 
immunized devils. A stronger signal and better resolution of bands was observed when 
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using the serum from devil 1, as compared to devil 2. Higher levels of background were 
also persistently observed using serum from devil 2 compared to the background 
observed with serum from devil 1.   
This analysis identified three major findings. Firstly, the sera from normal devils (non-
immunised) contained antibodies that reacted against DFTD proteins, as expected. The 
use of pre-immune sera resulted in the identification of four DFTD-specific protein 
species within the 35-70 kDa range. Secondly, a number or unique bands were detected 
using the sera of immunised devils. Two new bands around 100 and 70 kDa were 
clearly observed plus several bands within the 10-35 kDa range. Third, the polyclonal 
rabbit antibody used to detect the devil’s immunoglobulins, when used alone (i.e. 
without devil serum) produced a strong background band around 80 kDa and one less 
evident background band at 60 kDa (Figure 5.3).  
5.3.2 Two-dimensional electrophoresis (2DE) 
The previous results showed that the immunisation of devils with DFTD cells produced 
an immune response that was detected using western blot analysis. Thus, the next step 
was to pursue identification of the DFTD antigens responsible. For this, the DFTD 
proteins were separated by 2D-gel electrophoresis and antigen-antibody reactions 
detected using western blot analysis as described above. Spots of interest were excised 
from the gel and, after in-gel digestion, analysed by mass spectrometry. 
Approximately 15 unique spots were detected using serum from immunised devil 1, and 
5 unique spots using sera from immunised devil 2. At least one of the spots, around 15 
kDa, was common to both samples. The pre-immune serum from both devils showed 
some spots that were clearly different from any spots observed using sera from 
immunised devils. The rabbit polyclonal anti-devil antibody again produced two 
background bands of about 60 and 85 kDa (Figure 5.4). 
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Figure 5.3 Western blots of DFTD cell protein separated by one-dimensional electrophoresis and 
probed with pre-immune (P.I.) and immunised sera from Tasmanian devils. Two replicates (lanes) 
were run for each sample. A range of bands were observed with the immune sera of both devils (D 
and F), which were not detected using pre-immune (P.I.) sera (C and E). Negative controls are also 
shown (A and B). Two background bands (~80 and 60 kDa) were detected using the secondary 
polyclonal anti-devil immunoglobulin (B).  
 
Based on these results, a preliminary experiment was carried out in order to identify and 
characterize the antigens detected using the serum of immunised devil 1. To do this, 
matching spots from the immunoblots were identified in duplicate coomassie stained 
2DE gels. In some instances, a single immunospot covered more than one single protein 
in the gel. Thus, extra gel spots were taken (Figure 5.5). Twenty spots were finally 
excised from the 2DE gel and following trypsin digestion, analysed by MudPIT. This 
resulted in the identification of 29 different proteins (based on two or more unique 
peptides detected). In some cases, several isoforms for a single protein were detected. In 
this case, all isoforms were collectively counted as one protein (Table 5.1).  
The background present when the polyclonal anti-devil immunoglobulin antibody is 
used alone, was found to correspond to spots 19 and 2. Four different proteins were 
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characterized in spot 19, which were not identified in other spots. Four proteins were 
identified in spot 2. However, the same proteins were also identified in adjacent spots 
that are not related to the background band. Therefore, precaution should be taken when 
considering these proteins (unique proteins identified in spots 2 and 19) true tumour-
associated antigens.  
The protein from spot 3, identified as dachshund homolog 2, was immunodetected in 
both the pre-immune and immune sera from devil 2.  
In summary, 24 unique antigens were identified using serum from immunised devil 2. 
One antigen, characterized as protein stathmin (spot 16), corresponded to the antigen 
recognised using sera from both immunised devils. 
No proteins, meeting the criteria for inclusion (i.e. two or more unique peptides) were 
identified from spots 8 and 13. 
5.3.3 Biological relevance of the identified proteins 
A search of the literature using the PubMed database was performed in order to 
understand the biological relevance of proteins identified. Attention was given to 
proteins that have been previously identified as tumour antigens or as being associated 
with an immune response to cancer. From this search, 17 proteins were found to have 
well-documented information for their relation to cancer. Table 5.2 summarises these 
results. 
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Figure 5.4 Screening of antibodies directed against DFTD tumour antigens using sera from immunised Tasmanian devils. Total cell proteins from cultured DFTD cells were separated by 
two-dimensional gel-electrophoresis, transferred to nitrocellulose membrane and probed with pre-immune sera (B and E) or post-immunisation sera (C and F). Negative controls (no 
serum) (A and D) are shown. Red arrows indicate spots recognised by sera of immunised devils, which were not detected using pre-immune sera or in negative controls. The blue arrow 
indicates a spot recognised by the immunised sera in both devils. 
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Figure 5.5 DFTD tumour-associated antigens selected for further identification 
by mass spectrometry. Detected protein spots in the 2D blot using sera from 
immunised devil 1 (A) were matched to spots in duplicate coomassie blue G-250 
stained gel (B). Twenty matched spots were excised and identified using mass 
spectrometry methods. Their identities are listed in Table 5.1. 
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Table 5.1 DFTD tumour-associated antigens identified using sera from immunised devils. 
Spot 
Sequence Mas 
(kDa) Peptides 
Amino 
Acid 
Coverage 
Protein name 
Predicted Actual Read Unique 
9 28 28 16 6 33.3% 14-3-3 protein beta/alpha 
9 28 28 4 3 9.3% 14-3-3 protein eta 
9 28 28 39 7 32.0% 14-3-3 protein gamma 
9 28 27 12 4 25.7% 14-3-3 protein theta 
9, 10 28 27 76 9 47.3% 14-3-3 protein zeta/delta 
1 62 61 42 12 22.16% 60 kDa heat shock protein, mitochondrial 
19 85 87 10 4 6.3% Aconitate hydratase, mitochondrial 
10 28 24 11 2 13.6% ADP-sugar pyrophosphatase 
2, 4, 18 ~55 55 213 28 52.0% ATP synthase subunit beta, mitochondrial 
1 62 60 2 2 12.96% Beta-1-syntrophin 
12 27 37 7 2 4.7% Cathepsin B 
11, 20 ~15 15 167 11 48.2% Cellular retinoic acid-binding protein 
3 57 58 2 2 6.8% Dachshund homolog 2 
19 85 80 7 3 5.9% DCC-interacting protein 13-alpha 
19 85 82 19 4 7.3% Gelsolin isoform 2 
19 85 84 19 4 7.0% Heat shock protein HSP 90-alpha 
1, 2 ~55 51 20 5 14.68% Heterogeneous nuclear ribonucleoprotein K 
14, 15, 
16, 17 
18 13 14 2 19.0% Histone H2B type 1-F/J/L 
18 54 53 18 9 16.9% Perilipin-3 
7 30 28 22 5 23.37% Proliferating cell nuclear antigen 
3 57 57 23 7 12.4% Protein disulfide-isomerase 
10 28 23 41 6 36.3% Rho GDP-dissociation inhibitor 1 
16 18 17 22 5 34.9% Stathmin 
17 18 15 15 2 8.4% Superoxide dismutase [Cu-Zn] 
7 30 28 15 8 27.02% Tropomyosin alpha-4 chain-like isoform 4  
2, 4, 18 ~55 50 375 23 48.1% Tubulin alpha-1B chain 
4, 18 ~55 49 424 28 49.1% Tubulin beta chain-like isoform 1  
18 54 49 31 4 12.1% Tubulin beta-2A chain  
4, 18 54 49 45 6 16.0% Tubulin beta-2C chain 
18 54 50 4 2 3.8% Tubulin beta-3 chain  
18 54 50 91 13 23.5% Tubulin beta-5 chain  
18 54 45 5 3 9.1% Ubiquitin-like modifier-activating enzyme 5 
1, 2, 3, 
4, 5, 6, 
18 
~55 53 525 45 55.5% 
Vimentin 
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Table 5.2 Summary of biological relevance of selected DFTD antigens identified by mass spectrometry analyses  
Predicted protein 
14-3-3 protein  
Function: 
Contributes to cell cycle regulation, cell growth, differentiation, survival, apoptosis, migration and spreading. 
Associations with cancer: 
14-3-3 beta protein is involved in human gastric cancer progression and has potential as diagnostic and 
prognostic biomarker. 14-3-3zeta protein is currently undergoing extensive investigation as a novel 
therapeutic target. 14-3-3 theta protein has been identified as an antigen that induces a humoral response in 
lung cancer.  
References: 
(Freeman and Morrison, 2011, Fu et al., 2000, Mhawech, 2005, Pereira-Faca et al., 2007, Tseng et al., 2011, 
Yang et al., 2012, Zhao et al., 2011). 
60 kDa heat shock protein (HSP60), mitochondrial 
Function: 
Protein mostly localized in the mitochondrial matrix and outer mitochondrial membrane, constitutively 
expressed under normal condition, and induced by heat shock, mitochondrial damage, and mitochondrial 
DNA depletion. 
Associations with cancer: 
Overexpression reported in various cancers such as adrenal tumours and human breast, large bowel, 
bronchial, exocervical, ovarian and prostate cancers. It may have both pro and antiapoptotic roles in tumour 
cells. Serum antibodies against HSP60 are elevated in patients with osteosarcoma.  
References: 
(Cappello, 2003, Cappello et al., 2003a, Cappello et al., 2003b, Ciocca and Calderwood, 2005, Faried et al., 
2004, Hansen et al., 2003, Lebret et al., 2003, Pignatelli et al., 2003, Trieb et al., 2000, Wu et al., 2009). 
Aconitate hydratase, mitochondrial  
Function: 
Enzyme localised to the mitochondrion that catalyses the interconversion of citrate to isocitrate via cis-
aconitate in the second step of the TCA cycle.  
Associations with cancer: 
Plays a key role in cellular bioenergy production and cell proliferation of human prostate carcinoma cells. 
Increase in the enzyme activity has been observed in malignant prostate cells.  
References: 
(Juang, 2004, Singh et al., 2006). 
ATP synthase subunit beta, mitochondrial 
Function: 
Enzyme that catalyses ATP synthesis. Localised outside of the cell membrane. 
Associations with cancer: 
Ectopic (outside the cell membrane) the enzyme has been proposed as a marker for targeted tumour therapy. 
The downregulation of the catalytic subunit of the enzyme is a hallmark of most human carcinomas. 
References: 
(Cuezva et al., 2004, Lopez-Rios et al., 2007, Ma et al., 2010, Willers et al., 2010). 
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Predicted protein 
Cathepsin B 
Function: 
The protein is a lysosomal cysteine proteinase. It is also known as amyloid precursor protein secretase and is 
involved in the proteolytic processing of amyloid precursor protein (APP).  
Associations with cancer: 
The expression and subcellular localization of cathepsins change during cancer progression and cathepsins 
are involved in various aspects of tumourigenesis including metastasis and aggressive behaviour. Cathepsin B 
has been proposed as potential biomarker and therapeutic target in human cancers such as breast, human 
pancreatic ductal adenocarcinoma (PDA), cervical, colon, endometrial and pancreatic cancers. 
References: 
(Chan et al., 2010, Devetzi et al., 2009, Gopinathan et al., 2012, Watson and Kreuzaler, 2009, Wu et al., 2012) 
Cellular retinoic acid-binding protein 1 
Function: 
Specific binding protein for vitamin A and is thought to play an important role in retinoic acid-mediated 
differentiation and proliferation processes. 
Associations with cancer: 
Overexpressed in ovarian carcinoma tissues. 
References: 
(Hibbs et al., 2004, Turhani et al., 2006) http://www.ncbi.nlm.nih.gov/gene/1381 
DCC-interacting protein 13-alpha 
Function: 
Protein involved in the regulation of cell proliferation, apoptosis, cell survival, endosomal trafficking, and 
chromatin remodelling.  
Associations with cancer: 
Protein associated with the molecular pathway that promotes ovarian cancer cell proliferation. Its function as 
pro-survival or pro-apoptotic factor in cancer cells is still controversial. 
References: 
(Deepa and Dong, 2009, Liu et al., 2002, Tan et al., 2010, Zhao et al., 2010). 
Gelsolin isoform 2 
A ubiquitous actin-binding protein that plays a critical role in regulating ability of cells to migrate. 
Associations with cancer: 
The gelsolin gene is downregulated in multiple neoplasms and capable of suppressing tumourigenicity. 
Overexpression may be associated with progression of lung adenocarcinoma and is a potential target for 
therapy and as biomarker for lung adenocarcinoma. Gelsolin plays an important role in cellular proliferation 
and migration in cervical cancer and is also a promising marker for cervical cancer screening and prognosis 
References: 
(Gordon et al., 2005, Li et al., 2010, Liao et al., 2011, Rodriguez-Pineiro et al., 2010, Shao et al., 2011). 
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Predicted protein 
Heat shock protein HSP 90-alpha  
Function: 
HSP90 proteins are highly conserved molecular chaperones that have key roles in signal transduction, protein 
folding, protein degradation, and morphologic evolution. 
Associations with cancer: 
HSP90 interacts with a great number of molecules that are involved in the development and/or survival of 
cancer cells. HSP90 inhibition offers the potential of accomplishing the simultaneous disruption of multiple 
signalling events critical to tumour cell growth and survival. Phase II clinical trials are undergoing.  
References:  
(Cullinan and Whitesell, 2006, Jego et al., 2010, Khalil et al., 2011, Modi et al., 2011, Mojtahedi et al., 2011, 
Romanucci et al., 2012, Sankhala et al., 2011, Sidera and Patsavoudi, 2008, Whitesell and Lindquist, 2005). 
Heterogeneous nuclear ribonucleoprotein 
Function: 
Transcription factor and role during cell cycle progression.  
Associations with cancer: 
This protein has been implicated in tumourigenesis. It was found overexpressed in melanoma and colorectal, 
oral, lung, nasopharyngeal, pancreatic, prostate and liver cancers.  
References: 
(Barboro et al., 2009, Carpenter et al., 2006, Du et al., 2010, Jhaveri et al., 2012, Michelotti et al., 1996, 
Roychoudhury and Chaudhuri, 2007, Zhou et al., 2010). 
Perilipin-3 
Function: 
Protein required for endosome-to-Golgi transport. 
Associations with cancer: 
Protein strongly expressed in invasive tumours, lymph node metastasis in cervical dysplasia and invasive 
carcinoma. 
References: 
(Muthusamy et al., 2006, Szigeti et al., 2009) 
Proliferating cell nuclear antigen  
Function: 
Proliferating cell nuclear antigen (PCNA) is a cell cycle marker protein. It is well known as a DNA sliding 
clamp for DNA polymerase delta and as an essential component for eukaryotic chromosomal DNA replication 
and repair.  
Associations with cancer: 
PCNA is highly expressed in proliferating cells, including cancer and it is associated with enhanced 
malignancy. PCNA overexpression is correlated with cancer virulence. Its contribution to the cancerous state 
is mediated by its function in the processes that are necessary for tumour survival, such as DNA replication, 
repair of DNA damage, chromatin structure maintenance, chromosome segregation, and cell cycle 
progression 
References:  
(Chen et al., 2011, Kannouche and Lehmann, 2004, Naryzhny and Lee, 2007, Naryzhny, 2008, Rosental et al., 
2011, Stenner et al., 2012, Stoimenov and Helleday, 2009) 
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Predicted protein 
Protein disulfide-isomerase  
Function: 
This enzyme is involved in hydroxylation of prolyl residues in preprocollagen. It also catalyses the formation, 
breakage and rearrangement of disulphide bonds. 
Associations with cancer: 
This protein is upregulated in breast cancer and implicated in melanoma progression. 
References:  
(Carta et al., 2005, Hirata et al., 2007, Zhang et al., 2005). 
Rho GDP-dissociation inhibitor 1  
Function: 
Downregulator of Rho family GTPases. It prevents nucleotide exchange and membrane association. 
Associations with cancer: 
The expression of this protein is altered in a variety of cancers including oral squamous cell carcinoma and 
colorectal cancer. Overexpression of this protein promotes cell motility and lymph node metastasis. Higher 
frequency of autoantibodies against Rho-GDP proteins was found in nasopharyngeal and acute leukaemia 
patients. 
References: 
(Chiang et al., 2011, Cui et al., 2005, Dovas and Couchman, 2005, Harding and Theodorescu, 2010, Xiao et al., 
2007, Zhao et al., 2010). 
Stathmin 
Function: 
Stathmin is a member of a family of microtubule-destabilizing proteins that regulate the dynamics of 
microtubule polymerization and depolymerisation.  
Associations with cancer: 
Stathmin is overexpressed across a broad range of human malignancies including leukaemia, lymphoma, 
neuroblastoma, ovarian, prostatic, breast and lung cancers and mesothelioma. Stathmin is a potential target 
in cancer therapies that disrupt the mitotic apparatus. 
Stathmin is also upregulated in normally proliferating cell lines. In normal cells, stathmin is upregulated in 
neurons and anterior pituitary cells. In glial cells, stathmin is a constituent of the myelin sheath.  
References: 
(Belletti and Baldassarre, 2011, Cassimeris, 2002, Ghosh et al., 2007, Gould et al., 2008, Mistry et al., 2005, 
Rana et al., 2008, Rubin and Atweh, 2004, Zhang et al., 2006) 
Tubulin 
Function: 
Tubulin is an integral component of microtubules. It occurs mostly as soluble heterodimers consisting 
primarily of α- and β-tubulin isoforms or as assembled tubulin polymers that form microtubules. 
Associations with cancer: 
Autoantibodies against tubulin-alpha and tubulin-beta were detected in sera of renal and oral cell carcinoma 
and chronic myeloid leukaemia patients.  
References: 
(Kellner et al., 2002, Luduena, 1998, Prasannan et al., 2000, Shukla et al., 2007, Zou et al., 2005). 
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Predicted protein 
Vimentin 
Function  
Vimentin is a major constituent of the intermediate filament family of proteins. It is ubiquitously expressed in 
normal mesenchymal cells; it helps maintaining cellular integrity and provides resistance against stress. 
Associations with cancer: 
Vimentin is overexpressed in various epithelial cancers, including prostate cancer, gastrointestinal tumours, 
tumours of the central nervous system, breast cancer, malignant melanoma, and lung cancer. Overexpression 
in cancer correlates well with accelerated tumour growth, invasion, and poor prognosis. Autoantibodies 
against vimentin were detected in sera from patients with pancreatic cancer. Anti-vimentin therapeutic 
approaches have also been proposed.  
References: 
(Hong et al., 2006, Kokkinos et al., 2007, Lahat et al., 2010, Satelli and Li, 2011). 
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5.4 Discussion 
The identification of tumour-associated antigens (TAAs) eliciting humoral responses 
has been an important tool for understanding biological aspects of carcinogenesis and 
the interactions between cancer cells and the immune system (Ciocca and Calderwood, 
2005). In humans, more than one hundred TAAs have been identified and several have 
been useful in diagnosis, prognosis and immunotherapy in various types of cancer 
(Buonaguro et al., 2011). Based on the strategies applied in human models, the 
objective of this chapter was to use an immunoproteomic approach for the investigation 
of TAAs inducing a humoral response in Tasmanian devils immunised with non-viable 
DFTD cells.  
The strategy implemented involved a combination of techniques that included 
two- dimensional electrophoresis coupled with western blot analysis, immunodetection 
and mass spectrometry (MudPIT). This proteomic approach is broadly known as 
SERPA (serological proteome analysis).  
MudPIT is a method for rapid and large-scale proteome analysis by multidimensional 
liquid chromatography, tandem mass spectrometry (MS) and database searching. By 
exploiting a peptide's unique physical properties of charge and hydrophobicity, complex 
mixtures can be separated prior to sequencing by tandem MS. Tryptic digest is used for 
peptide fragmentation. This data is then used to identify the peptides are hence the 
proteins from which they are derived (Washburn et al., 2001). In the MudPIT approach, 
the mass of a single peptide is measured to such a high degree of mass accuracy that the 
peptide is “unique” at that mass in the theoretical unique proteome of an organism 
(Cargile and Stephenson, 2004).  
Non-unique tryptic peptides may affect the accuracy of accurate mass-based 
identification. This could include modified peptides, non-tryptic peptides (generated 
from cellular proteases), unpredicted/annotated peptides and other non-peptides sources 
(chemical noise). The specificity of the accurate mass approach is defined as the 
percentage of random noise that does not match unique tryptic peptides. Thus, 
specificity is equal to 100% minus the false positive rate. The false positive rate for 
protein (FPRprotein) identification is simply the combined probability that all the 
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peptides identifications for that protein are false for the number of peptides of a specific 
protein.  The FPRprotein identification is a function of the false positive rate of peptide 
identifications (FPRpeptide) and the number of peptides used to identify a protein. It is 
considered that the FPRprotein identification should be approximately 1% or less. Thus, 
a peptide false positive rate of 10% translates into an identification specificity of 90% 
and 99% for one- and two-peptides hits respectively (Cargile and Stephenson, 2004). As 
protein identified by single peptides exhibit higher false positive rates (Elias et al., 
2005), confident protein identification is generally restricted to those identified by two 
or more peptides (Kocharunchitt et al., 2012).   
In addition to the number of peptides identified, the degree of coverage of the protein by 
peptides may also be used as a measure to assess the validity of the identification. This 
is provided in terms of the percentage of amino acids in the protein covered by 
identified peptides. Amino acid coverage is particularly useful to increase the credibility 
of proteins identified by single peptides. However, it is important to note that, for a 
particular protein, only a portion of the peptides are actually observed experimentally by 
MS (Sanders et al., 2007).   
The molecular weight predicted for each protein was estimated form the SDS gels by 
comparison to pre-stained molecular weight markers. These markers runs differently 
than unstained proteins. Furthermore, factors such as protein structure, posttranslational 
modifications and amino acid composition are variables that can affect the 
electrophoretic migration of proteins. Therefore, the predicted molecular weight is 
better referred to as the apparent molecular weight. In the current research, proteins with 
an actual molecular weight of ± 10kDa the predicted molecular weight were included in 
the list of proteins identified.  
Using the SERPA approach and the criteria of two or more unique peptides identified, 
24 DFTD TAAs were preliminarily identified by this current study. Amino acid 
coverage ranged from 4.7% to 55.55% for the protein vimentin, which also had the 
highest number of unique peptides identified (55 peptides, see Table 5.1).  
In humans, the presence of antibodies against tumour antigens in the serum of cancer 
patients is well documented (Reuschenbach et al., 2009). Although some of the immune 
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responses in cancer patients recognize antigens that are found only in tumours, most 
antibodies are directed against self-antigens (Tan et al., 2009). This is because most 
cancer antigens are derived from mutated or modified self-proteins. These proteins are 
the product of the accumulation of several genetic modifications in somatic cells, which 
in turn provide cancer cells with the advantage of growth and clonal expansion during 
the tumourigenesis process (Pardoll, 2003, Vogelstein and Kinzler, 2004).  
How the TAAs elicit an immune response is not completely clear, especially as many 
described TAAs are intracellular proteins (Reuschenbach et al., 2009, Zinkernagel, 
2000). As the immunised devils received total cell extract, intracellular antigens would 
be released and the more immunogenic would induce a response. Antibodies to these 
intracellular antigens have been detected in the cancer process, thus they are likely to be 
true TAAs. It is believed that antibodies against these antigens develop as part of the 
natural immune response to the changes in protein structure and expression (Tabernero 
et al., 2010). These changes include protein modifications (point mutations or post-
translational modifications) or altered tissue expression (Fonseca and Dranoff, 2008, 
Houghton, 1994, Vesely et al., 2011). The overexpression of these tumour-associated 
antigens may result in a level of expression above the threshold for T cell recognition, 
breaking the immunological tolerance to self-antigens and triggering an anti-cancer 
response (Buonaguro et al., 2011). Another hypothesis suggests that aberrant tumour 
cell death such as necrosis can expose modified intracellular proteins, which are 
presented to the immune system in an inflammatory environment (Fernandez Madrid, 
2005, Tan et al., 2009).  
The DFTD antigens identified in this study are proteins with a wide variety of functions 
that may provide clues about the tumourigenesis processes occurring in devil facial 
tumour cells. They act in pathways that have been identified as commonly mutated in 
cancer (or “hallmarks of cancer cells” as described by Hanahan and Weinberg (2011)). 
These pathways include cell cycle progression (14-3-3 proteins), signal transduction 
(HSP90 and HSP60), cellular bioenergy production (aconitate hydratase and ATP 
synthase), proliferation (14-3-3 proteins, cathepsin B, cellular retinoic acid, gelsolin and 
proliferating cell nuclear antigen), migration (gelsolin and cathepsin B) and apoptosis 
(14-3-3 protein, HSP60 and DCC-interaction protein 13-alpha). Future studies are 
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required to confirm differential or aberrant expression of these proteins in devil facial 
tumour cells compared to normal tissues. Strategies to undertake this protein expression 
studies (e.g. immunohistochemistry or flow cytometry) or gene expression studies (e.g. 
quantitative PCR).  
A single protein, identified as stathmin induced an antibody response in both immunised 
devils. This is of particular importance because it is likely that different animals may 
recognise this DFTD antigen, which is crucial for the development of a vaccine. 
Although these are preliminary studies using sera from just two animals, it is a 
promising finding for future research.  
Stathmin may have a role in the development of DFTD cancer cells. The protein is a 
member of a family of microtubule-destabilizing proteins that regulate the dynamics of 
microtubule polymerization and depolymerisation. It was initially classified as an 
“oncogene” because mutations of the gene can cause uncontrolled cell proliferation as 
seen in cancer cells (Cassimeris, 2002). Whether mutations or structural alterations of 
the gene occur in DFTD it would be worthy of investigation.  
Antibodies against proteins such as vimentin, 14-3-3 proteins, and heat shock proteins 
have been found in a variety of human cancers (Table 5.2). These antigens have been 
the subject of extensive investigations as therapeutic targets for cancer and some clinical 
trials are underway because they participate in several pathways required for cancer cell 
survival, proliferation, and migration (Lahat et al., 2010, Sankhala et al., 2011, Yang et 
al., 2012). Their relevance in immunotherapy relates to the possibility of targeting 
multiple pathways simultaneously. These proteins could be also useful as anti-cancer 
therapeutic targets in DFTD.  
Antibody reactivity against few DFTD proteins was also detected in the pre-immune 
sera and sera from naïve devils. Similar findings have been reported in humans. Studies 
have showed that a considerable percentage of the sera of healthy subjects contain 
autoantibodies against several self-antigens. The studies proposed that these antibodies 
are produced in responses to non-malignant disorders (Li et al., 2006, Nolen et al., 
2009). This notion highlights the importance of including as many control samples as 
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possible (serum from naïve animals) in order to discriminate cancer-specific antigens 
from those not associated with tumour development.  
The opportunity to specifically identify and differentiate the antibody reactivity in sera 
from immunised devils from that of naïve individuals (i.e. by identifying cognate 
antigens) is also important because this is not currently possible using techniques such 
as flow cytometry and ELISA. Therefore, it is possible that spontaneous natural 
responses to DFTD (if they occur) could be better characterised using this approach.  
Initial flow cytometry studies from our group using intact DFTD cells and the sera from 
immunised devils allowed the detection of antibodies against cell surface antigens (data 
not shown). However, only intracellular proteins were identified in this study. This 
could be related to the use of 2DE for the separation of DFTD proteins. This technique 
is still considered the best method for the high-resolution separation of a complex 
mixture of proteins and the identification of protein isoforms (Tan et al., 2009). These 
advantages were observed in this study (e.g. five isoforms for 14-3-3 proteins were 
identified and five isoforms for tubulin beta). However, one of the main drawbacks of 
2DE is the limited separation of hydrophobic proteins and low abundant proteins (Zou 
et al., 2005). It is likely that DFTD membrane proteins were poorly represented in the 
samples. Specialised kits are available to increase the yield of non-soluble proteins 
during sample preparation. Incorporation of these techniques to this approach might 
allow to identification of cell surface TAAs. 
Although only preliminary, the results from this chapter highlight the feasibility of 
applying an immunoproteomic approach for the detection of DFTD TAAs using the 
sera from immunised devils. The characterization of these antigens has the potential to 
open new areas of research to increase our knowledge about the biology of the DFTD 
cancer cells. It may also provide opportunities for the development of a vaccination 
approach to protect devils against this cancer where alternative approaches are 
desperately required. 
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General Discussion 
DFTD is a contagious cancer that is transmitted as an allograft between related and 
unrelated individuals. Recent cytogenetic and molecular analyses have confirmed that 
the infectious agent is the cancer cell itself (Miller et al., 2011, Pearse and Swift, 2006, 
Siddle et al., 2007b). There is only one other known case of a naturally occurring 
transmissible cancer, canine transmissible venereal tumour (CTVT) of domestic dogs. 
CTVT tumours are also transmitted as an allograft and are maintained in the dog 
population by coitus and other social behaviours (Karlson and Mann, 1952). CTVT is a 
benign cancer where the tumours generally regress within six months (Das and Das, 
2000). Therefore, CTVT evolved to be a successful parasite in dogs even though they 
are capable of mounting an effective immune response against the tumours. In contrast, 
DFTD is an aggressive and invariably fatal cancer. Affected animals die within months 
of tumour appearance, generally from starvation due to the size and facial location of 
the tumours or by organ failure due to metastases (Pyecroft et al., 2007).  
There is no evidence for an effective natural immune response in the Tasmanian devils 
to the transfer, establishment and spread of DFTD tumour cells. This total lack of 
allograft response is, therefore one of the most intriguing aspects of this cancer. The 
immune system plays an important role in the defence against allografts and cancer cells 
(Vesely et al., 2011). Downregulation of MHC-I in cancer cells is a common 
mechanism of immune evasion and explains the transplantation of allogeneic cells in 
CTVT (Karlson and Mann, 1952). In contrast, our knowledge of DFTD cells is limited 
and the mechanisms of immune evasion are not yet understood. In regards to MHC-I 
expression in Tasmanian devils and DFTD cells, this has only been investigated at the 
genetic level. Therefore, this thesis focused on studying various aspects (including 
MHC-I) of devil facial tumour cell in order to elucidate the origin of the cells and the 
mechanisms involved in the immune evasion by this transmissible cancer.  
Schwann cell origin of devil facial tumour disease 
Results of this thesis provide significant evidence supporting a peripheral nerve origin 
of devil facial tumour cells. Previous genetic studies of the tumour transcriptome 
indicated that the cancer cells express several genes related to the myelination pathway 
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in the peripheral nervous system (Murchison et al., 2010). Results from Chapter 2 
demonstrated that the tumour cells express a range of myelin and other peripheral nerve 
proteins. Thus, the combined genetic and protein expression support the hypothesis that 
devil facial tumour cells are of Schwann cell origin. This is consistent with the proposed 
neuroectodermal nature of the tumour (Loh et al., 2006b). Furthermore, the expression 
of markers of highly differentiated Schwann cells provided additional evidence that the 
cancer cells are more likely to be of the peripheral nerve lineage rather than 
neuroendocrine as originally proposed (Loh et al., 2006b). 
There is known association between cancer and chronic injury (Coussens and Werb, 
2002). The features of Schwann cells may provide insights into their transformation to 
cancer cells during chronic injury in Tasmanian devils. Mature Schwann cells are 
extremely plastic and play an active role during nerve repair. After nerve injury, myelin 
proteins are downregulated and the cells regain the potential to proliferate. These cells 
then re-differentiate and re-myelinate regenerated axons as part of the repair process 
(Mirsky et al., 2008, Parkinson et al., 2008). Devil bites produce frequent injury and 
infection in areas highly innervated such as the devils’ vibrissae. Cells that participate in 
tissue regeneration, including Schwann cells, have an innate capacity of self-renewal, 
unlimited replication and the cells are relatively long-lived in comparison to other cells 
within the tissues (Beachy et al., 2004). This makes these cells particularly susceptible 
to the carcinogenic effects inflammatory mediators, such as free radicals, 
prostaglandins, and cytokines. Prolonged exposure to these factors promotes cell 
proliferation, mutagenesis, oncogene activation and angiogenesis (Shacter and 
Weitzman, 2002). Moreover, migration through tissues, which is a normal feature of 
neural crest cells and has been observed during repair in adult tissues, is a characteristic 
of cancer invasion and metastases (Beachy et al., 2004, Wilson and Gibson, 1997). 
Thus, the remarkable ability of Schwann cells for repair may actually predispose them 
to tumourigenesis resulting in the formation of aggressive tumours. Therefore, repeated 
tissue injury caused by aggressive, but natural devil interactions, may have contributed 
to the development of a facial malignant Schwann cell neoplasm in Tasmanian devils. 
The demonstration that DFTD cells consistently express proteins of highly specialised 
Schwann cells led to the significant discovery that periaxin, a myelin protein of the 
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peripheral nervous system, is a sensitive and reliable marker for the diagnosis of DFTD 
tumours in histology samples (chapter 3). There is a clear advantage of using this 
method for diagnosis compared to cytogenetics, as cytogenetic diagnosis requires 
collection of fresh samples and the establishment of cell cultures. Furthermore, periaxin 
is particularly useful for distinguishing DFTD from other common devil neoplasms or 
biting wounds, and its use will facilitate monitoring of the disease in the field.  
The identification of periaxin as a marker of DFTD during this study may have broader 
implications in cancer diagnosis. Peripheral nerve sheath tumours have also been 
described in humans and other mammals and studies suggest that most of these 
neoplasms, both benign and malignant, are derived from Schwann cells (Carroll and 
Ratner, 2008, Zhu et al., 2002). Currently, identification of these tumours lacks 
precision, as there is no known definitive marker. Therefore, periaxin represents an 
excellent candidate marker for diagnosis of peripheral nerve sheath tumours in other 
species.  
Identification of the Schwann cell origin of devil facial tumour cells gives insights 
into possible mechanisms of immune evasion by this transmissible cancer 
The constitutive levels of MHC-I protein expression across normal devil tissues were 
found to be similar to reported levels in matched tissues obtained from humans and 
other species. Devil spleen cells, lymph nodes and cells within the skin expressed high 
levels of MHC-I protein, whereas peripheral nerve tissue cells expressed low levels of 
MHC-I. Upon closer analysis of MHC-I expression in devil tissue, results of this thesis 
showed that in normal cells MHC-I expression was clearly associated with the cell 
membrane. This is of much significance as it demonstrates that the complex machinery 
required for MHC-I translation, assembly and trafficking is functional in the Tasmanian 
devil. This provides further evidence that Tasmanian devils have the necessary 
components of a competent immune system. 
In humans and other species, low levels of MHC-I expression in Schwann cells have 
been associated with the notion of immune privilege and protection given by the blood-
nerve interface in the peripheral nervous system (Armati et al., 1990, Forrester et al., 
2008, Tsuyuki et al., 1998, Weerasuriya and Mizisin, 2011). Since the cancer cells in 
 Chapter 6. General discussion 
 143 
DFTD are most likely derived from a Schwann cell, it was not surprising to find 
evidence that they also have low MHC-I expression. However, even a low level of 
expression in the DFTD cancer cells, which are exposed to the immune system, should 
provide a sufficient signal for immune recognition. 
A further significant observation during this study was that MHC-I was detected in the 
perinuclear region of devil facial tumour cells, with no evidence of MHC-I expression at 
the cell surface. The lack of antibodies specific to an external epitope of devil MHC-I 
meant that several methods were employed to verify the absence of MHC-I membrane 
expression. The most convincing evidence was confocal microscopy. The results from 
this work found no evidence for MHC-I expression at the cell surface. This was despite 
the presence of intracellular MHC-I.  
Recent preliminary experimental data from our work with collaborators at the 
University of Cambridge provided (during the writing of this thesis) extra evidence 
supporting the reduced expression of MHC-I at the cell surface of DFTD cells. Flow 
cytometry studies using a new polyclonal anti-devil beta-2 microglobulin (B2M) 
antibody showed that B2M was not detected at the surface of DFTD cells (A. Kreiss 
and H. Siddle, personal communication, December 2011). Furthermore, incubation of 
DFTD cells with a supernatant (containing cytokines) produced using mitogen 
stimulated devil leukocytes, induced B2M surface expression. Functional and stable 
MHC-I molecules are heterotrimers consisting of the MHC-I heavy chain, B2M and a 
peptide ligand, which are assembled within the endoplasmic reticulum (ER). Only 
stable MHC-I molecules are exported from the ER to the outer membrane (Flajnik and 
Kasahara, 2001). Thus, a reduced expression of B2M in devil facial tumour cells may 
contribute to a reduced trafficking of MHC-I to the cell surface.  
An absence of MHC-I antigens presented at the cell surface of devil facial tumour cells 
would impede recognition of tumour cells and therefore inhibit T cell-mediated 
destruction. However, cells with a deficiency in expression of MHC-I should be 
selectively rejected by NK cells according to the classical theory of the “missing self” 
(Ljunggren and Karre, 1990). Recent models that complement this hypothesis show that 
NK cell triggering also requires the expression of inducible ligands of activating NK 
receptors (Diefenbach and Raulet, 2001). Therefore, the activation of NK cells depends 
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on a complex balance between activating and inhibitory signals (Lanier, 2005). T cell 
functionality in devils has been demonstrated by skin grafts and strong mixed 
lymphocyte reactions (Kreiss et al., 2011a). On the contrary, detailed knowledge of the 
existence of a functional NK population is limited. Preliminary studies in devils 
immunised with devil facial tumour cells or the leukaemia human cell line K562 
suggest that devils have NK cells capable of producing functional cytotoxic responses 
against xenogeneic cells. However, in this study, NK cells were not able to recognise 
DFTD cells (Brown et al., 2011). Further investigation is required to study specific NK 
cell subpopulations and the expression of NK receptors that may mediate immune 
selection of cells deficient in MHC molecules. 
Because Schwann cells constitutively express low levels of MHC-I it is likely that the 
limited surface expression of MHC-I molecules in DFTD is a trait associated with the 
cell of origin rather than a selective response of the tumour cells (i.e. post carcinogenic 
transformation) to avoid immune destruction. Devil facial tumour cells may also 
inherited the immune privilege that characterises Schwann cells. Thus, features 
characteristic to Schwann cells may either directly or indirectly play a role in the 
process of evolution of a somatic cell into not only a malignant tumour but also into a 
transmissible cancer. This notion has important implications because it provides new 
lines of research to understand the underlying mechanisms that regulate MHC-I 
expression in the DFTD cancer cells.  
Studies in human cancer have shown that structural alterations in MHC-I genes (i.e. 
mutations or deletions) as a mechanism of immune evasion are rare (reviewed in 
Seliger, 2012 ). The more likely mechanism is de-regulated expression of MHC-I 
molecules and components of the antigen processing machinery (APM). This 
deregulation has been observed in several human cancers including peripheral nerve 
tumours (Ferris et al., 2006, Kamphausen et al., 2010, Lee et al., 2004, Lee et al., 2006, 
Lopez-Albaitero et al., 2006). Deregulation may result from a variety of mechanisms, 
transcriptional, posttranscriptional or epigenetic. Although epigenetic changes such as 
methylation and histone modifications are common in cancer (Esteller, 2008), 
epigenetic modifications of APM components are much less common and the frequency 
of them occurring compares to that of mutation rates. More frequently, transcriptional 
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and/or posttranscriptional modifications occur (Seliger, 2012 ). Moreover, up-regulation 
of MHC-I and APM components can be mediated by cytokines, which restores their 
expression (Respa et al., 2011, Rodriguez et al., 2007). Studies in CTVT provide a 
model of the regulatory process controlling MHC-I expression. During the progression 
phase CTVT tumour cells produce high concentrations of TGF-β which decreases B2M 
and MHC-I expression (Cohen et al., 1984). During the regression phase tumour-
infiltrating lymphocytes secret IFN-γ and interleukin-6 (IL-6) which block the 
inhibitory effects of TGF-β and induce the expression of MHC-I in the tumour cells 
(Hsiao et al., 2008). 
Although knowledge of the mechanisms that regulate expression of MHC-I in Schwann 
cells is limited (Meyer zu Horste et al., 2010), experimental studies suggest that 
modulatory pathways have a significant role in control. Normal Schwann cells 
constitutively express low levels of MHC-I molecules but this expression can be 
increased by pro-inflammatory cytokines such as IFN-γ (Armati et al., 1990, Lilje and 
Armati, 1997). The finding that DFTD tumour cells express different levels of MHC-I 
proteins under different conditions suggests that modulatory pathways also function in 
these cells. These results together indicate that alteration of MHC-I expression in DFTD 
cells is unlikely to occur due to irreversible structural genetic changes and it is more 
plausible that other cellular regulatory mechanisms control MHC-I expression in these 
cancer cells. 
MHC-I expression was shown to be restricted to the perinuclear region of the tumour 
cells suggesting that MHC-I molecules are retained at the ER compartment. This could 
be due to de-regulated expression of other components of the antigen processing 
pathway. Mechanisms of immune evasion by deregulation of APM components have 
been described in human cancers. For instance, a coordinated alteration in the 
expression of MHC-I,B2M, the proteasome subunit beta (LMP2), and the transporter 
associated with antigen processing (TAP1) was found in bladder cancer (Romero et al., 
2005). Our research group is currently in the process of studying the antigen presenting 
pathway and its role in DFTD by measuring gene expression of genes encoding B2M 
and the proteasome subunit, beta type, 8 (PSMB8, also known as LMP7). This 
proteasome is essential for the processing of MHC-I peptides (Fehling et al., 1994). 
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Preliminary data shows reduced expression of both B2M and PSMB8 in primary devil 
facial tumour cells compared to cells of normal spleen tissue (Howson, 2011). Thus, 
both reduced MHC-I expression and reduced expression of components of the antigen-
processing pathway may contribute to a significant lack of trafficking of MHC-I to the 
DFTD cell surface, ultimately resulting in a lack of immune recognition by CD8+ T 
cells.  
Preliminary data also shows that cell surface B2M expression in devil facial tumour 
cells could be recovered after cytokine treatment and this ability to re-establish surface 
B2M may be useful for the development of a DFTD vaccine. Studies in humans with 
normal and cancer cells have shown that cytokines such as IFN-β, IFN-γ, and TNF-α 
increase the coordinated expression of MHC-I and APM components (Epperson et al., 
1992, Liu et al., 2011, Respa et al., 2011). Therefore, it is feasible that using a similar 
approach, optimal immune responses against DFTD could be activated following 
induced upregulation of both MHC-I and associated APM components. This is the focus 
of current DFTD research.  
Alteration of MHC-I and APM components are only one aspect of the different 
strategies that tumours can use to escape immune cell surveillance (Stewart and 
Abrams, 2008). Tumours can also secrete immune suppressive factors, activate negative 
regulatory pathways and alter the cellular mechanisms of signal transduction. Any 
single or combined strategy would suppress either directly or indirectly, innate or 
adaptive immune responses, and therefore impair an effective anti-tumour immune 
response (Seliger, 2012 , Stewart and Abrams, 2008). Therefore it follows that study of 
the occurrence of additional mechanism of immune evasion by DFTD are required, as 
well as investigation of the functionally of other immune cells (such as NK cells and 
dendritic cells) that participate in the immune surveillance against tumours.  
Additionally, interleukins and other factors secreted by tumour cells can induce immune 
suppression and favour tumour progression. This has been observed during the 
establishment of CTVT tumours. The cancer cells produce high concentrations of 
TGF-β, which decrease MHC-I expression, suppress NK cell activity, and prevent 
dendritic cell maturation and activation (Hsiao et al., 2004, Liu et al., 2008). 
Preliminary studies in our laboratory detected both transforming growth factor beta 
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(TGF-β) and interleukin-10 (IL-10) in the DFTD tumour microenvironment. These 
studies also showed that although mature dendritic cells were identified in lymph nodes, 
only immature dendritic cells were observed surrounding DFTD tumours (Howson, 
2011). The combined actions of low MHC-I expression and secretion of immune 
suppression factors may together be responsible for the lack of effective immune 
responses to DFTD and this area requires further investigation.  
 
Devil facial tumour-associated antigens may provide a tool for the development of 
a vaccine  
The emergence of DFTD caused great concern about the possibility of losing the largest 
marsupial carnivore and Tasmanian icon. Conservation management strategies were 
promptly established. They included the removal of DFTD-affected devils from 
relatively isolated local populations in Tasmania and the establishment of insurance 
populations of healthy devils in mainland Australia and in Tasmanian free-range 
enclosures (http://www.tassiedevil.com.au/tasdevil.nsf).  
Evaluation of control measures such as selective culling of infected individuals has been 
ineffective (Lachish et al., 2010) and results from this thesis indicate that DFTD cells 
have mechanisms that allow immune escape. Thus, the original hope of finding resistant 
animals in the wild is rapidly becoming implausible. Vaccination is therefore an 
important and feasible strategy for the management and conservation of the species 
(Jones et al., 2007, Woods et al., 2007).  
While routine vaccination aims to induce a lasting immune response that prevents 
infectious diseases (Ada, 2005, Lombard et al., 2007, W.H.O., 2008), vaccination 
applied to cancer focuses on methods that enhance the avidity of MHC-I restricted T 
cells in order to overcome the relatively poor antigen presentation in tumours 
(Rosenberg, 2001).  
Chapter 5 of this study presented the development of an immunoproteomic approach for 
the identification of tumour-associated antigens (TAAs) in devil facial tumour cells. 
Using this approach, more than 20 preliminary TAAs were identified. An advantage of 
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characterizing TAAs in DFTD compared to similar strategies in humans (where the 
heterogeneity of tumour cells is high, even among patients affected by the same type of 
cancer) is the clonal nature of the tumours and the stability of the DFTD genome 
(Murchison et al., in press). This means that tumour antigens are more likely to be 
conserved and that the immune response will have a constant antigenic target, aspects 
that are essential for the development of a vaccination approach (Woods et al., 2007).  
In human cancer, humoral responses develop as part of the immune response to changes 
in protein structure and/or expression (Tabernero et al., 2010). These proteins are likely 
to have a role in tumour growth by regulating processes such as cell proliferation, 
angiogenesis and tumour invasion. Therefore, the identification of these antigens in 
devil facial tumour cells is also relevant for the understanding of underlying 
carcinogenesis processes. Examples of the DFTD TAAs identified include the 14-3-3 
protein and HSP-90, which contribute to regulating the cell cycle, survival and 
migration; aconitate hydratase protein which plays an important role in cellular 
bioenergy production; and cathepsin B that has been involved in cancer progression and 
metastases. The fact that these processes have been considered hallmarks of cancer 
(Hanahan and Weinberg, 2011), indicates that these mechanisms may play an important 
role in the development of devil facial tumours.  
In humans, the identification of antigens has also been useful for the development of 
immunotherapeutic approaches. Active vaccination attempts to elicit a specific host 
immune response against selected tumour antigens. It focusses on strategies that 
activate CD8+ T cells because they can recognise peptides derived from endogenously 
expressed proteins (Hirohashi et al., 2009). Cytotoxic T lymphocytes can recognise all 
tumour-associated antigens and therefore have the potential to directly kill their target 
cell (Poschke et al., 2011). These new strategies use a combination of approaches that 
trigger the innate immune system and adaptive humoral and cellular immunity. 
Approaches already adopted include whole tumour proteins containing multiple and 
relevant antigenic epitopes (Jager et al., 2000); vaccines using cytokines as adjuvants 
(Hara et al., 2000, Litzinger et al., 2007); and dendritic cells loaded with peptides or 
proteins in vitro (Osada et al., 2006).  
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A significant and promising result of this preliminary research of DFTD TAAs is that 
one antigen was recognised by immune sera from two different devils. The presence of 
common antigens is crucial for the development of a vaccination strategy because it is 
likely that they will evoke an immune response in all affected devils. The antigen 
identified was stathmin and this protein is relevant for targeted immunotherapy because 
of its role in the regulation of the dynamics of microtubule polymerization and 
depolymerisation (Cassimeris, 2002, Rubin and Atweh, 2004). Stathmin is 
overexpressed across a broad range of human malignancies including leukaemia, 
lymphoma, neuroblastoma, ovarian, prostatic, breast and lung cancers and 
mesothelioma (Ghosh et al., 2007, Mistry et al., 2005, Rana et al., 2008) and it is 
considered a potential target in cancer therapies that disrupt the mitotic apparatus 
(Belletti and Baldassarre, 2011, Zhang et al., 2006). It is now also a possible target for 
DFTD chemotherapy. 
The results of this thesis have made a significant contribution not only to the 
understanding of DFTD and to the mechanisms of tumourigenesis and immune invasion 
but have also identified proteins with potential for use in vaccine development and 
targets for chemotherapy.  
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Summary 
The research presented in this thesis has provided significant advances in our knowledge of 
the biology and pathology of devil facial tumour disease. It confirmed the neuroectodermal 
nature of the cancer and provided strong evidence indicating that the disease is a malignant 
peripheral nerve sheath tumour of Schwann cell origin.  
The identification of the Schwann cell as the cell of origin contributed to the discovery of 
periaxin as a sensitive and specific marker for the cancer that has improved diagnosis in 
histology samples. From these results, periaxin could provide a promising diagnostic 
marker for peripheral nerve tumours in other species, especially humans.  
A Schwann cell origin of DFTD is relevant for the understanding of the emergence and 
spread of devil facial tumour cells. The plasticity of Schwann cells and their role in nerve 
tissue repair may have contributed to the development of facial tumours. This relates to the 
characteristic biting behaviour of the Tasmanian devils and the concept that chronic 
inflammation promotes carcinogenesis in plastic cells. 
This research also contributed to the notion that Tasmanian devils are immunocompetent. It 
was found that cells in normal devil tissues synthesise MHC-I proteins which are expressed 
at the cell surface. This suggests that normal cells have the functional machinery to 
transport cellular antigens to surface and present them to the immune system. 
More importantly, this thesis provided evidence that downregulation of surface MHC-I 
expression is a possible mechanism used by devil facial tumour cells to avoid immune 
detection. Tumour cells expressed low levels of MHC-I proteins, which were not associated 
with the cell membrane. This provides devil facial tumour cells with a survival advantage, 
as they would be able to grow undetected by the immune system. Normal Schwann cells in 
peripheral nerve bundles also showed very low levels of MHC-I protein expression. Thus, 
the poor immunogenicity observed in devil facial tumour cells is likely to be a trait inherited 
from the cell of origin.  
This thesis also showed that devil facial tumour associated antigens (TAAs) eliciting 
humoral immune responses in immunised devils can be detected using an 
immunoproteomic approach. These antigens are important for understanding the 
tumourigenesis process as many of the antigens detected have been characterised in a range 
of human cancers. These antigens offer potential immunological targets for a prospective 
vaccine strategy.  
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Appendix 2 
 
List of Reagents 
  
   
1. Reagents 
Reagent Supplier Catalogue Number 
2-Mercaptoethanol Sigma-Aldrich M6250 
3-Aminopropyltriethoxysilane Sigma-Aldrich A3648 
Acrylamide (30%) Bio-Rad 161-0156 
Antibody Diluent Dako S0809 
APS Bio-Rad 161-0700 
Bromophenol Blue Serva 15375 
Coomassie Brilliant Blue G-250 Dye 
Thermo 
Scientific 
20279 
DC™ Protein Assay Bio-Rad 500-0111 
Dispase Invitrogen 17105-041 
Di-sodium hydrogen phosphate Merck 1.06586.0500 
DTT Invitrogen 15508-013 
Dulbecco's Modified Eagle Medium (DMEM) Gibco 11965 
EnVision+ System-HRP Labelled Polymer Anti-
Mouse 
Dako K4005 
EnVision+ System-HRP Labelled Polymer Anti-
Rabbit 
Dako K4003 
Ethanol Merck 4102309020 
Foetal Calf Serum Gibco 1099-141 
Fibroblast Growth Factor Promega G5071 
FIX & PERM® reagents Invitrogen GAS003 
Formalin, 10% Neutral Buffered Sigma-Aldrich F5554 
Forskolin Sigma-Aldrich F6886 
GelCodeTM Blue Safe Protein Stain 
Thermo 
Scientific 
24594 
Gentamicin Sulphate Pfizer 61022027 
Glycerol Sigma-Aldrich G6279 
Glycine Sigma-Aldrich G8898 
Halt™ Protease Inhibitor Cocktail 
Thermo 
Scientific 
87786 
Harris Haematoxylin CliniPure 
CP-L-HAEMHARR-
06 
Histopaque®-1077 Sigma-Aldrich 10771 
   
Reagent Supplier Catalogue Number 
Hydrogen Peroxide Solution Sigma-Aldrich 216763 
Immobilon Western Chemiluminescent HRP 
Substrate 
Millipore WBKLS0500 
In-Gel Tryptic Digestion Kit 
Thermo 
Scientific 
89871 
Iodoacetamide Bio-Rad 163-2109 
L-glutamine Sigma-Aldrich G7513 
Liquid DAB+ Substrate Chromogen System Dako K3468 
Methanol Merck 901459020 
Montanide Adjuvant Essai 70M10645101 Seppic L 13206 
N,N-dimethylacrylamide Sigma-Aldrich 274135 
NuPAGE® Antioxidant Invitrogen NP0005 
NuPAGE® LDS Sample Buffer (4X) Invitrogen NP0007 
NuPAGE® MOPS SDS Running Buffer (20X)  Invitrogen NP0001 
NuPAGE® Novex® 4-12% Bis-Tris Gels Invitrogen NP0322BOX 
NuPAGE® Sample Reducing Agent (10X) Invitrogen NP0004 
NuPAGE® Transfer Buffer (20X) Invitrogen NP0006-1 
Paraformaldehyde Sigma-Aldrich P6148 
Penicillin-Streptomycin Sigma-Aldrich P4333 
PERTEX Mounting Medium HD Scientific CP MD 41-4012-00 
Pituitary Extract bovine Sigma-Aldrich P1476 
Poly-L-Lysine Sigma-Aldrich P-4832 
Potassium chloride Calbiochem 529552 
Potassium phosphate monobasic Sigma-Aldrich P5655 
Protease Inhibitor Cocktail 
Thermo 
Scientific 
87786 
Protein Block Serum-Free Dako X0909 
RIPA Buffer 
Thermo 
Scientific 
89901 
RPMI 1640 Medium Gibco 22400-089 
Skim Milk Powder Diploma - 
Sodium Chloride Sigma-Aldrich 631014 
SDS Bio-Rad 161-0302 
Spectra™ Multicolor Broad Range Protein Ladder Fermentas SM1841 
   
Reagent Supplier Catalogue Number 
Target Retrieval Solution Dako S1700 
TEMED Bio-Rad 161-0801 
Tris-HCl Merck 1.08219.1000 
Trizma Base Sigma-Aldrich T1503 
Triton™ X-100 Sigma-Aldrich X100 
Trypan Blue Sigma-Aldrich T6146 
Trypsin Solution 10X Sigma-Aldrich 59427C 
Tween 20® Sigma-Aldrich P1379 
Xylene M & B Pronalys L864 
ZOOM® 2D Protein Solubilizer 1 Invitrogen ZS10001 
ZOOM® Carrier Ampholytes pH 3-10 Invitrogen ZM0021 
 
2. Disposables 
Product Supplier Catalogue Number 
0.1-20 μl Eptips Eppendorf 022492012 
0.45 μm Nitrocellulose Membrane Bio-Rad 162-0094 
1.0 mm zirconia/silica beads Biospec Products 11079101z 
15  ml Centrifuge Tube IWAKI 2325-015 
2-200 μl Eptips Eppendorf 022492039 
50-1000 μl Eptips Eppendorf 022492055 
70 μm Cell Strainer BD Falcon 352350 
Axygen MaxyClear Microtube Axygen Scientific  MCT-175-C 
Conical Screw Cap Microtube 
Quality Scientific 
Plastics 
522 
Coverglass HD Scientific 24 × 50 
Fluorescent Mounting Medium Dako S3023 
Sponge Pad for Blotting Invitrogen EI9052 
T75 Tissue Culture Flask IWAKI 3110-075 
ZOOM® Strips pH 3-10 Invitrogen ZM0018 
10  ml Lithium Heparin Tube BD Vacutainer LH-367526 
   
3. Equipment 
Product Supplier Catalogue Number 
-80°C Freezer Sanyo MDF-U32V 
Centrifuge Eppendorf 5430R 
Chemi-Smart 5000 Vilber Lourmat 06 16314 
Class II Biological Safety Cabinet  LAF Technologies BSC 1200 
Digital Microscope Camera Leica DFC320 
Fume Hood Conditionaire HC-05 
Heat Block Labline 2002-LC8 
Light Microscope Olympus BX50 
Milli-Q® Biocel Millipore QGARD00R1 
Mini BeadBeater Biospec Products 607 
Minispin Plus Microcentrifuge Eppendorf 5424 
pH Meter  Inolab pH level 1 
Power Pack BioRad PowerPac 300 
Pressure Cooker Russell Hobbs RHNPC401 
Raymond A Lamb Drying Hotplate Thermo Scientific 3120061 
Section Dryer Thermo Scientific 3120064 
XCell II™ Blot Module CE Mark Invitrogen EI9051 
XCell SureLock™  Mini-Cell Invitrogen EI0001 
Flow Cytometer BD Biosciences FACSCanto II 
5% CO2 Incubator Flow Laboratories 220 
Confocal Microscope Zeiss LSM 510 Meta 
Microson™ Ultrasonic Cell Disruptor  Qsonica XL 2000 
Mini-PROTEAN® II Multiscreen Apparatus Bio-Rad 170-4017 
iBlot® Gel Transfer Device Invitrogen IB1001 
ZOOM® IPGRunner™ Cassette Invitrogen ZM0003 
  
   
4. Solutions 
General Solutions 
PBS (pH 7.3) 
Di-sodium hydrogen phosphate 1.15 g/L 
Sodium chloride   8.0 g/L 
Potassium dihydrogen phosphate 0.2 g/L 
Potassium chloride   0.2 g/L 
TBS (pH 7.5) 
Tris base    2.42 g/L 
Sodium chloride   11.7 g/L 
 
SDS Electrophoresis 
Sample loading buffer 
1M Tris-HCl ph 6.8   2.4  ml 
20% SDS    3  ml 
Glycerol (100%)   3  ml 
B-mercaptoethanol   1.6  ml 
Bromophenol blue   0.006 g 
Store at 4oC 
7% Separation Gel 
Water     8.5  ml 
Buffer (5×)    3  ml 
Acrylamide (30%)   3.5  ml 
APS (10%)    150 µl 
TEMED    6 µl 
APS 10%:  Ammonium per sulfate in ultra-pure water. Prepare always fresh. 
 
 
   
Stacking gel 
Water    8  ml 
Buffer (10×)   1  ml   
Acrylamide (30%)  1  ml 
APS (10%)   30 µl    
TEMED   12 µl 
5× separation buffer (1.9 M)    10× stacking buffer (1.3 M) 
Tris base  112.5 g  75.5 g 
SDS   2.5 g   5 g 
ph   8.8   6.8 
Make to 500 ml     Make to 500 ml 
Western blot 
Running buffer Tris-glycine (pH 8.3) 
25 mM Tris base 
190 mM Glycine       
0.1% SDS     
Transfer buffer (pH 8.3) 
25 mM Tris base 
190 mM Glycine       
20% Methanol      
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
Appendix 3 
 
Chromogranin (CGA) Immunohistochemistry 
  
   
 
 
 
Expression of CGA in normal and DFTD tissues. A, immunolabelling detection of chromogranin A 
(CGA) in cells of the devil’s anterior pituitary gland. B, CGA immunoreactivity  was not observed in 
devil facial tumour cells. Immunolabelling using a polyclonal rabbit anti-CGA (A0430, Dako), 
detection with Envision+ system (Dako) and hematoxylin counterstain.  
 
 
  
A B
   
 
 
 
 
 
 
 
 
 
Appendix 4 
 
Mass Spectrometry Analysis (MudPIT) 
DFTD Protein ~ 60 kDa band 
  
   
1. Total proteins extracted from a DFTD cell line were separated using one dimensional 
SDS gel electrophoresis. A band of approximately 60 kDa was excised from the gel and 
proteins identified using mass spectrometry analysis (MudPIT). 
Sequence Mass 
(Daltons) 
Peptides Unique AA Coverage Description 
61,449 25 3 7.2% 26S proteasome non-ATPase regulatory 
subunit 3-like   
58,746 11 3 6.7% apoptosis inhibitor 5   
66,872 12 2 4.4% catalase-like   
55,905 11 2 7.3% coiled-coil domain-containing protein 47   
67,425 3 2 4.2% cytoskeleton-associated protein 4-like 
isoform 2   
62,403 26 9 21.2% dihydropyrimidinase-related protein 2-
like isoform 2   
62,528 31 4 10.3% glucose-6-phosphate isomerase-like   
51,882 38 5 10.6% heterogeneous nuclear ribonucleoprotein 
K-like   
64,532 9 2 4.9% MAGUK p55 subfamily member 6-like   
54,965 11 2 4.0% mRNA cap guanine-N7 methyltransferase-
like   
55,747 64 5 14.3% non-POU domain-containing octamer-
binding protein-like   
57,616 73 9 16.7% protein disulfide-isomerase-like   
70,454 25 4 8.2% pyruvate kinase isozymes M1/M2-like   
58,500 6 2 6.0% seryl-tRNA synthetase, cytoplasmic-like   
58,072 34 8 14.8% t-complex protein 1 subunit delta   
63,360 5 3 7.9% t-complex protein 1 subunit eta-like   
53,053 8 2 5.8% t-complex protein 1 subunit zeta-like 
isoform 2   
66,467 18 2 4.1% WD repeat-containing protein 1 isoform 1   
 
  
   
2. Total proteins extracted from a DFTD tumour xenografted into a NOD/SCI mouse 
were separated using one dimensional SDS gel electrophoresis. A band of 
approximately 60 kDa was excised from the gel and proteins identified using mass 
spectrometry analysis (MudPIT). 
Sequence Mass 
(Daltons) 
Peptides Unique AA Coverage Description 
55,905 7 2 7.3% coiled-coil domain-containing protein 
47   
62,403 9 3 8.2% dihydropyrimidinase-related protein 2-
like isoform 2   
62,528 38 5 9.2% glucose-6-phosphate isomerase-like   
51,882 24 5 13.0% heterogeneous nuclear 
ribonucleoprotein K-like   
64,532 12 2 4.9% MAGUK p55 subfamily member 6-like   
55,747 43 4 10.1% non-POU domain-containing octamer-
binding protein-like   
56,763 4 3 5.9% protein disulfide-isomerase A3-like   
57,616 78 7 12.0% protein disulfide-isomerase-like   
70,454 22 5 10.9% pyruvate kinase isozymes M1/M2-like   
58,072 30 8 14.8% t-complex protein 1 subunit delta   
63,360 2 2 5.8% t-complex protein 1 subunit eta-like   
53,662 3 2 4.5% vimentin-like   
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Invitrogen ZOOM® IPGRunner System Manual 
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